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Abstract 
 
Cell-based therapies have been proposed as novel approaches to treating Osteoarthritis and 
Rheumatoid Arthritis. A non-invasive means of monitoring cell populations, post 
implantation could prove valuable in the clinical translation of such therapies. We propose 
the use of superparamagnetic iron oxide nanoparticles (SPIONs; internalised by cell 
populations) with magnetic resonance imaging (MRI) to image and track cell populations in 
vivo.  
We investigate the potential of commercially available SPIONs (SiMAG, Lumirem, 
Nanomag and P904) as potential labelling/tracking agents for in vivo investigations. Human 
mesenchymal stem cells (hMSC) and porcine chondrocytes were labelled with SPIONs 
under passive incubation conditions in either serum free media or serum containing media 
(24 hrs). SiMAG (10 μgFe/ml) demonstrated greatest potential with highest comparative 
internalised Fe content (labelled in serum free media) in vitro. SPION-labelled cell 
population maintained viability and proliferative capacity apart from SiMAG-labelled 
chondrocytes (10 μgFe/ml). Furthermore, SiMAG-labelled hMSC populations demonstrated 
successful differentiation down mesodermal lineages and retained key cell surface markers.  
MRI visibility thresholds were investigated (in vitro and ex vivo). Dose dependant contrast 
was generated only by SiMAG-labelled populations in vitro when MR imaged. In vitro 
minimum visibility of SiMAG-labelled populations was influenced by various ex vivo tissues 
with similar contrast developing in muscle and fat tissue samples but not for ligament. 
Finally, an ex vivo model of articular cartilage damage confirmed the potential clinical 
application of SPIONS as cell tracking agents at optimised conditions (cell dosage and 
SiMAG concentration) using a clinical system.  
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An AIA murine model (Rheumatoid Arthritis) and a MNX rat model (Osteoarthritis) were 
implemented to image and track implanted SiMAG-labelled MSCs (murine) in vivo for 7 
and 29 days, respectively. Additionally, clinically relevant functional outcomes were also 
monitored. Relevant in vitro assessment was performed where mMSCs efficiently 
internalised SiMAG with no impairment on cell activity. Good contrast was generated in 
both studies with SiMAG-labelled cell population located within the synovial cavity after 7 
days (mouse study) and 29 days (rat study) by MRI. Administration of MSCs significantly 
reduced joint swelling in the mouse study without influence from the presence of SiMAG. 
mMSCs significantly influenced weight bearing asymmetry with little influence on paw 
withdraw threshold indicating potential antinocieotive properties of MSCs. In summary, 
SiMAG has demonstrated great potential as a labelling and tracking agent to be implemented 
for imaging and tracking cell populations. 
Keywords: Superparamagnetic Iron Oxide Nanoparticles (SPIONs), Magnetic Resonance 
Imaging (MRI), Mesenchymal stem cells (MSCs), Chondrocytes, Rheumatoid Arthritis 
(RA), Osteoarthritis (OA). 
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1.1. The Promise of Regenerative Medicine and Stem Cell 
Therapies 
 
Regenerative medicine (RM) is a pioneering field which aims to develop strategies to replace 
and regenerate human cells, tissues and organs in order to restore normal function (1). The 
field thrives on the cross collaboration of multiple disciplines to develop tissue engineering 
approaches to achieve these goals. It harnesses the tools and knowledge developed by 
material scientists, molecular biologists, engineers and clinicians for the design and 
development of cellular therapies to treat a broad range of diseases and conditions. RM 
primarily employs the use of stem cells as the fundamental component of most therapies. 
The field of RM has experienced several exciting breakthroughs over the years; for example, 
the development of induced pluripotent stem cells which saw Yamanaka receive the Nobel 
Prize for this discovery (2). In addition, Macchiarini and his colleagues succeeded in 
implanting the first functioning human tissue engineered trachea (3). Popular avenues of 
research currently include; Parkinson’s, Alzheimer’s, spinal cord injury, diabetes and 
arthritis (1). Due to the successful progress by Brittberg and his team (4), cartilage 
restoration approaches are currently in clinical use today and primarily focus on targeting 
osteoarthritis. Nonetheless arthritis still remains to be a burden on healthcare systems 
worldwide. 
This thesis will therefore focus on the contributions regenerative medicine has made in 
tackling rheumatoid arthritis (RA) and osteoarthritis (OA) of the knee and how 
multidisciplinary approaches can contribute to the further understanding and enhancement 
of these therapies.  
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1.2 Arthritis 
 
Arthritis is used to describe a set of musculoskeletal disorders affecting one or more joints 
within the body. Examples include, Rheumatoid Arthritis (RA; a type of inflammatory 
arthritis) and osteoarthritis (OA; classified as degenerative arthritis), (5). The mechanisms 
by which these diseases progress are significantly different with RA being a systemic 
autoimmune disorder whereas OA is a non-systemic degenerative, mechanical disorder (6, 
7). Both forms of arthritis however result in pain and inflammation of the joint and are 
accompanied by joint destruction resulting in an eventual loss of function (6). The knee joint 
is the largest, most common joint affected by arthritis and is the focus of much research 
combating this disease. For this reason the knee joint will be the main joint of focus of this 
thesis. To fully understand arthritis of the knee, it is important to first grasp the key 
anatomical and physiological components making up the knee joint.  
 
1.2.1 The Biology of the Knee 
Characterised as the largest joint in the human body (8, 9) the knee plays a vital role in the 
mobility and movement of the lower body. It is a prime example of a synovial hinge joint 
due to the presence of the synovial lining and the single plane of joint movement. In basic 
anatomy terms, the knee is made up of 3 bones, the femur, the tibia and finally the patella 
(10). The movement of the joint is dependent on the shape of the bones, the characteristics 
of the ligaments and the surrounding soft tissue (11). Figure 1.1 illustrates the general 
anatomy of the knee highlighting the main components.  
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Figure 1.1 Basic anatomy of the human knee. Adapted from Gillian et al. 2000 (12). 
   
The distal ends of the femur progress into two condyles (9).  The surface of these condyles 
are lined with articular hyaline cartilage, a highly load bearing tissue effectively allowing 
for the smooth, almost frictionless movement of one bone over the other and is critical to the 
function of the joint (10, 13). The function of hyaline cartilage is aided by the production of 
synovial fluid which not only nourishes the cartilage but also keeps the coefficient of friction 
low. This fluid is produced by the surrounding membrane (the synovium), and has a tough 
outer layer (the capsule), which essentially prevents excessive movement of the bone.  
Excessive movement of bones is further restricted by the ligaments, which run either within 
or just outside the capsule and hold the three bones mentioned above, together (8). The main 
stabilizing ligaments are the anterior cruciate ligament (ACL), posterior cruciate ligament 
(PCL), medial collateral ligament (MCL) and the lateral collateral ligament (LCL), which 
provide combined stability throughout a range of motions characteristic to the knee (9). 
Furthermore, two “C” shaped pieces of cartilage (meniscus) are located between the cartilage 
layers of the femur and tibia (8). Unlike the cartilage found at the surface of the condyles, 
the meniscus is fibrocartilage in nature and effectively resists compression of weight bearing 
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loads and also allows for the correct alignment of the femoral condyle to the tibial condyles 
(9). Finally, tendons function to attach the muscles to bone (8), and act in an antagonistic 
manner to provide appropriate joint movement. Finally, the patella tendon attaches with the 
patella (kneecap) acting to protect the tendon at the back of the knee (11).  
Major considerations in the efficient functioning of the knee are: a) the geometry of the bone 
and articulating surfaces, b) the functional and anatomical integrity of the surrounding 
supportive structures such as ligaments, tendons and muscles, and c) the mechanical 
properties of the articular cartilage and subchondral bone. Any short comings of these pre-
requisites can ultimately result in a broad range of disorders such as articular cartilage 
damage (14).  
 
1.2.2 Cartilage 
Cartilage is a specialised connective tissue found in various forms and in numerous sites 
within the body playing a key structural and supportive role (15, 16). Cartilage located within 
different areas of the body are subjected to various site specific mechanical stresses (tensile, 
shear and compressive) and therefore have different physical properties to account for such 
site specific biomechanical properties (13, 17). For example, Hyaline cartilage is found at 
the surface of synovial joints functioning to resist compression during joint movement whilst 
also facilitating the smooth and frictionless movement of joint. Furthermore, hyaline 
cartilage makes up the rings of the trachea and the plates in the bronchi providing the 
necessary structural support required by the respiratory system. Fibrocartilage on the other 
hand is found within the intervertebral disks and the meniscus on the knee where its main 
role is to resist tensile loads under stresses. Finally, Elastic cartilage makes up the outer part 
of the ear and is adapted to providing flexible support (16).  
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In general, cartilage is a complex structure made up of collagen fibres, proteoglycans, and 
water, which collectively make up the extracellular matrix (ECM) (9, 17). The ECM is 
maintained by chondrocytes which is the only cell type that sparsely resides within this tissue. 
The specific ratio of these biochemical components effectively dictates the type of cartilage 
present (17).  
Collagen is a highly abundant fibrous protein found within the human body playing a 
significant role in contributing to the strength, structure and 3D shape of cartilage (14) . The 
general structure of collagen can be described as being a triple helix made up of three helical 
α chains twisted around each other to form a superhelix (9). Variations in this structure 
results in alternative forms of collagen such as collagen type I, II, IX and XI, with the various 
types having specific roles in the overall structure of cartilage (14). Collagen type I is 
primarily found in fibrocartilage whereas collagen type II makes up 80-90 % of  hyaline 
cartilage and elastin (9, 16).  Attached to the collagen fibrils, are proteoglycan aggregates 
which contribute to the formation of ECM. Proteoglycans are complex macromolecules 
comprising of a protein core covalently attached to glycosaminoglycan side chains linked 
with a variety of sulphated polysaccharides (chondroitin 4, 6 and keratin sulphate) (9, 14). 
Proteoglycans play an important role in maintaining cartilage function by promoting 
lubrication, providing a structural element within the connective tissue, mediating the 
adhesion of cells to the ECM and providing binding factors that effectively stimulate cell 
proliferation (13, 14). The water content in cartilage varies according to cartilage type, age 
and specific location in the body and is an essential part of maintaining tissue integrity, 
supporting loads and nourishing chondrocytes (7, 9). 
The specific ratios of these biochemical components (collagen and proteoglycans) 
effectively dictate the type of cartilage present (17). Orientation of the collagen fibres further 
impacts the biomechanical properties of cartilage tissue. Longitudinal fibre orientation, (type 
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I collagen) has greater tensional strength in comparison to transverse collagen fibre 
orientation (type II collagen) which are more adapted to  resist compressive forces (18). The 
relative quantities of collagen and proteoglycans making up hyaline and fibrocartilage are 
shown in Table 1.1. Therefore, the function of hyaline cartilage is aided by the presence of 
type II collagen and the high proteoglycan quantity, whereas type I and type II collagen 
content of fibrocartilage allow for resistance to both compression and tension forces. It is 
important at this point to note that fibrocartilage does not have the same biochemical 
composition or structural organisation to provide the mechanical function demanded by the 
knee thus resulting in faster degradation over time due to insufficient load bearing 
capabilities (13, 19). This is an important consideration in tissue engineering of cartilage.  
Table 1.1 The relative proportions of the three major components in hyaline and 
fibrocartilage (19) 
 
Tissue Type Type I collagen Type II collagen Proteoglycan 
Fibrocartilage ++ + + 
Hyaline cartilage 0 +++ +++ 
 
Healthy cartilage is maintained by a dynamic equilibrium between the production and 
degradation of cartilage matrix over time in a process referred to as “cartilage homeostasis” 
(7, 9, 13).  This process is regulated by chondrocytes residing within the cartilage tissue and 
is governed by a variety of soluble catabolic (degrading), anabolic (pro-synthesis), 
inflammatory and apoptotic mediators derived from chondrocytes and the synovium (7, 9). 
Normal homeostasis is dependent on the ability of chondrocytes to detect changes in the 
matrix composition and consequently respond by triggering the degradation of ECM via the 
secretion of matrix degrading enzymes to allow for the deposition of newly synthesised ECM 
specific molecules (collagen, proteoglycans and glyosaminoglycans) (16).  It is vital to have 
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a firm understanding of the factors involved in cartilage homeostasis in order to better 
understand disease pathology. A detailed overview of factors involved in cartilage 
homeostasis are stated in Table 1.2. Furthermore, homeostasis is partially driven by 
mechanical stimulation (mechanotransduction) of chondrocytes where the loading of the 
joint creates mechanical, electrical and chemical signals which are transduced through the 
cartilage matrix effectively directing chondrocytes towards anabolic activities (16).  
However, with age, cells are less able to respond to these signals resulting in a disruption in 
the homeostasis balance (13, 16). In fact, any event (such as trauma, disease and age) causing 
a disruption in this balance may result in excessive catabolic events over anabolic events. 
This ultimately causes the overall breakdown of the matrix subsequently causing cartilage 
damage, pain and reduced mobility (7, 13). Given the limited proliferative capacity of mature 
chondrocytes, these cells are not able to compensate for this damage, resulting in disease 
progression (7).   
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Table 1.2 Catabolic and anabolic factors of normal cartilage homeostasis (9) 
 
 
1.2.2.1 Articular Hyaline Cartilage 
From the Greek word, “hyalos”, meaning glass, articular hyaline cartilage is identified as the 
smooth, glistening white, glass-like tissue found covering the surface of articulating joints 
(13, 16). Hyaline cartilage is a metabolically active tissue whose function lies in the ability 
to provide resistance to compressive, shear and tensile forces occurring during normal joint 
motion. This is made possible by distributing applied forces to the underlying bone in the 
knee without sustaining wear (16, 20).  Although hyaline cartilage is considered to be a fairly 
tough and robust tissue, recovery from damage to the articular surface is not easily overcome 
Catabolic Factors Anabolic Factors 
Cytokines: Interleukin (IL-1) and Tumour 
necrosis factor (TNFα). 
Cytokine inhibitors: Interleukin 
antagonist (IL-1RA) and human cytokine 
synthesis inhibitory factor (IL-10) 
Proteinases:  
a) Cysteine and serine proteinases  
b) Metalloproteinases (MMP). E.g. MMP-1 
(interstitial collagenase), MMP-2 
(gelatinases), MMP-3 (Stromelysin), 
MMP-13 (Collagenase-3), ADAMTS 4 &5 
(A Disintegrin And Metalloproteinase with 
Thrombospondin Motifs) 
Aggrecanase -1 &2                       
Proteinase Inhibitors: Tissue inhibitors of 
matrix metalloproteinase (TIMP) 
 
 
 
 Growth Factors: FGF (Fibroblast growth 
factors), EGF (Epidermal growth factor), 
TGFβ (Transforming growth factor) 
 Mechanical Loading: 
Mechanotransduction 
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(16). This is attributed to the avascular nature and consequent lack of blood supply 
accounting for the limited healing capacity and regeneration of the articular cartilage (13, 16, 
21, 22).   
The mechanical properties of articular cartilage are attributed to the arrangement of the 
macromolecules making up cartilage ECM, as mentioned in section 1.1.2 (16). The relative 
quantities of each constituent making up hyaline cartilage are shown in Figure 1.2. Collagen 
is the major matrix protein found in hyaline cartilage ECM with type II collagen being the 
most abundant and prominent of all collagen types present. Type IX, XI, X and VI are also 
present and work to facilitate interactions with proteoglycans and cells, regulate fibril size 
and organize collagen into 3D structures (13, 16).  The arrangement of collagen fibres not 
only provide the tensile strength for cartilage but can also respond to swelling pressures of 
proteoglycans (15).  
Proteoglycans are made up of: glyosaminoglycans (GAGs), hyaluronan, chondroitin 
sulphate and keratin sulfate. The attachment of GAGs to a protein core essentially creates a 
proteoglycan monomer. Aggrecan is the most abundant proteoglycan found in hyaline 
cartilage, comprising of a protein core with keratin sulfate and chondroitin sulfate side chains.  
These molecules are stabilized by link proteins and are attached to hyaluronic acid molecules 
within the ECM. Up to 200 aggrecan molecules can attach to one hyaluronan molecule, 
forming a macromolecular aggregate, which is shown in Figure 1.2. Negatively charged side 
chains that repel each other encourage the adsorption of water and providing the tissue with 
swelling properties. This is a key aspect in resisting compression and contributing to the 
mechanical properties of the tissue (13, 16). Other proteoglycans (decorin, biglycan and 
lumican) can also be found within hyaline cartilage. The collaborative effect of all 
proteoglycans contributes to the function of cartilage (capacity to resist excessive loads and 
provide frictionless movement of joints) (15, 16). Furthermore, multi-adhesive proteins 
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(non-collagenous and non-proteoglycan linked proteins) found within the matrix are present 
to encourage and facilitate interactions with chondrocytes and cartilage matrix molecules, 
by playing roles in cell anchoring (16). 
Hydration of cartilage matrix is a particularly important aspect of maintaining cartilage 
health and function. Water molecules residing within the pores of ECM not only facilitate 
the diffusion of nutrients and waste to and from the chondrocytes and the synovial fluid, but 
also act to maintain tissue integrity when the joint is in motion. This is significantly 
important given the avascular and alymphatic nature of cartilage (13, 16, 22). During motion, 
cartilage can respond to varying pressure loads resulting in the rapid pressurisation of the 
fluid inside the tissue resulting in the ability to withstand the load (9, 13, 16). 
Chondrocytes reside within the lacunae of ECM and become attached to the ECM via 
integrins (specialised cell surface proteins mediating bidirectional signalling between the 
intracellular and extracellular regions of the cell). This is essential in the maintenance of 
homeostasis, viability and morphology (23).  
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Figure 1.2. Structure and molecular composition of hyaline cartilage, adapted from 
(13, 16) 
 
Hyaline cartilage is divided into zones classified by collagen fibre orientation and 
chondrocyte morphology (Figure 1.3). The composition of each zone varies from top to 
bottom i.e. from the surface of the tissue down to the subchondral bone. These regions are 
known as; superficial, middle/intermediate and deep regions. Chondrocyte morphology, 
size, collagen fibre orientation and biochemical composition vary throughout these zones 
and for this reason are identified accordingly (9, 13). 
 The superficial zone forms approximately 10-20 % of the tissue and is characterised 
by; a) densely packed collagen fibres orientated parallel to the cartilage surface, b) 
relatively low proteoglycan content and c) few densely packed and flattened 
chondrocytes, aligned along the neighbouring collagen fibres (9, 13). 
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 The middle zone comprises of about 40-60 % of the tissue thickness. This zone is 
characterised by: a) collagen fibres arranged in an oblique manner, b) high 
proteoglycan content and c) low chondrocyte density with cells more spherical in 
shape (9, 13). 
 Finally, the deep zone is characterised by: a) large collagen bundles orientated 
vertically to the articular surface and fixed to the underlying bone, b) low 
proteoglycan content and c) very low cell density. The chondrocytes in this area are 
elongated and grouped together in a columnar manner (9, 13). 
 
Figure 1.3. Zonal classification of hyaline cartilage highlighting the composition and 
structure in terms of cell morphology and collagen fiber orientation at every level. 
Adapted from  (9, 13) 
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1.2.3 Arthritis Pathology. 
1.2.3.1 Osteoarthritis 
Osteoarthritis (OA) of the knee is considered to be one of the most prevalent forms of joint 
diseases affecting approximately 8.5 million people in the UK (8, 24). It is a chronic disorder 
characterised by the degeneration of articular cartilage ultimately resulting in the destruction 
of the synovial joint (24-26). This consequently causes pain, stiffness and inflammation of 
the diseased joint resulting in a loss of joint function and significantly impacting the quality 
of life of the patient. In fact, OA is considered to be the third leading cause of disease burden 
accounting for a sizeable contribution to morbidity and disability (particularly among the 
elderly) within a population (24, 27, 28).   
OA primarily affects those at risk of developing cartilage damage such as those possessing 
various risk factors. Risk factors (described in Figure 1.4) can be categorised as either 
general susceptibility risk factors or specific biomechanical risk factors. Increasing age and 
obesity for example, significantly enhance a person’s chances of developing OA. These are 
considered general susceptibility risk factors describing those with a predisposition for 
developing OA. Various activities demanding strenuous repetitive activities (such as, sports 
and occupations) place a person at high risk of developing OA. These are considered as 
biomechanical risk factors where everyday activities play a role in OA incidence. It is 
important to appreciate the interplay between risk factors (4, 9, 27).   
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Figure 1.4  Risk factors associated with the development of OA. Adapted from (9, 13, 
26, 29) 
 
OA is initiated by damage to the articular cartilage surface creating a delicate balance of 
homeostasis. This is governed by the release of various catabolic factors by chondrocytes 
and synovial fibroblasts in response to a traumatic event (stress response). IL-1β and TNF-
α are key mediators in this process effectively up regulating the expression of various 
proteinases (such as MMP) enzymes working to degrade components of ECM matrix 
(collagen and proteoglycans) (7).  The overall breakdown of ECM matrix consequently leads 
to articular cartilage loss (24, 27). Various intrinsic repair mechanisms efficiently secrete 
anti-inflammatory and anabolic factors to restore the degraded ECM by inhibiting cytokine 
induced MMPs and blocking chondrocyte apoptotic pathways. (7). However, due to the 
notoriously limited healing capacity of articular cartilage, small injuries can progress into 
full degeneration (4, 26). In such cases, damage becomes so severe that the subchondral bone 
becomes exposed, triggering the production of bone and cartilage in the form of osteophytes 
(this response is thought to be a repair mechanism of the joint). This consequently causes 
the misalignments and instability of the joint relying on the stabilising ligaments to work to 
stabilise the joint. These structures therefore become thicker and tougher further limiting 
movement (16, 24-26, 30). Figure 1.5 highlights the key structural changes occurring within 
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an osteoarthritic knee. It can be summarised that OA is not a disease affecting only the 
articular cartilage but in fact a number of components related to the knee (30, 31).  
 
1.2.3.2 Rheumatoid Arthritis  
RA (a systemic autoimmune disease) is characterised by chronic inflammation of the 
synovial joint ultimately leading to joint destruction and subsequent disability or morbidity 
(32-34). It commonly affects multiple symmetrical joints such as the knee, finger and ankle 
in parallel, causing severe pain, inflammation and stiffness (33). RA is considered to be the 
most common autoimmune disease affecting approximately 1 % of the global population 
(32-34) and 400 000 people in the UK (30).  Similar to OA, it bares significant economic 
burden (33) with an annual cost of £8 billion to the NHS in the UK (30). Further disability 
and morbidity is attributed to infection and inflammation of extra-articular organs over time. 
Issues related to pericarditis, pulmonary fibrosis, vasculitis are all examples of complications 
associated with RA (33, 34) further contributing to economic burden and reduced quality of 
life (33, 34).  
People of all ages may be affected by RA, however, it is more prevalent with increasing age 
primarily affecting those over the age of 50. It is also 2-3 times more common in woman 
than in men (33, 34). Within 10 years of diagnosis approximately 40 % present with severe 
disability to the extent that they cannot work (34). The causes of RA are believed to be 
attributed to a combination of genetic and environmental factors (33-36). Genetic factors 
only account for approximately 30 % of the total number of diagnosed cases of RA whilst 
additional risk factors such as smoking, alcohol, stress, diet and infection are also believed 
to further contribute to the onset of RA (33, 34). 
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It is thought that these genetic and environmental factors can trigger the immune system to 
initiate the inflammatory process. This involves the infiltration of inflammatory cells such 
as; neutrophils, macrophages, lymphocytes and monocytes into the synovium causing 
inflammation, pain and swelling (5, 35-38). The subsequent activation of inflammatory cells 
causes a cascade of events whereby pro-inflammatory factors such as TNF –α and IL-B are 
secreted further causing the up regulation of other catabolic factors such as MMPs. This 
consequently causes disruption in cartilage homeostasis resulting in the destruction of the 
articular cartilage (34-38). Furthermore, the diseased, inflamed synovium of the knee is 
characterised by the presence of fibroblast-like synoviocytes (FLS). These cells grow in 
mass resulting in the development of the pannus. This process is fairly invasive resulting in 
continued erosion of bone and cartilage (6, 38). As a result, the patient experiences pain and 
disability.  
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Figure 1.5. Lateral view of: A) healthy, B) OA, C) RA joint highlighting the destruction 
of the synovial joint adapted from Arthritis Research UK (ARUK); (8, 30). 
 
The physical changes in the OA and RA joint are easily diagnosed by X-Ray or magnetic 
resonance imaging (MRI), by evaluating changes in the joint space causing the narrowing of 
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the cartilage and changes in bone thickness. In general, MRI is far more informative of the 
stages and the degree of disease (28, 33). 
 
1.2.3.3 Treating OA and RA 
There are no known cures for either forms of arthritis discussed in this document. Treatment 
regimens are focused on relieving painful symptoms, minimising disability and maintaining 
quality of life.  These range from simple non - pharmacological approaches, to invasive 
surgical techniques (34, 39). Non-pharmacological options such as education, exercise and 
weight loss regiments are implemented in the early stages of the diseases and are aimed at 
improving general wellbeing, reducing stress, whilst increasing the strength of muscles local 
to the knee in order to improve joint alignment (9, 24). These approaches however are not 
effective at tackling the pain and inflammation associated with the disease and thus require 
pharmacological interventions (9). Basic pharmacological approaches implemented in early 
stages of the disease aim to address symptoms such as pain and inflammation by prescribing 
pain killers (analgesia) or anti-inflammatories. In fact, pain is considered to be the worst 
symptom of these diseases affecting even the most basic activities and increasing in intensity 
with disease progression. In extreme cases, pain may even persist at rest (24, 40). Treatments 
for pain have limited efficacy encouraging researchers to find better, more effective means 
of tackling this symptom. Nonetheless, these approaches do not impact disease progression 
(40). Whilst pharmacological interventions are the primary form of treatment for RA (34), 
they are also implemented to address pain and inflammation in early cases of OA forming 
the basic core treatments for OA (24). Nonetheless, these approaches do not impact disease 
progression and so alternative means of tackling these diseases are currently under 
investigation.   
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Osteoarthritis 
When core treatments have failed, and the disease still bares significant burden on the patient; 
surgical approaches become necessary. In these cases, the diseased joint can be replaced 
with an artificial implant (arthroplasty) (13). Joint replacement techniques however are not 
suitable for patients under the age of 50 due to the limited life span of the prosthesis (5-10 
years) (4, 24).  This has motivated research into developing a means of restoring damaged 
hyaline cartilage through cartilage replacement techniques (4, 24, 39, 41). Examples of 
surgical techniques targeting the regeneration and restoration of damaged cartilage mainly 
include microfracture, debridement, ACI (Autologous Chondrocyte Implantation) and 
mosaicplasty. 
 Microfracture involves the release of mesenchymal stem cells (MSC) from the 
underlying bone marrow by arthroscopically drilling into the subchondral bone 
within the defect area (21, 39). This initiates the flow of blood containing 
mesenchymal stem cells (MSCs) and cartilage progenitor cells to enter and clot 
within the micro fractures (20). Although this technique has received some positive 
results, the regenerated cartilage tends to be fibrocartilage in nature, which does not 
compare in terms of mechanical properties (strength) to hyaline cartilage therefore 
undergoing severe degradation within two years (42). Further to this, this technique 
has proved ineffective for elderly patients, overweight patients and for patients with 
lesions larger than 2.5 cm. The success of this approach is heavily dependent on the 
quality and health of native mesenchymal stem cell population and may account for 
the conflicting clinical outcomes (39).  
 Mosaicplasty involves the isolation of osteochondral grafts from non-weight bearing 
regions of the knee to be subsequently transplanted within the defect area (20, 43). 
Practical limitation associated with this technique involves the mismatching of 
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surface shapes resulting in gaps between grafts in addition to damage to the donor 
site. Therefore, this technique is only suitable for smaller lesions (20, 21, 44). 
Issue with these techniques has driven the development of cell therapy strategies to treat 
articular cartilage damage. This involves the administration of cells to the body for 
therapeutic purposes (45). The first articular cartilage focused cell based therapy was 
introduced by Brittberg et al in 1984, in a technique known as Autologous Chondrocytes 
Implantation (ACI). After a series of clinical successes it was later commercialised in 1994 
by Genzyme (4, 42, 46). Multiple hospitals in the UK and worldwide provide ACI in routine 
clinical practices with good manufacturing practise (GMP) laboratories to provide cell 
culture services. 
Autologous Chondrocyte Implantation is a surgical technique whereby samples of the 
patients’ healthy cartilage are harvested from non-load bearing areas of the knee, digested 
to extract chondrocytes, expanded in culture (± 6 weeks) in order to obtain adequate cell 
numbers (5-10x106) and then re-implanted into the area of cartilage damage (Figure 1.6). In 
early versions of this technique, the periosteal flap was sutured over the defect (4). Within 
three months, the defect had closed and was occupied by cartilaginous tissue. Further to this, 
patients experienced a reduction in pain and swelling (47). The actual mechanism of 
cartilage repair in ACI is unknown, however, three theories have been proposed. These 
include;  
1) Repopulation of the defect site by implanted chondrocytes. This causes the synthesis 
of specific cartilage ECM components with the periosteum acting as a physical 
support in localising the cells in place.  
2) Repopulation of the defect site by implanted chondrocytes through the synthesis of 
specific cartilage ECM components stimulated by the periosteum.  
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3) The periosteum and transplanted cells act to stimulate chondrocytes in the 
surrounding cartilage to enter the defected area, divide and regenerate damaged 
cartilage (4). 
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Figure 1.6. Flow chart highlighting critical steps in performing first generation ACI and MASI (matrix associated chondrocyte 
implantation). 
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Although the formation of hyaline cartilage is the ultimate clinical goal of ACI, this is often 
not the case and results in the formation of fibrocartilage instead in certain cases (21, 48). In 
a study with 23 patients, it was found that success was very much dependant on the site of 
the defect (49). Nonetheless, ACI has since undergone various iterations and has evolved to 
enhance its therapeutic potential. Iterations have focused on the replacement of the periosteal 
flap with natural polymers such as collagen, fibrin, and hyaluronic acid (to minimise surgery 
time and donor site morbidity) (50); the use of biocompatible scaffolds in matrix-associated 
chondrocyte implantation (MACI) approaches where scaffold have been implemented to 
support chondrocytes during the remodelling process (42). Little is actually known about the 
fate of cells in the defect. This is a topic of much interest and of vital importance. A better 
knowledge of cell fate post implantation can contribute to the understanding of mechanism 
of repair and with this, enable therapies to be optimised for maximal therapeutic output.  
 
Rheumatoid arthritis 
RA is primarily managed with drugs aimed at either treating the symptoms of the disease 
(pain and inflammation) or by disease modifying agents aimed at preventing further disease 
progression (34).  These include: 
 Anti-inflammatory agents: typically referred to as “non-steroidal anti-
inflammatory (NSAID) drugs”. These are primarily prescribed to address the 
inflammation of the knee whilst also offering some pain relief to the patient. 
Unfortunately, such recommendations are limited in their ability to prevent or 
suppress joint damage with various formulations varying in efficacy. Low doses of 
corticosteroids are also thought to effectively tackle pain and inflammation of the 
diseased joint, however these are limited to offering only short term relief (33, 34).  
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 Disease Modifying Anti-rheumatic drugs (DMARDS) are aimed at reducing or 
preventing further joint damage, hence preserving joint function. Unfortunately, 
DMARDS are limited in their ability to control pain, taking from weeks, up to 
months, to have an effect (33, 34) 
 Cytokine antagonists work to inhibit the activity of cytokines (e.g.TNF-α) 
participating in the onset and progression of inflammation in RA. However, these are 
very expensive requiring intravenous administration and are associated with 
unpleasant toxic effects (51).  
For optimal results, a combination of these drugs is prescribed to address disease symptoms 
in addition to disease progression. However, such drug regiments are particularly unpleasant 
to the patient causing significant side effects whilst also being very expensive. Additionally, 
these drugs have varying effects and results are highly patient dependant. In some cases, 
patients may even become resistant to these drugs, thus continuing to cause significant 
disability (51, 52). In certain extreme cases, minor operations may become necessary to 
either correct deformities or replace the damaged joint in the case of the hip and knee (53).  
The chronic inflammatory environment of the rheumatic arthritic joint renders cartilage 
regeneration techniques (implemented in OA) ineffective, as similarly to the original native 
cartilage, newly formed cartilage undergoes destruction within the hostile environment (6).  
This highlights the growing need for more effective means of restoring damaged cartilage in 
RA patients (42). 
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1.3 Motivation for Cell Therapies.   
 
Pain and inflammation can be effectively treated offering some relief for OA and RA 
sufferers. Although some progress has been made in the restoration of damaged cartilage, 
these techniques (mosaicplasty and microfracture) are not always successful in offering the 
OA patient full function of their joint and are not suitable for RA sufferers (6). Cell therapies 
based on ACI are believed to hold most promise in treating full cartilage defects, even though 
long term follow up studies have not conclusively demonstrated the clinical advantage of 
implementing ACI over microfracture (49) and moisacplasty (54).  
A number of limitations have been attributed to ACI: 
1. The dedifferentiation of chondrocytes when cultured in monolayer encouraging the 
formation of fibrocartilage as opposed to hyaline cartilage when replaced in the joint 
(50).  
2. Quality of isolated chondrocytes is highly donor dependant (age and degree of 
disease progression) leading to impaired cartilage repair (50). 
3. The need to isolate healthy cartilage from a non-weight bearing region in the knee 
placing further burden on the patient, donor site morbidity and increased risk of 
developing OA in the future (50). 
4. The use of the periosteum to localise cells to the defect increases surgery time and 
donor site morbidity. Although commercial product such as Chondroguide have 
reduced this issue (50). 
5. The unpredictable and non-reproducible variability in tissue quality (50). 
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ACI forms a solid foundation to develop alternative cell based therapies for OA and RA. In 
ACI, the cartilage defect is used to trigger the production of cartilage. This environment has 
all the necessary physical and chemical factors required for cartilage regeneration (55). This 
has encouraged the development of approaches mimicking this in vivo environment whereby 
the implanted cells can either repopulate the damaged area or stimulate the surrounding 
cartilage cells to divide and repopulate defected areas (6). ACI is only effective in those 
suffering from OA but not RA. The hostile environment of the rheumatic joint renders this 
approach ineffective as similar to native cartilage the newly synthesised cartilage will also 
undergo destruction. However, by diversifying this approach to include alternative cell types 
such as mesenchymal stem cells, novel and plausible approaches to tackling RA can be 
developed based on the traditional ACI approach. The application of stem cell-based 
therapies therefore has the potential to develop a reproducible means of promoting high 
quality tissue (comparable to that of native cartilage in terms of biochemical and mechanical 
properties). The therapy would aim to replace and/or repair damaged cartilage and provide 
the opportunity for full recovery along with total joint function. This would ultimately hold 
promise to fully eliminating diseases such as OA and RA (21, 24).   
 
1.3.1 Cell Therapies 
The newly established Cell Therapy Catapult in the UK, defines a cell therapy as: “Any 
treatment for a medical condition that employs at its core one or more types of viable human 
cells” (56). Cell therapy is a platform technology employed in many fields of medicine 
including regenerative medicine (57). Cell types employed in the development of such 
therapies include the use of the patient's own cells (autologous), donor derived (allogeneic) 
cells, stem cells (adult stem cell, embryonic stem cells and induced pluripotent stem cells) 
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and immune cells. Examples of cell therapies include; bone marrow transplantation (earliest 
stem cell-based therapy dating back to 1968), the application of chondrocytes in treating 
cartilage lesions as described previously for ACI (56, 58),  the autologous transplantation of 
limbal stem cells for corneal disorders and finally the implementation of  T cell  in 
autoimmune therapies (59). In the context of regenerative medicine, cell therapy approaches 
are implemented to replace, regenerate and restore the function of damaged or injured 
tissues/organs, primarily using stem cells (1, 57) 
Tissue Engineering (TE) is one particular branch in the cell therapy industry (57) and 
involves the combined use of cells, engineering materials and biochemical factors to develop 
ex vivo living tissues and organs that can be implanted within the body to repair injury or 
replace the function of a failing organ (42, 45, 60). TE skin grafts were some of the earliest 
TE strategies developed dating back to 1981 (42). Since then, TE strategies have extended 
to the development of the first bio-artificial neo bladder by Atala and colleagues (61). In fact, 
the possibilities of TE has extended to the engineering of whole organs such as livers, 
pancreases, and cartilage (62). 
Cell therapies are believed to significantly impact the way OA and RA are treated in the 
future.  The precedent for developing cell therapies in treating debilitating diseases such as 
OA and RA lie with ACI (58). The ultimate clinical goal of ACI is to restore and repair 
damaged articular cartilage offering the patient complete function of the joint resulting in 
the improvement of quality of life (63). The choice of cells is vital in the success of such 
therapies. Tissue specific cells, (chondrocytes) and stem cells (MSCs) are ideal candidates 
in the development of cell-based therapies for OA and RA. Reasons will be discussed below.  
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1.3.2 Cell Types 
1.3.2.1 Mature Chondrocytes 
Chondrocytes isolated from articular hyaline cartilage possess the desired phenotype and are 
pre-conditioned to synthesise the correct components required to repair damaged cartilage. 
This makes them potentially the ideal cell source for cartilage regeneration (12)(13). 
Chondrocytes may be isolated from a host, and used either for the same host defining an 
autologous cell therapy or for a different host (of the same species) defining an allogeneic 
cell therapy (45). The standard argument for use of autologous cells versus allogeneic cells 
apply here, where the major disadvantage of using allogeneic cells concerns immune 
rejection and the risk of disease transmission (10). While, isolating autologous chondrocytes 
from healthy tissue limits the amount of cells that can be sourced due to the risk of donor 
site morbidity. This makes it particularly difficult to meet specific patient needs and requires 
the in vitro expansion of isolated chondrocytes to obtain clinically relevant numbers (13, 42, 
62, 64). This introduces the problem of dedifferentiation. Chondrocytes are known to 
dedifferentiate rapidly when cultured in monolayer becoming more fibroblastic like (64). 
Under these conditions, chondrocytes have been known to lose their phenotypic markers 
rapidly subsequently causing the loss in their characteristic expression and instead promoting 
the synthesis of collagen type 1 (characteristic of fibrocartilage). Hence, newly synthesised 
cartilage will lack the mechanical properties required to withstand loads in the knee (7, 13, 
23). These issues are overcome by applying various culture techniques including; a 3D 
culturing environment, hypoxic conditions, mechanical stimulation and growth factors (64). 
Finally, the quality of isolated chondrocytes is highly donor dependant (age and degree of 
disease progression) further limiting the application of chondrocytes in cell therapy 
application (50). Hence, alternative cell sources are desired for better cartilage regeneration 
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such as stem cells which are potential candidates to be incorporated into cartilage tissue 
engineering strategies. (24, 64).  
 
1.3.2.2 Stem Cells 
Stem cells are defined by: a) their ability to self-renew via symmetrical cell divisions to 
maintain the pool of undifferentiated stem cells and b) the ability to undergo asymmetric cell 
division giving rise to daughter progenitor cells capable of differentiation (45, 65). These 
properties are particularly important in vivo to reconstitute any given tissue as a repair 
mechanism (66). Stem cells are found within specialised 3D micro environments also 
referred to as niches. Stem cell niches are responsible for controlling the properties, activities 
and gene expression through signalling molecules, cell-cell interactions and interaction with 
the ECM. Stem cells are further categorised by their plasticity or their flexibility to 
differentiate into mature cell types and are defined as being either totipotent (giving rise to 
all embryonic and extra embryonic cell types e.g. Zygote), pluripotent (giving rise to all cell 
types of the embryo apart from the placental cells e.g. Embryonic Stem Cells ) or multipotent 
(giving rise to few specialised cell lineages e.g. Adult Stem Cells )(42, 66).  
Although embryonic stem cells may have a greater differentiation capacity than adult stem 
cells, their clinical application is limited by ethical concerns linked to their isolation and 
potential teratoma formation (in vivo) (1, 42, 62). In comparison, adult stem cells are easily 
sourced from a range of tissues including, bone marrow, blood, brain, liver, muscle, and skin 
potentially forming the basis of a number of therapies such as diabetes, neural degeneration 
and ischemia (62). Table 1.3 highlights the various adult stem cells available. For these 
reasons adult stem cells are the preferred choice in tissue engineering purposes.  
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Table 1.3. Examples of adult stem cells, their location in vivo and their differentiation 
capacity (67). 
Cell Type Tissue Specific Location Differentiation Capacity 
Hematopoietic 
stem cells 
Bone marrow  
Peripheral blood 
Bone marrow and blood 
lymphohematopoietic cells 
Mesenchymal 
stem cells 
 
Bone marrow  
Peripheral blood 
Bone, cartilage, tendon, adipose 
tissue, muscle, marrow 
stroma, neural cells 
Neural stem 
cells 
Ependymal cells, astrocytes 
(subventricular zone) of 
the central nervous system 
Neurons, astrocytes, 
oligodendrocytes 
Skeletal-muscle 
stem cells or 
satellite cells 
Muscle fibres Skeletal muscle fibres 
 
Bone marrow derived MSCs are considered to be the ideal candidate in the development of 
stem cell-based therapies. This is attributed to the well-established, optimised and 
characterised isolation and expansion protocols with proven therapeutic potential associates 
with this cell source (6, 68). 
 
Mesenchymal Stem cells (MSCs) 
MSCs (also known as bone marrow stem cells and  bone marrow stromal cells)  are 
multipotent cells with the ability to differentiate towards tissues of the mesenchymal lineage 
to form osteocytes, chondrocytes and adipocytes both in vitro and in vivo (69-71). More 
recently it has been discovered that MSCs may potentially have greater plasticity than 
originally thought, as demonstrated by their differentiation into neurons, hepatocytes, 
fibroblasts, tenocytes and cardiomyocytes (72, 73).  MSCs reside within specialized 3D 
micro environments (niches) of connective tissues within various tissues (e.g. bone marrow, 
synovium, adipose tissue and umbilical cord) (24, 31, 46, 69). The bone marrow stroma is a 
complex structure housing a variety of cell populations creating the niche for haematopoietic 
stem cells; synergistically the haematopoietic stem cells also create the required niche for 
the bone marrow stromal population (74). Within the bone marrow cell populations, 
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approximately 0.001-0.01% are known to be multipotent MSCs (68). However, similar to 
chondrocytes, donor variability may play a significant role in impacting quality and 
therapeutic potential of cells.  
MSCs do not possess a unique panel of markers that can be reliably and accurately used for 
characterisation purposes, consequently relying on a combination of techniques to 
successfully identify these cells (46, 68, 69, 75). The following criteria have been set by The 
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular 
Therapy. These include;  
 Ability to adhere to plastic when maintained under standard culture conditions (75).  
 Positive expression of:  CD (cluster of differentiation) 73, CD90, and CD105  
 Negative expression of haematopoietic markers:  CD11b, CD14, CD19, CD34, 
CD45, CD79a, and HLA-DR (24, 75) 
 Ability to differentiate to osteoblasts, adipocytes, and chondroblasts (75) 
MSCs have had a significant impact in the field of regenerative medicine as demonstrated 
by the extensive and impressive portfolio of therapies in research today. Examples include 
the use of MSCs to treat myocardium infarction (76), spinal cord injuries and osteogenesis 
imperfecta, with successes being demonstrated in a range of animal studies (68).  
The therapeutic potential and consequent clinical application of MSCs are further governed 
by the release of soluble factors (such as growth factors and chemokines) by MSCs, 
generating a regenerative environment by mediating anti-apoptosis, cell proliferation, 
differentiation of stem cells, mitosis and angiogenesis, immunomodulation, anti-scarring and 
chemo-attractant properties (6, 70). This potential is known as trophic activity (6). The 
factors involved in each of these activities are shown in Figure 1.7.  
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Figure 1.7. Paracrine effects of MSCs highlighting key bioactive molecules secreted 
defining the theraputic properties of MSCs; Immunomodulation, Anti-apoptosis, 
Angiogenesis, Chemoattraction, Antiscarring, Growth and differation (70). 
 
It has been suggested that cell therapies focused on treating cartilage defects should not 
ignore other components of the knee such as bone and ligament, as these are also affected 
by the disease. MSCs can therefore not only address the structural issues (attributed to their 
ability to differentiate towards bone, cartilage and adipose tissues - the tissues of interest ) 
(6) but their immunosuppressive and anti-inflammatory properties enable the inflammation 
and autoimmune aspects of the disease to also be addressed (24). The release of cytokines 
and growth factors such as interleukins (IL)-10, (IL)-6, (IL)-11 and TGF-β (transforming 
growth factor – β) act to inhibit T cells and dendritic cells (77, 78) whilst the secretion of 
soluble antigens such as HLA-g (human leukocyte antigen G) effectively disable natural 
killers and moderate dendritic cell and T cell activity. In addition, secreted 
immunosuppressive enzymes such as IDO (Indoleamin 2, 3-dioxygenase), suppress 
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leukocytes such as B cells (77, 78). The combined secretion of these factors, their role in 
tissue homeostasis and repair (governed by signalling mechanism) (79) and the cartilage 
forming ability of MSCs, provide a trophic regenerative environment, stimulating the 
proliferation and differentiation of tissues to achieve intrinsic repair whilst protecting the 
neo tissue in a localised immunosuppressive manner (6, 77, 78). The immunomodulation 
effects have been shown in vivo in animal models where MSCs have shown success in 
treating grafts versus hosts disease (24, 69, 70). This supports the use of MSCs in cartilage 
tissue engineering as a means of treating OA and RA (6). 
 
1.4. Imaging and Tracking – The Need  
 
The clinical adoption of any cell-based therapy demands the systematic and regulated 
progression from bench to bedside to evaluate and demonstrate the safety and efficacy of the 
proposed therapy before ultimately receiving clinical approval (80).  Animal models are in 
place to not only address safety concerns, but also to assess the efficacy of the therapy. Issues 
related to the extent of tissue integration, migratory patterns post transplantation, dosage 
schemes and optimal delivery route, are primarily addressed with the implementation of 
relevant animal models (19, 36).  These questions are central to a wide range of cell based 
therapies, the answers to which are vital in the assessment of the risks and success rates of 
the therapy whilst optimising the therapy’s potential and are of key importance to the 
regulatory bodies (such as the Food and Drug Administration; FDA)(80). These studies can 
fundamentally offer an insight into the short and long term survival of the cells, rate of repair, 
and the number of cells remaining or migrating to/from the desired location (bio-
distribution). With this data, physiological repair mechanisms can be better understood 
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which allows for delivery methods and dosage schemes to be fully optimised (81), therefore 
enhancing therapeutic potential (82). 
Traditionally, gathering such data has been performed by carrying out histological and 
immuno-histochemical tests (83-85). This is highly invasive, as a biopsy of the tissues of 
interest needs to be taken (86) and often demands the euthanization of animals to collect 
tissue samples for assessment. Furthermore, continuous and repetitive long term follow up 
of animals is impossible, therefore high numbers of animals are required to thoroughly 
investigate all parameters to make statistically significant conclusions (83, 86, 87). The 
initiative in place by NC3Rs aims to reduce, refine and replace the number of animals used 
in research. This highlights the need for a non-invasive means of accurately and reproducibly 
evaluating in vivo events occurring post-implantation to evaluate the success and risks of the 
given therapy (86, 88, 89).  
A range of non-invasive clinical imaging modalities are currently available and possible 
candidates to image and track stem cell populations in vivo. These include, Magnetic 
Resonance Imaging (MRI), Magnetic Resonance Spectroscopy (MRS), Positron Emission 
Tomography (PET), Single Photon Emission Computed Tomography (SPECT), 
Bioluminescence Imaging (BLI) and X-ray based computed tomography (CT). However, 
there are pros and cons associated with each of the mentioned imaging modalities for cell 
tracking applications. MRI for example, suffers from low sensitivity but benefits from high 
resolution, i.e. 25-100 µm (90). On the other hand, SPECT, PET and BLI have higher 
sensitivity but unfortunately much lower resolution when compared to MRI (1-2 mm) (90). 
Furthermore, MRI is traditionally linked to the use of FDA approved iron based magnetic 
nanoparticles (SPIONs) contrast agents, which endeavour to improve the sensitivity of the 
technique without the exposure of ionizing radiation (as is the case for SPECT, CT and PET) 
(91). Its non-invasive nature, coupled with the rapid and repetitive acquisition of images (92) 
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and the ability to distinguish between soft and hard tissues at high contrast, makes MRI a 
very powerful clinical diagnostic tool (93) and a highly suitable candidate for the imaging 
and tracking of implanted cell populations in vivo. (84).  
It is thought that superparamagnetic iron oxide nanoparticles (SPION) can be employed in 
conjunction with the use of magnetic resonance imaging (MRI) to track implanted cells in 
vivo (94, 95). In essence, stem cells are encouraged to internalise SPION; in this way, 
implanted cells can be distinguished against host cells/tissues when MR imaged, facilitating 
the identification and tracking of cells in vivo when imaged by MRI (Figure 1.8)  (96). The 
non-invasive imaging and tracking of implanted cells in vivo requires the labelling of cell 
populations with suitable SPIONs at significant quantities to allow implanted cells to be 
distinguished against host cells/tissues (97). It is essential to select biocompatible label e.g 
SPIONs that do not interfere with the basic function of the cell and in turn also not affect 
any aspects of stem cell differentiation (95). With this a great deal of in vivo information can 
be gathered and therapies optimised, not only for arthritic cases but for a large portfolio of 
cell based therapies (89). 
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Figure 1.8. Schematic highlighting the principle of in vivo cell imaging and tracking 
with the application of MRI and SPIONs, image modified and adapted from (86). 
 
Early SPION-based tracking studies involved the intravenous administration of SPIONs 
which were subsequently taken up by various cells such as macrophages. The migratory 
patterns and location of labelled macrophages were easily identified as hypointense regions 
of signal loss on MRI images (98)(97). This proved particularly useful in the in vivo 
evaluation of inflammatory disease models. For example, areas of liver damage were 
identified by the lack of hypointense regions on MR images, implying that the damaged 
structure of the liver prevented the infiltration of labelled Kupffer cells (specialised 
macrophages) (98)(97). Other examples include the monitoring, biodistribution and activity 
of macrophages in rat and mouse models of autoimmune encephalomyelitis as well as 
models of ischemia renal damage. Beckmann et al  demonstrated using SPION and MRI 
technologies, the ability to monitor the infiltration of macrophages into a rat knee of antigen 
induced arthritis (99). Finally, this technology has also been implemented in the visualisation 
of organ engraftment or rejection where a good correlation was found with hypointense 
signal (signifying macrophage infiltration) and graft rejection (100). The practicality and 
usefulness of these studies encouraged the utilisation of MRI and SPION based in vivo 
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molecular imaging in regenerative medicine and tissue engineering applications in order to 
evaluate aspects of cell migration and tissue integration. Stem cell-based therapies primarily 
involve the implantation of stem cell populations within the body, which in contrast to the 
above studies require the labelling of cell populations in vitro as opposed to in vivo (97). 
Since the development of in vivo labelling strategies, small animal in vivo tracking studies 
have been developed (101). Table 1.4 summarises some of the recent SPION and MRI based 
tracking studies in tissue engineering and regenerative medicine.  
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Table 1.4: Recent SPION and MRI based Studies.  
Study Tracking 
system  
Cell Type Particles Size of 
particle 
Concentration  MRI Results Ref 
Tracking the 
delivery and 
engraftment of 
MSCs in 
tumours 
In vivo; 
Rat 
MSC FluidMag 200 nm 0.5 mg/ml 9.4 T Efficient uptake of particles. 
MSC characteristics maintained. 
Proliferation not affected,  
1000 cells visualised at 28 days  
 (102) 
Tracking 
autologous 
MSC in knee for 
ACI 
In vivo; 
Rabbit 
MSC Endorem 150 nm 25 µg/ml 1.5 T  Labelled cells can be visualised by MRI 
Autologous MSC not located within defect  
MSC characteristics maintained,  
Proliferation not affected 
(83) 
Tracking 
autologous 
MSC in knee for 
ACI with 
microsized iron 
oxide particles; 
Defect size 
5mm x 9 mm 
Ex vivo; 
Bovine 
knee 
 
MSC Unknown 1630 nm 2.8  µg/ml 3 T  Efficient uptake of particle by cells 
MSC characteristics maintained,  
Proliferation not affected 
MPIO visualised in the defect  
Effect of MPIOs in chondrogenic 
differentiation showed that pellet did form 
but aggregation of Fe in pellet hinders ECM 
visualisation  
(103) 
Tracking  MSC 
injected into the 
heart 
In vivo; 
Mini pigs 
MSC Resovist  60 nm 25-400 µg/ml 1.5 T Cell growth and viability not affected by Fe 
concentration 
 
(104) 
Detectability of 
labelled MSC 
and gene 
expression 
In vitro;  
Agarose 
gel  
MSC Resovist vs  
Endorem  + 
transfection 
agent 
60 nm 
and 150 
nm 
12.5 µg/ml 
 
 
1.5 T More efficient uptake of particles with 
Feridex than Resovist 
Feridex had greater signal loss implying 
better detectability by MRI. 
Proliferation not affected by either particle. 
Particles lost one week after loading due to 
dilution effect 
Change in expression of Oct -3/4 and CD 45 
of labelled cells 
(105) 
Investigating the 
detectability of 
chondrocytes 
In vitro;  
Hollow 
Chondrocytes Endorem + 
transfection 
agent 
150 nm 25 µg/ml 
bioreactor 
9.4 T Chondrocytes can be labelled efficiently and 
imaged  
No negative effect on chondrogeneic genes. 
(96) 
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within tissue 
engineered 
scaffold 
fibre 
bioreactor,  
Hydrogel   
67 µg/ml 
Hydrogel  
 
Tracking MSC 
in liver cirrhosis 
model 
In vivo; 
Rats 
MSC Ferrite core 
Silica shell 
and 
fluorescent 
material 
(name 
unknown) vs 
Feridex 
Informati
on not 
available 
100 µg/ml  
 
3 T  
 
 
Labelled cells could be seen in the liver 
No significant difference between Feridex 
and Silica labelling 
(106) 
Assess the 
effect of SPIO 
labelling on 
adult human 
chondrocytes 
behaviour 
  
 
In vitro; 
Alginate 
Chondrocytes Endorem 
  
150 nm 168 µg/ml Ex vivo  
3 T 
Cells 
suspen
ded in 
alginate 
Inserting 1000 cells in a defect 4mm in size, 
could not be detected. However, when 10 
000 and 100 000 cells were implanted, clear 
signals were observed and easily 
distinguishable from surrounding cartilage 
This shows how MRI can be used to 
investigate the number of cells required for a 
successful therapy. 
(107) 
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1.5. Nanoparticles 
 
In recent years, nanoscale materials have been the focus of much research in regenerative 
medicine and tissue engineering. Nanoscale materials in the forms of nanoparticles, 
nanofibers, and nanotubes have been fabricated and specifically tailored to suite their role 
and function in the development of cell based therapies and tissue engineering strategies 
(108).  
Of particular interest are nanoparticles due to their unique, electronic, optical, and magnet 
properties. Nanoparticles are organic or inorganic materials with three external dimensions 
at equal nanoscale (109). Their specific size and dimensions allow them to be accurately 
manoeuvred and targeted to a specific biological entity or biological component (110) and 
interact on a cellular (10-100 μm), subcellular (20-250 nm), protein (3-50 nm) or genetic 
scale (10-100 nm) (111, 112). This facilitates a broad range of applications in the biomedical 
field in terms of cell isolation, drug delivery, diagnostics (MRI), cellular imaging and 
magnetic hyperthermia (111, 112). Examples of nanoparticles include liposomes, quantum 
dots, polyplexes, magnetic nanoparticles (MNPs) (86, 113) and carbon-based nanoparticles 
(114). MNPs in particular have a multifunctional role within the field of regenerative 
medicine and tissue engineering where they can be used in the tagging, tracking (115) and 
activation of stem cells with significant implications in cartilage tissue engineering (116-
118). 
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1.5.1 Magnetic Nanoparticles (MNPs) 
Magnetic nanoparticles are principally magnetic materials with three dimensions of equal 
nanoscale.  Various materials can be used to convey the magnetic properties of MNPs such 
as nickel, cobalt and iron. It has been found that cobalt and nickel are toxic to biological 
entities effectively eliminating their biomedical application while iron based particles are 
considered safer for biomedical use (119, 120). Figure 1.9 illustrates the structure of a 
magnetic nanoparticles.  Improved biocompatibility and handling is achieved by coating the 
magnetic core with a variety of organic (fibronectin, polysaccharides) and inorganic (silica 
and gold) polymers (119). The biocompatibility minimises the risk of toxicity as a result of 
being in indirect contact with the metal core, whilst offering a platform to further customise 
the particle for specific applications (121, 122). Surface coating can be functionalised in 
terms of; charge, protein binding capacity and biomolecules (118). This encourages 
enhanced interaction with biological entities with minimal toxic effects (111, 123). The 
nature of the polymer coating and the consequent modifications determine the ultimate 
physical and biological properties of the particles such as the size, charge, toxicity and 
degradability (91). This dictates the success of the chosen application demonstrating how 
important particle characteristic choice is. The versatility of MNP means that they can be 
tailored to specific purposes and so this opens up an enormous range of potential applications. 
In the field of nano-medicine, MNPs have been utilised for applications such as targeted 
gene/drug delivery, hyperthermia treatment of tumours, or stem cell tracking by MRI (124). 
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Figure 1.9. Structure of a magnetic nanoparticle. 
 
The behaviour of a MNP within an applied magnetic field is governed by the magnetic 
properties of the particles and can be categorised according to their susceptibility to the 
application of an external magnetic field (125). In general, magnetism observed in nature is 
categorised by the orientation of the magnetic moments and can be defined as: a) 
diamagnetic, b) paramagnetic, c) ferromagnetic, d) antiferromagnetic and e) ferrimagnetic. 
Diamagnetism is considered a very weak type of magnetism displayed by all materials (126) 
while paramagnetic substances are only magnetised when exposed to a magnetic field. On 
the other hand, ferromagnetic or ferrimagnetic materials remain magnetised even after the 
magnetic field has been removed (119). Importantly, ferromagnetic materials develop 
paramagnetic properties as they decrease in size to approximately 20 nm in diameter (110, 
127). This implies that once the magnetic field has been removed, the particles are no longer 
magnetic but still maintain a high magnetic saturation magnetism. This is known as 
superparamagnetism. For the biomedical application of MNPs, particles exhibiting 
superparamagnetic properties are preferred as this implies that the particles will not be 
attracted to each other and so the risk of agglomeration in a medical setting is minimised 
(128, 129).  
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1.5.2 Superparamagnetic Iron Oxide Nanoparticles (SPIONs) 
SPIONs are a specific class of magnetic nanoparticle, which are well known for their 
application as a T2 weighted MRI contrast agent (130). They are typically composed of either 
a magnetite (Fe3O4) or maghemite (γ-Fe2O3) core (125, 131), both of which are ferrimagnetic 
in nature. However, as they decrease in size below 30 nm, they lose their permanent 
magnetism and become superparamagnetic (109). These cores can then either be coated with 
a biocompatible polymer as described previously (121, 132), or precipitated through a larger 
porous polymer hence generating overall larger particles (greater than 30 nm in diameter) 
whilst maintaining superparamagnetic properties (Figure 1.10) (125, 133). Alternatively, the 
larger nanoparticles may be generated by controllably aggregating nanoparticles. SPIONs 
can be further categorised by size although there is no clear consensus as to the specific size 
range making up each class. However, as a general indication, ultrasmall superparamagnetic 
iron oxide nanoparticles (USPION) are below 50 nm in diameter; SPIONs are hundreds of 
nanometers in diameter and micron-sized MNPs are (MPIO) >1 μm (134). For the purpose 
of this thesis, the term SPION will be used to refer to iron oxide nanoparticles with 
superparamagnetic properties of all sizes.  SPIONs are particularly suited in their application 
as MRI contrast agents given their biocompatible nature and ability to generate significant 
contrast with little risk of in vivo agglomeration (97, 120, 129, 135). This highlights the 
potential use of SPIONs to image and track stem cell population in vivo using MRI 
technologies.  
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Figure 1.10. SPIONs demonstrating the size and distribution of superparamagentic 
iron cores within biocompatible polymers to generate UPSIONs and MPIOs.  
 
The use of FDA approved SPIONs are particularly attractive in the implementation of MRI 
based tracking protocols. Endorem (also referred to as Feridex) and Resovist are all 
examples of FDA approved, iron-based MRI contrast agents which have been used to image 
and track cells by MRI in recent years (125, 136). However, these particles have recently 
been removed from the market (125, 137) and alternative particles have been investigated 
for biomedical application such as cell tracking purposes. Based on the intended application 
of these particles, a list has been devised stating the properties that a SPION should have, 
before being considered for cell tracking purposes. The commercial market for SPIONs is 
both large and extensive (119) and therefore, commercially available particles may also be 
suitable for biomedical applications as long as the particles comply with the below list.  
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PROPERTIES OF SPIONS FOR BIOMEDICAL APPLICATIONS (133) 
1. Low toxicity 
2. Biocompatible  
3. Chemically stable in physiological conditions 
4. Biodegradable 
1.6. SPION labelling of cell populations 
 
SPION labelling of cell populations is a necessary prerequisite in the imaging and tracking 
of cell populations by MRI. Intracellular and extracellular approaches have been suggested 
as a means of SPION cell labelling (82, 138, 139) (Figure 1.11). The ability to functionalise 
the surface of SPIONs with various ligands (such as; small molecules, antibodies or specific 
proteins) allows for SPIONs to be specifically targeted to various cell surface receptors or 
ion channels and encourage extracellular labelling (118, 124).  Alternatively, cells can 
actively internalise SPIONs within the cell cavity resulting in intracellular labelling. The 
general mechanism of internalisation in non-phagocytic cells (such as stem cells) is believed 
to be endocytosis with this specifically been divided into the following categories; clathrin-
mediated endocytosis, caveolaemediated endocytosis, macropinocytosis,  phagocytosis and 
receptor mediated endocytosis (86, 91). This technique results in the intracellular 
accumulation of SPION and is shown in Figure 1.11.   
Internalisation is more suited for in vivo tracking as this approach results in increased iron 
concentrations improving the detectability of detecting implanted cells in vivo whilst also 
increasing the resolution of the image (86, 95). Furthermore, SPION internalisation 
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facilitates long term monitoring of implanted cell populations as SPIONs are less likely to 
be dissociated from the cells in the early stages of labelling and tracking (103, 123). However, 
internalisation is limited by the dilution of the SPION label during the proliferation and cell 
division of cells or via the physical removal of the particle by exocytosis. The rate of 
internalisation depends on a number of factors including, cell type, particle size, 
hydrophobicity, surface charge of particle polymer and the rate of cell proliferation (118). 
This method tends to be time consuming and is limited to cells that have a high degree of 
phagocytosis (140). Cells exhibiting a low degree of phagocytosis may require prolonged 
incubation for the efficient internalisation of SPIONs. This may be undesirable, as extended 
culture could impair the potency of the cells or redirect differentiation towards an unwanted 
lineage (141). The use of transfection agents (TA) can be employed to increase labelling 
efficiency in a shorter period of time, as they can form complexes with SPIONs, therefore 
increasing uptake by phagocytosis (98, 123). Examples include poly–L-lysine, protamine 
and cationic liposomes (140).  In a study by Kostura et al it was found that Feridex- poly-
L–lysine inhibited chondrogenesis; however, this was not found with Feridex – protamine 
(142, 143). Thus the effect of the TA must be investigated further as it could interfere with 
the activities of the cell (144). To overcome these limitations incurred by internalisation and 
the use of TA, a technique known as “magnet electroporation” has been introduced (137). 
Essentially, a magnetic field is used to induce the accumulation of the contrast agent in the 
cytoplasm of the cell by increasing membrane permeability (140). This eliminates the need 
for transfection agents (TA) but unfortunately this is considered somewhat damaging to cells 
(137). Past studies demonstrated the ability of SPIONs to be taken up by a wide variety of 
cells by simple incubation, these included; fibroblasts, lung cells, liver cells, stem cells, 
kidney cells, macrophages, nerve cells, endothelial cells and various cancer cells lines (109). 
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Figure 1.11. Schematic highlighting intracellular and extracellular cell labelling. 
Intracellular labelling involved the internalisation of SPION via various endocytic 
mechanisms; clathrin-mediated endocytosis, macropinocytosis, phagocytosis and 
receptor mediated endocytosis. Extracellular labelling involves the attachment of 
SPION to various integrin receptors or ion channels aided by the functionalization of 
particles with specific biomolecules.  
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1.7. Toxicity 
 
When considering SPION for any biomedical application, the toxic nature of the particles 
must be considered (145). SPIONs are considered to be inert and biocompatible given the 
nature of iron (146). Iron is a naturally occurring element in the human body (ferritin) 
playing an important role in cellular metabolic processes such as DNA synthesis, oxygen 
transport, and redox reactions (117, 147). The body is therefore adapted for iron metabolism 
and thus labelling cells with SPIONs is not likely to affect biological properties of cells (147). 
However, in high quantities and in various oxidation states, Fe can possibly impair cell 
viability by damaging cell membranes, causing morphological changes in proteins and DNA 
(105, 147). This can have adverse effects on cell viability, proliferation, metabolic activity 
and impair the therapeutic efficiency of the therapy (148, 149). Iron is found in two main 
oxidation states; Fe (II) and Fe (III). Fe (II) is thought to be the main source of cellular 
damage as a direct consequence of free radical generation (150). At the cellular level, 
oxidative stress is thought to be the main cause of toxicity by MNPs. Oxidative stress arises 
when there is an imbalance between damaging oxidants also referred to as reactive oxygen 
species (ROS) such as hydrogen peroxide, hydroxyl radicals, and the protective antioxidants 
of which vitamin C and glutathione are examples. ROS are primarily formed by the 
incomplete reduction of oxygen. The accumulation of oxidants eventually leads to 
destruction of cellular proteins, enzymes, lipids, and nucleic acids, and as a consequence the 
normal cellular processes become impaired leading to the development of diseases and cell 
apoptosis and necrosis (117).  Therefore, it is important to obtain a balance between Fe 
incorporation for the required role and cell function (105). Labelling stem cells for this 
application, therefore demands the preservation of physiological cellular properties and the 
retention of SPIONs over prolonged periods (140).  
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The toxicity of SPIONs on biological entities is highly dependent on a range and  
combination of factors related to the properties of the SPION itself as well as structural 
properties, dosage and the intended use are also among dominating factors (148, 151). The 
chemical composition of the particles themselves can be naturally toxic. Additionally, the 
location of SPIONs in relation to the cells is an extremely important consideration (148). 
For instance SPIONs could invoke a cytotoxic response when internalised by potentially 
interfering with the biological function of the cells but not when attached to the cell 
membrane (123, 148). However, in other cases, SPIONs attached to the surface of cells, may 
interfere with cell surface interaction (123). Furthermore, the physical properties such as the 
particle size, shape and surface coating can also evoke a toxic response by aggregating and 
coagulating according to size and shape (148, 151).  When addressing the possible in vivo 
application of SPION, it is equally important to consider the fate of the SPION after they 
have been released by the cells. Further issues arise when considering the degradation of the 
SPION and the outcome of accumulated SPION or SPION by-products in various tissues 
and organs (109).  Degradation products are thought to possibly react with various 
components of the body or cells. Therefore, the  effects of the breakdown products on the 
surrounding tissue should be fully investigated (98, 109).  
Many investigations have assessed the effect of labelling cells with SPIONs on the viability, 
proliferation and differentiation of stem cells (138). Majority of the studies have reported 
that SPIONs are frequently non-toxic to stem cells and do not affect differentiation (142, 
152). Balakumaran et al reported that the use of SPIONs as tracking agents for MSCs in no 
way interfered with their multi-lineage differentiation potential towards adipogenic, 
chondrogenic and osteogenic lineages (153). Table 1.5 highlights the range of studies and 
the finding on SPION toxicity.  
                                 Chapter 1- Literature Review                                                                                 
51 | P a g e  
  
Table 1.5 Summary of in vitro studies performed in recent years highlighting commonly used assays aimed at investigating toxicity of 
SPIONs on stem cells and the findings. 
Particle  Coating Size Cells  Concentration Toxicity Assay Result Ref 
Feridex  Dextran 80-150 
nm 
MSC 
(human, 
rat, 
mouse) 
ESC 
(Embryo
nic stem 
cells ) 
25-250  µg/ml Live/dead (7 days post labelling)  
Comet assay 
FACS to evaluate cell death 
Trypan Blue 
No loss of cell viability 
observed after 7 days 
with or without either 
TA 
(136) 
(106) 
(92) 
(154) 
Non 
commercial 
Silica 110 nm hMSCs 200 µg/ml MTT ( 1 hr and 24 hrs) 
Trypan Blue 
No reduction in viability 
after 1 hour. No 
reduction in cell 
proliferation.  
(148) 
Iron 
fluorescent 
particle 
Polystyrene  900 nm Porcine 
MSC 
Unknown Trypan Blue, MTT 
Morphological observations 
Cells maintained 
viability and retained 
label for up to 3 months. 
Differentiation capacity 
not altered.  
(155) 
Manganese 
oxide 
nanoparticles 
Mesoporous silica 65 nm mMSCs Unknown MTT 
 
75 % cell viability 
Limited cell 
differentiation in the 
osteogenic lineage.  
(156) 
Unknown HEDP 
(hydroxyethylide 
bisphosphonic 
acid) 
n/a rMSC 25,  50, 100  
µg/ml 
MTS Cell viability not affected 
at lower concentrations 
but viability decreased to 
70 % at 100 µg/ml 
(157) 
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1.8. MRI 
 
Magnetic Resonance Imaging (MRI) is a clinically relevant imaging modality capable of 
distinguishing between healthy and diseased tissues aiding in the diagnosis of a wide range 
of diseases (130, 158). MRI has rapidly revolutionised the medical diagnostics field with its 
conception dating back to the early 1970`s. The system rapidly developed through the 1980s 
with the first 0.15 T clinical scanner being installed at the Hammersmith Hospital, London. 
By 1996, there were over 10 000 scanners worldwide (130). Today, it is not uncommon to 
find 1.5 and 3 T (tesla) MRI scanners in every hospital (159) whilst 4.7, 7.4, 9 and 11 T  
(160) are being used throughout research labs. MRI permits tracking of implanted cell 
population, whilst still monitoring the surrounding anatomical structures. This is particularly 
useful for the clinician as information on the pathology of the surrounding tissue is a major 
issue when assessing the success of the therapy (82). MRI scanner strength significantly 
influences resolution and contrast, not only defining MRI detection thresholds but also 
defining the quality of images and the extent to which information can be gathered. In 
general, higher strength scanners (similar to those used in research; 4.7, 7, 11.7 T) offer 
better contrast, resolution and specificity (130).  These are all highly attractive qualities in 
the evaluation of cellular therapies in vivo (161). Such resolution however is difficult to 
achieve in clinical grade scanners (1.5 T). Therefore, scanner strength must be carefully 
considered when devising tracking protocols for clinical therapies as it is unlikely that 
resolution achieved in research (4.7, 7, 11.7 T) will be maintained clinically (1.5, 3 T). It 
must also be noted that in addition to scanner strength, SPION properties and total 
intracellular Fe content also impact the detection threshold of implanted cells in vivo.  
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1.8.1 Equipment 
An MRI scanner consists of the follows components (Figure 1.12);  
a) Magnet: produces a strong constant magnetic field. In standard clinical MRI grade 
scanners, superconducting magnets are primarily used with the magnet field present 
at all times. The strength of an MR system is expressed in terms of its magnetic 
strength for example 1.5 T and 3 T where T (tesla) is a unit of magnetic flux (130). 
b) Radio frequency (RF) transmitter coil. This generates the RF pulses that excite 
protons, therefore producing a signal, which can be detected. These are commonly 
built into the magnet although organ specific coils such as knee and head coils are 
also available (130). 
c) RF receiver coil. This detects the MR signal produced by the body in response to 
the RF pulse (130). 
d) Gradient coils. Localisation of the MR signal in the body to produce images and 
controls the pulse sequence in all three directions (x, y and z) to produce a gradient 
field (130). 
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Figure 1.12. Components of an MRI scanner. 1) Magnetic Shield, 2) Magnet 
(commonly superconducting in clinical grade scanners), 3) Gradient Coil and 4) RF 
coil.  
 
1.8.2 Theory 
It is important to understand that MRI is a technique primarily sensitive to protons associated 
primarily within the hydrogen atom of the water and fat molecules. These protons are 
positively charged and are in a constant spin motion spinning about their axis effectively 
generating a small magnetic field Figure 1.13 a. In the presence of an external magnetic field, 
the protons align themselves either with (parallel) or against (antiparallel) the direction of 
the applied magnetic field with opposing moments cancelling out resulting in a net magnetic 
moment Figure 1.13 b. While protons are in alignment, they precess, (following a similar 
motion to a spinning top) Figure 1.13 c with the speed of precession known as the precession 
frequency (Lamor frequency) and is dependent on the strength of the magnetic field. The 
stronger the magnetic field, the faster the precession rate (130, 157) 
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Figure 1.13. Behaviour of protons. A) Proton alignment in a random fashion in the 
absence of a magnetic field. B) Alignment of protons either parallel or anti-parallel to 
the external magnetic field. C) Precession of protons within a strong magnetic field. 
Adapted from Schild et al, 1990 (158) 
 
A person develops a net magnetic charge when placed into the MRI scanner. The magnetic 
moments of the body are aligned with the main field of the MRI scanner (permanent magnet) 
typically the longitudinal or z axis. During scanning, a RF pulse is applied to disrupt the 
alignment of the protons causing the protons to move from the z axis (longitudinal axis) to 
the y axis (transverse axis). This allows for the magnetization of the body to be measured 
(130, 158) and as a result, a signal is created. Once the RF pulse is removed, the 
magnetization reverts back to its equilibrium or relaxes either via spin lattice or spin-spin 
relaxation. Spin lattice relaxation controls the growth of magnetization along the z axis and 
is known as T1 or longitudinal relaxation (Figure 1.14 Aii). Spin- Spin relaxation, controls 
the decay of the signal in the transverse plane and is known as T2 relaxation (Figure 1.14 Ai) 
and is attributed to the dephasing of protons in the transverse plane. Each tissue will have its 
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own characteristic proton density, T1 and T2 values, which all contribute to the image (Figure 
1.14 B). However, by controlling various parameters the contrast of the image can be altered 
to be dependant of just one of the parameters, i.e T1 or T2 weighted contrast where contrast 
is dependant mainly on T1 or T2 relaxation respectively. All MRI images are produced using 
pulse sequences. These sequences are made up of radiofrequency pulses and gradient pulses 
which all have very specific durations, timing and flip angles. These parameters can be 
altered depending on the imaging required. The simplest MRI sequences begins with the 90o 
pulse which knocks the magnetization from the z-axis to the y-axis. There are a great deal 
of MRI sequences available and are most commonly referred to by acronyms. Table 1.6 
highlights some of these acronyms (130).  
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Figure 1.14. T1 and T2 relaxation profiles. A) General relaxation profiles demonstrating 
i) decay curve significant of T2 relaxation and ii) build up curve significant of T1 
relaxation. B) Comparative i) T2 and ii) T1 and relaxation profiles for various tissues 
where white matter refers to the white matter in the brain and the CSF, the 
cerebrospinal fluid. Adapted from (130, 157, 160). Red dashed line demonstrates the 
variation of T1 and T2 values for the different tissue types at a time (t).  
 
Table 1.6. Commonly used MRI Pulse sequence acronyms (130) 
 
 
 
 
 
 
FSE Fast Spin Echo 
RARE Rapid Acquisition with Relaxation Enhancement 
GE Gradient Echo 
FLASH Fat Low Angle Shot 
FISP Fast Imaging With Steady State Precession 
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1.8.3 Contrast Agents 
Contrast agents are applied to aid in the diagnosis of several pathologies where contrast is 
defined as the relative difference in the signal intensities between two adjacent regions. 
Therefore, contrast agents work to enhance the differences between normal and diseased 
tissues by modifying the intrinsic parameters of the tissue. It must be noted that it is the 
effect of contrast agents on the surrounding tissues that we primarily see, not the contrast 
agent itself.  Contrast agents improve the visibility of internal structures by modifying 
relaxation time of protons in the tissue where they accumulate, causing changes in the MR 
signal intensity and consequently imaging contrast. Contrast agents induce shortening of 
relaxation time in either T1 (longitudinal) or T2 (transverse) and exhibited by the shift in the 
relaxation curves (Figure 1.15; denoted by the arrow) (162). Contrast agents are further 
classified as either positive contrast agent or negative contrast agents. Positive contrast 
agents are paramagnetic compounds such as Gadolinium and are used in the clinic as 
extracellular hepatobiliary or blood pool agents by shortening T1. Therefore, tissue/organs 
incorporating these agents appear bright in T1 weighted sequences (159). Negative contrast 
agents are superparamagnetic iron oxide compounds and are applied clinically in order to be 
used as blood pool agents for the diagnosis and imaging of organs such as the liver. T2 
contrast agents work by influencing the relaxation of the protons in the water molecules in 
the near vicinity of the agent. These compounds therefore cause a shortening of T2 causing 
tissues to appear dark in T2 weighted sequences. The magnetic field of the contrast agent 
effectively perturbs the nuclear spin relaxation process of the protons leading to shortening 
of T2 of the protons affected (163). Contrast is dependent on the combination of a variety 
factors; these include intrinsic factors such as proton density and extrinsic factors such as; 
the type of pulse sequence, timing parameters, and the strength of the magnetic field (159).  
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Superparamagnetic iron oxides agent are generally preferred over Gadolinium based contrast 
agents as labelling agents due to their overall better T1 and T2 relaxivity properties, implying 
that contrast can be created at lower concentrations.  (97, 130, 134, 164).  
 
 
Figure 1.15. Schematic illustration demonstrating the effect of MRI contrast agent on 
T1 and T2 weighted MRI scans. The presence of a MRI contrast agents cause the 
shortening of T1 and T2 (shown by the arrow) resulting in decreasing signal for T2 and 
increase in signal for T1 weighted scans.  
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1.9. Multifunctional Application of SPIONs in Regenerative 
Medicine 
 
The use of SPIONs has a multifunctional role in regenerative medicine and can be used for 
the tracking, targeting and activation of stem cells both in vitro and in vivo and these aspects 
are explored in greater detail. 
 
1.9.1 Targeting of Magnetically Labelled Stem Cells 
Incorporating SPIONs into cells allows for non-contact manipulation of cells using an 
external magnetic field gradient. This can be used to precisely position or target the cells to 
the site for regeneration or repair (165, 166), which is a powerful, non-invasive tool in stem 
cell therapy (167, 168). This technology has been applied in the vascularisation of various 
tissues by endothelial progenitor cells (EPC). Attaching magnetic particles to these cells 
displayed no affect on differentiation or proliferation of the cells, and also did not alter the 
membrane proteins which are essential for vascularisation (169). It is thought that attaching 
magnetic particles to EPCs can help in localised cell based therapies as vascularisation is 
essential for tissue formation. Thus, directing these cells from a distance with an external 
magnetic field to areas that require vascularisation can enhance the regeneration/repair of 
damaged tissues. Therefore, the targeting of cells to a specific site and monitoring their 
behaviour in a model system can be examined and translated to in vivo studies (167). 
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1.9.2 Guided Differentiation of Stem Cells using SPIONs 
Mechanical stimulation can be used to facilitate cell proliferation, differentiation and 
migration of stem cells (170). Physical forces include; fluid flow, axial compression, tension, 
and magnetism (116). Biological responses are achieved through the process of  
mechanotransduction, whereby cells convert physiological mechanical stimuli into 
biochemical signals to activate the biological response (171). Using SPIONs functionalised 
with antibodies or peptides, it is possible to attach SPIONS to specific mechano-sensitive 
cell surface receptors and ion channels. This has been shown to result in membrane 
polarisation, receptor activation and subsequent downstream second messenger signals in 
hMSC (172). Using this technology it has been possible to promote an osteochondral 
phenotype of hMSC and human osteoblasts in response to magnetic activation using an 
external oscillating magnetic field (173, 174). 
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1.10 Thesis Aims and Objectives 
 
The overall aim of this project is to develop and implement a non-invasive means of imaging 
and tracking implanted cell populations in vivo with arthritis as the main focus. This imaging 
and tracking modality relies on the combined use of (SPIONs) and magnetic resonance 
imaging (MRI). Through this work it is anticipated that cellular bio-distribution, integration 
and tissue regeneration can potentially be evaluated.  
The specific aims of this thesis are to: 
 Identify a suitable SPION that can be used to label MSC and chondrocytes 
populations 
 Establish and optimise a SPION based labelling protocol 
 Evaluate cellular functions as a result of SPION labelling 
 Investigate MRI visibility threshold in both in vitro and ex vivo environments 
 Apply the developed labelling protocol to animal tracking study.
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2.1 General Cell Culture  
 
Human mesenchymal stem cells (hMSCs), murine mesenchymal stem cells (mMSCs) and 
porcine chondrocytes were cultured and expanded under standard cell culturing practice with 
cells receiving total media changes with their relevant media every 2-3 days and passaged 
when 80-90 % confluent. Incubation conditions were as follows; 5% CO2 and at 37 
oC. All 
activities took place within a class II Biological Safety Cabinet under sterile conditions.  
 
2.1.1 Cell Isolation  
2.1.1.1 Human Bone Marrow Derived Mesenchymal Stem Cells. 
Human MSCs were directly isolated from human bone marrow aspirate (Donor Details; 20 
year old Caucasian male) (Lonza, UK). Flasks (T75) were coated with fibronectin (Sigma-
Aldrich, UK, cat # F0895; 10 ng/ml; prepared in PBS) and incubated at room temperature 
for 1 hr. Bone marrow aspirate was then seeded (mononuclear cell density of 1.5 x103 
cell/cm2) in 15 ml isolation media comprising of low glucose (1 mg/ml) DMEM (Lonza 
Biowhittaker, UK Cat # BE12-614 ) supplemented with 10 % Fetal Bovine Serum (FBS; 
Lonza Biowhittaker, UK Cat # DE14-801F), 1 % L-Glutamine (Sigma-Aldrich, UK Cat # 
G7513) and 1 % Penicillin/Streptomycin (Sigma-Aldrich, UK Cat# P4333). Cells were then 
cultured in hMSC isolation media for one week. After this period, a 50 % media change with 
hMSC isolation media was performed followed by a 100 % media change one week later to 
hMSC proliferation media (high glucose (4.5 mg/ml) DMEM (Lonza Biowhittaker, UK Cat 
# BE12614F) supplemented with 10 % FBS, 1 % L-Glutamine and 1 % 
Penicillin/Streptomycin). hMSCs were identified as those which had adhered to the tissue 
culture vessel after 14 days in culture. Adherent hMSCs were then cryopreserved using 
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freezing down media (90 % FBS; 10 % DMSO) at approximately 5x105 cells/ml or expanded 
up until passage 3 for subsequent experiments.  
 
2.1.1.2 Murine Bone Marrow Derived Mesenchymal Stem Cells. 
Murine mesenchymal stem cells (mMSCs) were isolated from BALB/c mice as described 
by Chamberlain et al (175). Femurs and tibia’s were flushed to remove and isolate bone 
marrow cells. Cells were subsequently plated and cultured in mMSCs isolation media 
consisting of RPMI-1640 (Lonza, UK Cat # BE12-702F) media supplemented with 9 % FBS, 
9 % horse serum (Gibco, Life technologies, UK) Cat # 26050088), 1 % L-Glutamine and 1 % 
Penicillin/Streptomycin and incubated in standard conditions 5 % CO2 and at 37 
oC for 24 
hrs. Non-adherent cells were then removed and adherent cells cultured for a further 4 weeks 
at which point cells were re-plated at a seeding density of 100 cells per cm2 in proliferation 
media (IMDM  media (Gibco, Life technologies Cat # 211786) supplemented with 9 % FBS, 
9 % horse serum   1% L-Glutamine and 1 % Penicillin/Streptomycin for mMSC expansion. 
 
2.1.1.3 Porcine Chondrocytes 
Chondrocytes were isolated from porcine articular knee cartilage (Staffordshire Meat 
Packers, Stoke-on-Trent, UK) two hours post slaughtering based on a technique adapted 
from Hayman et al (23). Cartilage was carefully removed from the upper condyles of the 
knee, finely diced, weighed and then rinsed three times in a solution of phosphate buffer 
solution (PBS) and 2 % Penicillin/Streptomycin. The extracellular matrix (ECM) of the 
cartilage was digested overnight in chondrocyte isolation media consisting of DMEM 
HAMS F12 (Lonza Biowhittaker, UK Cat # BE12-719F), 2 % Penicillin/Streptomycin, 50 
µg/ml sterilised ascorbate (Sigma-Aldrich, UK, Cat # A4544), 1 mg/ml clostridal 
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collagenase (Sigma-Aldrich, UK, Cat # C6885 ) and 0.1 mg/ ml DNAse (Deoxyribonuclease) 
(Sigma-Aldrich, UK, Cat # D4263) while being continuously agitated using a magnetic 
stirrer at 37 oC and 5 % CO2. Digested cartilage suspension was filtered to remove tissue 
debris through 100 µm cell strainer. Supernatant containing chondrocytes was collected and 
centrifuged at 600G for 10 mins. Trypan blue (Sigma-Aldrich, UK, Cat # T8154) exclusion 
test was carried out at this point in order to determine cell viability (%). Chondrocytes were 
then re-suspended, seeded at 2x104 cells/cm2 and cultured under standard cell culturing 
conditions (5 % CO2 and 37 
oC in chondrocytes proliferation media; DMEM HAMS F12 
supplemented with 10 % FBS, 1 % L-Glutamine and 1 % Penicillin/Streptomycin) up to a 
maximum passage number of 3. 
 
2.2. Cell Characterisation 
 
Cell (hMSCs, mMSCs and chondrocytes) were characterised upon isolation prior to the 
establishment of cells banks. Cell banks were continuously maintained by cryopreserving 
(90 % FBS; 10 % DMSO) a minimum of 5x105 cells at each passage (P1-3). 
 
2.2.1 Multi-lineage Differentiation of MSC.  
MSCs (human and murine) were tested for their ability to undergo differentiation into 
osteocytes, adipocytes and chondrocytes. Cells (2.5x103) were seeded into 24 well plates 
(n=3) and cultured in the relevant differentiation media (Table 2.1) or standard proliferation 
media (control samples) for 21 days. Media change was performed every three days.  Cells 
were fixed using 95 % methanol (Fisher Scientific UK, Cat # M395021) (15 mins) for both 
osteogenic and chondrogenic samples and in 4 % formalin (15 mins) for adipogenesis at all 
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time point samples (Day, 0, 7, 14, 21). Fixed cells were then stained with the relevant 
histology staining (section 2.5). In brief, osteogeneisis was confirmed by Alizarin red 
staining (section 2.5.1.1), adipogenesis by oil red “O” staining (section 2.5.1.3) and finally 
chondrogensis by alcian blue staining (2.5.1.2).  
 
Table 2.1. Relevant differentiation media compositions to drive the chondrogenic, 
adipogenic and osteogenic differentiation of hMSCs and mMSCs. 
 
Reagent 
 
hMSCs mMSCs 
CHONDROGENESIS (176) 
ITS (Insulin, Transferin, Sellenium Prefix) (Sigma-
Aldrich, UK, Cat # I3146) 
1 % v/v 1 % v/v 
Dexamethasone (Sigma-Aldrich, UK, Cat # D2915) 0.1μM 0.1 μM 
Ascorbic Acid (Analar, BDH, UK, Cat # 103033E) 50 μM 50 μM 
L-proline (Sigma-Aldrich, UK, Ca t# P5607) 40 μg/ml 40 μg/ml 
Sodium Pyruvate (Sigma-Aldrich, UK, Cat# S8636) 1 % v/v 1 % v/v 
TGF-β3 (Peprotech, UK, Cat # 120-14E) 10 ng/ml 10 ng/ml 
FBS 1 % v/v 1 % v/v 
ADIPOGENESIS hMSCs (71) mMSCs (175) 
3-Isobutyl-1-methylxanthine (Sigma-Aldrich, UK, 
Cat# I5879) 
0.5 mM 0.5 μM 
Dexamethasone 0.5 μM 1 μM 
Insulin (Sigma-Aldrich, UK, Cat # 19278) 10 μg/ml 0 
Indomethecin (Sigma-Aldrich, UK, Cat # 17378) 100 μM 100 μM 
ITS 0 1% v/v 
OSTEOGENESIS hMSCs 
(177) 
mMSCs (175) 
Dexamethasone 0.1μM 0.01μM 
Ascorbic Acid 50 μM 88 ng/ml 
Β-Glycerophosphate (Sigma-Aldrich, UK, Cat# 
G9422) 
50 mM 10 mM 
 
 
2.2.2 Flow Cytometry 
Flow cytometry (Fluorescence-Activated Cell Sorting; FACS) was implemetnted to evaluate 
cell surface markers for hMSCs and mMSCs. hMSCs (P1) and mMSCs (P12) were expanded, 
trypsinised, and re-suspended at a cell dose of 106 cells/ml in blocking solution (hMSCs; 10 % 
Human IgG (Flebogamma), mMSCs; 2 % BSA (Bovine Serum Albumin) in PBS). 
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Following an incubation period of 1 hr at 4 oC, cells were centrifuged at 400 g for 4 min at 
4 °C and the supernatant discarded. Cells were then re-suspended in 2 % BSA/PBS solution 
resulting in a cell density of 1x106/ml and dispensed at a cell density of 8x104 per 5 ml 
Falcon tube. The directly conjugated antibody or the respective isotype control was then re-
suspended in 2 % BSA/PBS and added to cells for a further incubation period of 30 min at 
4 oC on a rocker in the dark. Cells were centrifuged twice (400g, 5 mins) before being re-
suspended in a final volume of 200 µl 2 % BSA/PBS to be analysed. 
 
2.2.2.1 Antibodies 
hMSCs 
Directly conjugated antibodies and their corresponding dilutions (made up in 2 % BSA) used 
in this study were as follows: CD 14 (1:50), CD 19 (1:50), CD 34 (1:100), CD 31 (1:50) CD 
45 (1:200), CD 105 (1:50), (Immunotools, Germany) CD 73 (1:20), CD 90 (1:200) (BD 
Biosciences, UK).  Isotype control antibodies used in this study were HLA – DR (1:200), 
IgG1 (1:50), IgG2a (1:50) (Immunotools, Germany). In this study, propidium iodide staining 
was not included. 
mMSCs 
Antibodies used in this study were as follows: anti-mouse CD 31 (PECAM-1) PE (5 µg/ml), 
anti-human/mouse CD 44 PE (5 µg/ml), anti-mouse CD 11d PE (5 µg/ml), anti-mouse CD 
45 PE (5 µg/ml), anti-mouse Ly-6A (Sca-1) PE (5 µg/ml), anti-mouse CD 105 PE (12,5 
µg/m1). Isotype control antibodies used in this study were: rat IgG2a-PE (5 µg/ml) and rat 
IgG2b-PE (5 µg/ml) (eBioscience). Propidium iodide staining was included in the 
immunophenotyping to evaluate the viability of the cells.  
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2.2.2.2 Flow Cytometric Analysis 
The samples were analysed on a Becton Dickinson FACScan flow cytometer. Fluorescein 
isothiocyanate (FITC) fluorescence was detected using the FL-1 channel, while R-
phycoerythrin (PE) fluorescence was detected in the FL-2 channel. FITC has maximum 
absorbance at 494 nm and maximum emission at 518 nm; R-PE has maximum absorbance 
at 490 and 565 nm and maximum emission at 578 nm. Excitation was achieved at 488 nm 
with an Argon laser. Data gated to exclude dead cells and select the required cell population 
on the basis of forward scatter versus side scatter profiles. Mean fluorescence intensity (MFI) 
and percentage positive cells were measured. Data were collected and displayed in dot plot 
and histogram format using CellQuestPro software (Becton Dickinson, Oxford, UK). 
 
2.2.3 Histological Evaluation of Chondrocytes 
Chondrocytes (P3) were tested for their ability to secrete sulphates glyosaminoglycans.  
Cells (12x103) were seeded into 96 well plates (n=6) and cultured in the chondrogenic 
differentiation media (Table 2.1) or standard proliferation media (control samples) for 21 
days. Media change was performed every 3 days.  Cells were fixed using 95 % methanol (15 
mins) and stained for the secretion of GAG (glycosaminoglycans) using Alcian blue staining 
(section 2.5.1.2).  
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2.3 Particle Labelling  
 
 2.3.1 Superparamagentic Iron Oxide Nanoparticles (SPIONs) 
SPIONs (SiMAG, Lumirem, Nanomag, P904) ranging in size from 25 nm to 1000 nm in 
diameter were selected and assessed as potential labelling agents. The specific properties of 
these particles are listed for comparative purposes in Table 2.2.  
 
Table 2.2. Properties of the four SPIONs selected for this study. 
 
 SiMAG Lumirem Nanomag  P904 
Iron Core Maghemite (Fe2O3) Maghemite (Fe2O3) 
and Magnetite 
(Fe3O4) 
Magnetite (Fe3O4) Maghemite (Fe3O4) 
(178) 
Size 1000 nm 300 nm 50-75 nm 25-30 nm 
Polymer 
Coating 
Silica non porous Siloxane Dextran Glucose derivative 
 
Iron (Fe ) 
contents 
15000 μgFe/ml 175 μgFe/ml 2400 μgFe/ml 22000 μgFe/ml 
FDA approval No Yes No Pre-clinical  
Magnetisation Superparamagnetic Superparamagnetic Superparamagnetic Superparamagnetic 
Application Purification of 
DNA 
MRI contrast agent Magneto-immuno 
assay 
MRI contrast agent 
Functional 
group 
Silanol None None unknown 
Supplier Chemicell, 
Germany (Cat# 
1101) 
Guebert, France 
(Cat# 211786) 
Micromod, 
Germany (Cat# 79-
00-501) 
Guebert, France 
(Cat# G00904.016) 
 
 
2.3.2 SPION labelling of cells 
Cells (hMSCs and porcine chondrocytes, P2 or P3; mMSCs, P12 or P13) were labelled with 
SPIONs. Cells were trypsinised (1% Trypsin and EDTA (Lonza Biowhittaker, UK Cat # 
BE02007E) solution in PBS; 5 mins incubated at 37oC) and then plated at the desired seeding 
density per specific experiment. Cells were allowed to attach for 24 hrs in standard 
proliferation media at 37 oC before aspirating media and washing once with PBS to remove 
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any residual FBS. SPIONs were re-suspended in SF (serum free) proliferation media at the 
desired Fe concentration (Equation 2.1 Appendix) and vortexed well before adding to cells. 
Cells were then incubated with the particle solution for 24 hours at 37 oC. A ratio of 1 ml of 
particle suspension at the desired Fe concentration per 2x105cells was maintained for all 
particles across all experiments. Following incubation, cells were thoroughly washed with 
PBS (3 times) to remove excess particles attached to the surface of the cells, trypsinised, 
collected and counted for subsequent experiments. 
 
2.3.3 Characterisation of cell populations post SiMAG labelling 
SiMAG-labelled cells (hMSCs, mMSCs and chondrocytes) were characterised to ensure that 
the presence of SiMAG had not affected cell properties. hMSCs were characterised by 
evaluating their multi-lineage differentiation abilities as described in section 2.2.1 and the 
expression of key cell surface markers (section 2.2.2). Characterisation of chondrocytes was 
performed by evaluating sulphated GAG secretion (Section 2.2.3). In each case, cells were 
seeded at the required cell density (as described section 2.2.1, 2.2.2 and 2.2.3) and labelled 
according to the particle-cell labelling protocol described in section 2.3.2. Briefly, cells were 
allowed to attach for a period of 24 hrs in standard proliferation media prior to the addition 
of SiMAG solution (10 μgFe/ml; SFM) and allowed to incubate for 24 hrs. The particle 
solution was then removed, cells thoroughly rinsed in PBS (three times) and characterised 
accordingly. 
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2.4 Particle Characterisation 
 
2.4.1 Particle Size 
Hydrodynamic particle size was measured using a Malvern ZetaSizer 3000 HSa. This 
operates on the principal of dynamic light scattering and is an important indicator of particle 
behaviour and size distribution within a colloidal suspension. Working concentrations were 
initially assessed by re-suspending a range of volumes (5 μl – 100 μl) of each particle stock 
solutions (SiMAG, Lumirem, Nanomag and P904) in 3 ml (the total holding volume of the 
cuvette) of dH20, vortexed and analysed using the ZetaSizer. Working volumes were chosen 
based on the volume that resulted in a KCps (count rate) ranging from 50 – 200 counts as 
this was recommended for accurate particle size measurements. Therefore 10 μl volumes 
(SiMAG and P904) and 100 μl volumes of (Nanomag and Lumirem) were used in all 
subsequent zeta-size measurements. Accurate reflection of particle properties relevant to the 
cells was performed at 37 oC in either serum free or serum containing DMEM to obtain 
actual measurements (146). Measurements were taken at 0 and 24 hr incubation periods. 
Three individual samples were prepared with 10 measurements taken for each sample. 
Statistical analysis was performed with two way Anova with Bonferrioni post-test using 
GraphPad.  
 
2.4.2 Particle Surface Charge 
Surface charge of each particle was measured also using the Malvern Zetasizer 3000 HSa 
with the settings being changed from size mode to the zeta potential mode. This is an 
important indication of particle stability and colloidal suspension. Contrary to the size 
measurements, analysis was carried out in dH20 and not in labelling media so as to negate 
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the charge of the particles in the labelling media, (n=5) (179). Here, 10 μl (SiMAG and P904) 
or 100 μl (Nanomag and Lumirem) were re-suspended in 10 ml dH20 and passed through 
the system using a syringe (10 ml) taking care not to allow any air bubbles through the 
system. 
 
2.4.3 Fe Content 
Fe content of each particle was measured using ICP-OES (Inductively Coupled Plasma –
Optical Emission Spectrometry). A serial dilution in dH20 was used to achieve 
concentrations ranging from 0.01, 0.1, 0.5, 1, 5, 10 μgFe/ml of each particle (SiMAG, 
Lumirem, Nanomag, P904). Each sample was then digested by adding 1 ml concentrated 
analytical grade nitric acid (Fisher Scientific, UK, Cat #: N/23001PB17) and heated to 60 oC 
overnight in a chemistry oven. Samples were diluted with dH20 to achieve a final acid 
concentration of less than 10 % prior to scanning using ICP at 3 wavelengths (239.563, 
259.940, and 238.204 nm). Samples were measured against a selection of Fe ICP standards 
(0.1, 1, 5, 10 ppm (parts per million)) made from a Fe stock of 1000 ppm in ddH2O.  
 
2.4.4 Particle Relaxivity 
The relaxivity (R2) of each particle was measured by MR imaging varying concentrations 
of particles and applying T2 specific sequences on the Brucker 2.3 T animal scanner.  
Through serial dilution, 40, 20, 10, 5, 2, 1, 0.5, 0.1, 0.01 μgFe/ml of each particle were 
prepared in water and 100 μl of each sample was then aliquoted in a customised 96 well 
plate and MR imaged using MSME sequences. The inverse of the T2 values for each particle 
were then plotted against particle concentration and the slop of the curve taken as the R2 
values. 
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2.5 Histological Staining  
 
2.5.1 In vitro Histological Staining 
2.5.1.1 Alizarin Red 
Characterisation of osteogenic differentiation of MSCs was confirmed by staining with 
Alizarin Red (Sigma-Aldrich, UK Cat# A5533) prepared at 1% in dH20 and syringe filtered 
using a 2 μm filter. Samples were washed in PBS and treated with 500 μl of alizarin red for 
5 min at room temperature. The stain was then removed and washed 3 times with dH20. 
Calcium ions secreted into the extra cellular matrix were stained red (positive) and imaged 
using a bright field microscope AMG-EVOS x l CORE. 
 
2.5.1.2 Alcian Blue 
Alcian Blue stain (Sigma-Aldrich, UK Cat# A3157; 0.1%) was prepared at pH 1.5 using 3 % 
acetic acid made using dH2O and syringe filtered (0.2μm filter). Fixed samples were 
immersed in the stain overnight at room temperature. Upon removal of the stain, samples 
were washed 3 times in dH20. The presence of GAGs secreted by chondrocytes was 
identified as by areas stained as blue. Stained samples were imaged using a bright field 
microscope Olympus CKX41. 
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2.5.1.3 Oil Red O  
Oil-Red-O (Sigma-Aldrich, UK, Cat # O-0625) stain was prepared at 0.18 % in 60 % 
isopropyl alcohol (IPA) and syringe filtered (0.2 μm filter). Samples were first washed in 
dH20 followed by 60 % isopropyl alcohol. The stain was then added to wells and allowed to 
stain the samples for 15 min at room temperature. Following the incubation period, the stain 
was removed and rinsed 3 times. Lipids secreted by differentiated MSCs into adipocytes 
appeared as small red droplets. Samples were imaged using a bright field Olympus CKX41 
microscope.  
 
Representative images for each stain were taken of various samples at x4, x10 and x20 
magnifications in at least 3 different areas of each sample. 
 
2.5.2 In vivo Histological Assessment. 
2.5.2.1 Knee Joint Processing 
Once all the animals (mice and rats) had been MR imaged, animals were culled and joints 
were collected for histology. Joints were fixed in neutral buffered formal saline, and 
transported to Robert Jones and Agnes Hunt Orthopaedics Hospital Histopathology labs to 
be further processed. Briefly, fixed joint were decalcified with formic acid at 4 oC before 
embedding in paraffin. Mid-sagittal serial sections (4 µm thickness) were obtained using a 
Buehler Isomet low speed saw with a diamond tipped blade (Buehler, An ITW Company, 
Germany).   
 
Joint sections were prepared for subsequent staining by initially de-waxing sections in 100 
% Xylene (Sigma-Aldrich, UK Cat# 534056) for 5 mins. Samples were then rehydrated in 
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100 % ethanol for a further 2 min followed by washes in PBS for 5 min prior to subsequent 
staining.  
 
2.5.2.2 Hematoxylin and Eosin (H&E) Staining 
H&E staining was carried out by the Histopathology Department at the Robert Jones and 
Agnes Hunt Orthopaedic Hospital.  
 
2.5.2.3 DAPI  
The fluorescent dye DAPI (1:200 dilution prepared in PBS; Sigma-Aldrich, UK, Cat# D9542) 
was added (1 ml) over joint sections using a pasture pipette. Hydromount (Analar, UK, Cat# 
360294 H) mounting solution was then used to mount the glass cover slip and allowed to dry 
overnight before imaging using a UV fluorescent microscope (Nikon Eclipse Ti-S).  
 
2.5.2.4 Toluidine Blue 
Joint sections were stained using 0.25 % solution of Toluidine blue with a final pH ranging 
from 3.7-4.1 prepared in buffer (0.63 g citric acid, 0.3 g disodium phosphate and 400 ml 
H20). Samples were treated with 500 μl of toluidine for 20 sec at room temperature. The 
stain was then removed and washed 3 times with dH20. Toluidine blue stained GAGs purple 
whilst nuclear material was stained blue. Stained joint sections were imaged using a 
bright field microscope AMG-EVOS x l CORE. 
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2.5.2.5 Prussian Blue  
A 20 % Aqueous (aq) solution of hydrochloric acid (HCL; Analar, UK, Cat #10307) was 
prepared and added to 10 % aq solution of potassium ferrocyanide (Sigma-Aldrich, UK Cat 
# P3289) in equal parts, immediately prior to use. This involved the reaction of ferrocyanide 
with Fe particles to effectively stain any Fe particles bright blue. 1ml of this solution was 
added to each joint section and left for 20 mins at room temperature. Joint Sections were 
subsequently washed with PBS prior to having coverslips mounted. Sections were imaged 
with a light electron microscope (Nikon Eclipse TS100) equipped with a Canon Eos 400D 
digital SLR camera. 
 
2.6 Particle Uptake Assessment 
 
2.6.1 Inductively Coupled Plasma Optical Emission Spectrometry (ICP-
OES) 
ICP-OEAS was performed to quantify the uptake of all particles (SiMAG, Lumirem, 
Nanomag and P904) by hMSCs, mMSCs (SiMAG only) and chondrocytes. This technique 
allows for the accurate evaluation of Fe within a sample therefore allowing the quantification 
of particle uptake by cells. 6-well plates were seeded with 1x105 cells per well and allowed 
to attach overnight. 10 μgFe/ml of each particle (SiMAG, Lumirem, Nanomag and P904) 
solutions were prepared (Section 2.3.2) in either serum free or serum containing media 
relevant for each cell type. 2 ml of each particle suspension was added to each well (n=3). 
Control plates were set up as follows: Cell control; cells treated with no particles; (n=3) and 
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B) Particle controls: 2 ml of each particle solution added to empty wells to serve as a 
reference to the total amount of particles and subsequent total Fe added to each well. 
 
Following the incubation period, media was removed from each well and collected into 
individual 15 ml centrifuge tubes. Cells were washed twice in PBS with PBS washes also 
collected into the same tubes. After trypsinisation (1 ml), detached cells were then removed 
and collected in a separate tube and washed once with PBS to ensure all cells had been 
collected. 1 ml concentrated analytical grade nitric acid was then added to each tube and 
heated to 60  oC overnight using a chemistry oven to digest the particles thus releasing Fe. 
Finally, samples were diluted with dH20 to achieve a final acid concentration of less than 
10 % prior to being analysed using ICP at 3 wavelengths (239.563, 259.940, and 238.204 
nm) vista-mpx. During each experiment, an ICP standard (1 PPM) was prepared and 
analysed to ensure correct calibration of the instrument.  
 
Data Analysis 
The total Fe content (PPM) within a given sample was calculated by averaging the Fe (PPM) 
detected at each of the 3 wavelengths and subtracting the cell control to find the total net Fe 
content associated with the cells. This value is then adjusted to account for the dilution of 
the sample pre ICP analysis. Finally, the amount of Fe per cell was calculated by dividing 
for all cells in the sample (initial seeding density). Two way Anova followed by Bonferroni 
post test, statistical analysis was applied using Graphpad prism. 
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2.6.2 Prussian Blue 
Prussian blue stain was carried out as a visual assessment of particle uptake. Here, 105 cells 
(hMSCs, mMSCs and chondrocytes) were seeded within 6-well plates and labelled with each 
particle at 0, 1, 5, 10 and 100 μgFe/ml as described previously in Section 2.3.2. Labelled 
cells were fixed and permealised using 95 % methanol for 15 mins at room temperature. 20 % 
(aq) solution of HCL was prepared and added to 10 % (aq) solution of potassium 
ferrocyanide in equal parts immediately prior to use. 1 ml of this solution was added to each 
well and left for 20 mins for the reaction to occur. Potassium ferrocyanide solution was 
removed and samples washed with dH20 three times. Cells were imaged using bright field 
inverted Nikon TI eclipse. 
 
2.6.3 Particle Retention 
The ability of hMSCs and chondrocytes to retain internalised SiMAG over a 28 day period 
was assessed by ICP-OES and Prussian blue staining. Experiments were set up according to 
Sections 2.6.1 and 2.6.2 using hMSCs and chondrocytes labelled with 10 μgFe/ml SiMAG. 
Samples were then either collected to be analysed by ICP-OES or fixed to be stained by 
Prussian blue at various time points  (1, 7, 14, 21 and 28 days) with all samples receiving a 
full media change every two days for the duration of this experiment. Standard students t 
test was performed using Excel.  
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2.7 Cell Viability and Proliferation  
 
2.7.1 MTT Assay 
To determine the effect of particle labelling on the viability and proliferation rate of hMSCs, 
mMSCs and chondrocytes, a tetrazolium salt (MTT; Sigma-Aldrich, UK, Cat #M5655) 
assay was applied. Cells were seeded at 105 cells per well of a 6-well plate and labelled under 
serum free conditions with each particle (SiMAG, Lumirem, Nanomag and P904) at 0, 10 
and 100 μgFe/ml (Section 2.3.2) (n=6). Samples were analysed 24 hrs and 7 days post-
labelling.  A negative control mimicking toxic events was induced at each time point by 
exposing healthy unlabeled cells to 1 ml DMSO (Dimethyl sulfoxide; Sigma-Aldrich, UK, 
Cat# D8418) for 5 mins. At the relevant time points, 0.5 mg/ml MTT working solution 
(prepared in SFM) was added to each well and allowed to incubate for 4 hours at 37 oC. 
Following incubation period, MTT solution was carefully removed and 1ml of DMSO added 
for a further 10 mins to solubilise the crystals. Finally, 200 μl aliquots of this solution were 
then transferred to 96 well plates and read using the plate reader (Synergy 2, Biotek) at a 
wavelength of 570 and 690 nm (excitation/emission). Data was analysed by subtracting the 
blank (DMSO) from each value at the given OD and then subsequently subtracting OD value 
at the 690 nm wavelength from the 570 nm wavelength. All data was then normalised to the 
24 hr untreated samples.  
 
2.7.2 Live Dead Staining 
A live dead assay was implemented to further investigate the toxicity of particle labelling on 
hMSCs, mMSCs and chondrocytes using the LIVE⁄DEAD® Viability⁄Cytotoxicity Kit 
(Invitrogen, UK, Cat# L3224). This assay consists of Calcein-AM and Propidium Iodide (PI) 
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solutions, respectively staining viable cells green and dead cells red. Here, 2 x 104 cells were 
seeded per well of a 24 well plate and labelled with 0, 10 and 100 μgFe/ml of each particle 
(SiMAG, Lumirm, Nanomag and P904) under serum free conditions (Section 2.3.2). Live 
dead staining was applied directly after the labelling period (24 hrs and after 7 days of 
culture). In both cases, the particle media solution was removed after the initial 24 hours of 
culture and cells thoroughly washed with PBS. Fresh proliferation media was added to 
samples continuing in culture for a further 7 days. At the relevant time points (24 hrs and 7 
days) 1 % Calcein AM and 2 % Propidium Iodide solutions prepared in PBS as per 
manufacturer’s instructions and 200 μl added to each well. Following, 45 minutes of 
incubation (37 ᵒC; complete darkness) samples were immediately imaged using a UV 
fluorescent microscope (Nikon Eclipse Ti-S) where live cells appeared green (FITCI filter),  
whilst dead cells appeared red (TRITC filter). 
 
2.7.3 Trypan Blue Exclusion Assay 
Trypan blue exclusion assay was applied to assess cell viability during cell culture. In brief, 
a 10 µL volume of cell suspension was mixed with 10 µL of trypan blue solution. 10µL of 
the mixed solution was then pipetted onto a disposable haemocytometer and cells counted. 
Live cells appeared clear in the centre with a blue outer membrane whilst dead cells appeared 
totally blue.  Viable and non-viable cells were counted separately and an overall average and 
percentage viability gained.  
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2.8 Magnetic Resonance Imaging 
 
2.8.1 MRI Scanners 
2.8.1.1 Bruker 2.35 T Small Animal Scanner 
A research grade Bruker 2.35 T animal scanner was used for all experiments unless 
otherwise stated.  This scanner was operated by Dr Robert Morris of Nottingham Trent 
University. In general samples were placed within the scanner (within the RF (radio 
frequency) coil) (Figure 2.1 Aii) and adjusted to ensure that the samples were placed within 
the centre of the coils and the magnet for best results (approximately 933 mm from the front 
plate, Figure 2.2). A tripilot (3 orthogonal reference image) scan was always performed to 
ensure that the samples were placed in the optimal location to adjust scanning parameters 
accordingly.
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Figure 2.1. The Bruker 2.35 T animal scanner where: (A) is the front of the scanner, (B) the back of the scanner and (C) the side view 
of the scanner. (Ai) highlights the entrance of the scanner with the gradient visible. The RF coil is positioned within the gradient coil 
highlighted by the green box (Aii). The dimensions of this coil are clearly shown in Aii * and Aii ** when the inner diameter of the RF 
coil is 7 cm and the total length of the coil 29 cm 
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Figure 2.2. Cross sectional dimensions of the Bruker 2.35 T animal scanner highlighting key features of the scanner: (A) Gradient coil 
(B) Radio frequency coil (C) Front entrance.
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2.8.1.2 Siemens Symphony 1.5 T Clinical Grade Scanners 
Experiments involving the use of porcine knee specimens (Section 2.8.5.2) were performed 
at the MARIARC centre part of Liverpool University using a clinical grade 1.5 T scanner 
(Figure 2.3). The equipment was operated by Miss Valerie Adams.   
 
Figure 2.3. Siemens Symphony 1.5 T MRI scanner. Image courtesy of Miss Valerie 
Adams (University of Liverpool).  
 
 
 
 
              Chapter 2 - Materials and Methods                                                                                              
86 | P a g e  
 
2.8.2 MRI Sequences and Parameters 
2.8.2.1 Bruker 2.35 T Animal Scanner 
Table 2. 3 Sequences and corresponding parameters for each MRI experiment performed using the Bruker 2.35T animal scanner.  
Experiment 
  
 
Section Sequence Repetition 
time (ms) 
Echo time 
(ms)  
Number 
of echoes  
Matrix 
size  
Spatial resolution 
(mm)
  
In vitro dose 
response    
Gel 
optimisation 
T2 
2.8.4.1 MSME 1000 10.25 8 256 x 192 0.469 x 0.625 
Gel 
optimisation 
T1 
2.8.4.1 MSME 100 - 5000  10.25 8 256 x 192 0.469 x 0.625 
Collagen Gels 2.8.4.2 MSME 1000 10.25 8 256 x 192 0.469 x 0.625 
Ex vivo  
dose 
response 
  
  
Orthopaedic 
tissues – 
(Muscle, Fat, 
Ligament)  
2.8.5.1 MSME 1000 10.25 8 256 x192 0.391 x 0.365 
In vivo  dose 
response 
 
Mouse model  2.8.6.1 RARE 4000 10.25 4 256 x 192 0.469 x 0.417 
Rat model  2.8.6.1 RARE 4000 10.25 4 256 x192 0.312 x 0.260 
Tracking 
studies 
  
Mouse model  
  
2.8.6.2 RARE day 3 4000 10.25 4 256 x192 0.312 x 0.260 
FLASH day 3 1000 3.35 4 256 x 256 0.45 x 0.29 
RARE day 7 4000 10.25 4 256 x192 0.312 x 0.260 
GEFI day 7  500 4.7 8 256 x 256 0.47 x 0.47 
Rat model 2.8.6.2 MSME day 29 200 11 1 128 x128 1.172 x 1.172 
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2.8.2.2 Siemens Symphony 1.5 T Clinical Grade Scanner 
The following scanning parameters (table 2.4) were implemented in the ex vivo cadaveric porcine model experiment. These sequences are 
considered highly appropriate as these are applied in routine MR diagnosis of knee pathology   
 
Table 2. 4 Sequences and corresponding parameters for the set of ex vivo porcine model performed using the Siemens Symphony 1.5 T 
Clinical Grade Scanner. 
 
Experiment 
  
 
Section Sequence Repetition 
time (ms) 
Echo time 
(ms)  
Number 
of echoes  
Matrix 
size  
Spatial resolution 
(mm)
  
Ex vivo cadaveric porcine 
model study    
 
2.8.5.2 & 
2.8.5.3 
DESS 3500 15-240 (30 ms 
intervals) 
16 256 x 256 0.6 x 0.6 x 3 
 
              Chapter 2 - Materials and Methods                                                                                           
   
88 | P a g e  
 
2.8.3. MRI Data Analysis 
2.8.3.1 Bruker 2.35T Animal Scanner 
Data generated by each scan is received by standard ParaVision 4 software. Data managed 
by this software is then saved in the Bruker format, a format that cannot be opened on a 
standard laptop or PC without specialist software. Therefore, data in this format is processed 
using a purpose written Matlab programme (Dr Robert Morris). This programme is capable 
of extracting representative T2
eff values from the Bruker data files and fitting these values 
exponentially to the envelope of the echoes thus generating T2
eff maps.  All gel MRI data 
(section 2.8.4) was processed in this manner. Alternatively, Bruker folders were converted 
to a different format; “Analyze” using a Bruker- to- Analyze converter (Br2Anz) allowing 
for these files to be processed by the MRIcron programme, effectively allowing for all MRI 
images to be opened and analysed on simple windows operating system but not allowing for 
relaxation measurements to be obtained. All animal and tissue work were processed in this 
way.  
 
2.8.4 In vitro MRI. 
2.8.4.1. Optimisation 
2.8.4.1.1 Plate Layout 
The high cost of performing MRI scans limits the number of samples that can be imaged and 
analysed. It thus became necessary to devise a means of increasing throughput to increase 
the number of samples that can be imaged at one time. Early plate layouts (Figure 2.4 i) 
involved the fabrication of an eppendorf holder aligned with the inner dimensions of the 
scanner allowing for 6 x 1.5 ml eppendorf tubes to be places and MRI imaged. This set up 
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limits the number of samples to 6 per scan and also requires a relatively high volume of 
collagen (0.5 ml) per sample. The modification of a standard 96 well plate (Figure 2.4 ii) 
allows for the number of samples capable of being imaged at one time to increase from 6 to 
24. Note, not every well of the modified 96 well could be used due to the restricted field of 
view of this particular MRI scanner, this area is clearly marked (Figure 2.4 ii). Furthermore, 
the very shallow depth of the plate allows for 2 plates to be imaged at the same time, by 
placing one plate over the other further increasing the number of samples to be scanned from 
6 – 48 samples per scan. In this instance, the number of slices are simply increased to account 
for 2 plates with no extra time being added to the overall scan time. Further to this, the use 
of a 96 well plate, reduces the amount of collagen required to be used from 500 μl to 100 μl.  
 
Figure 2.4. Plate layouts. i) Early plate layout facilitating the imaging of 6 samples 
within 1.5ml eppendorf tubes ii) Optimised plate layout facilitating the imaging of 18 
samples within a 96 well plate format.  
  
2.8.4.1.2 Collagen gels concentration optimisation 
Type I collagen gels were prepared at various concentrations (0.5, 2, 5 and 9 mg/ml) by 
combining 10 x DMEM, NaOH (Sigma-Aldrich, UK, Cat # S8045), stock collagen gel (BD 
Biosciences, UK Cat # 354249) and water in certain ratios where the amount of each 
component are worked out according to the following set of equations (Equation 2.2 
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Appendix). All gel components were mixed and stored on ice until use to prevent gelation. 
Standard students t- test was performed using Excel.  
Gels were produced by forming a solution of 10 X DMEM, NaOH, and water with the 
addition of stock collagen solution at the end in order to prevent premature gelation. Gel 
solutions were homogeneously mixed creating a uniform colour solution taking care to not 
create any air bubbles. 100 μl of each gel solution was carefully pipetted into the customised 
96 well plates (n=6) and allowed to set for 1 hr at 37 oC. Plates were then MR imaged using 
Bruker 2.35 T animal scanner applying MSME sequences as described in Table 2.3.  
 
2.8.4.1.3 MRI sequences; 
T1 and T2
eff weighted MRI sequences were investigated by re-suspending hMSCs labelled 
with varying concentrations of SiMAG (0, 1, 5 and 10 μgFe/ml) at various cell densities (103, 
104, 105,  3x105,  5x105) in 2 mg/ml rat tail type I collagen (optimised gel concentration) 
(made up according to equation 2.2 ). 100 μl of each sample was carefully aliquotted within 
the wells of a customised 96 well plate. Samples were MR imaged and relaxation parameters 
T1 and T2
eff estimated for each of the samples using a MSME imaging (Table 2.3). 
T1 relaxation. This involves the realignment of moments with the main magnetic field or 
longitudinal axis (z axis) and is defined as the time taken for magnetization to revert back to 
63% of its full longitudinal magnetization (130, 164).  
T2 relaxation: This involves the loss of transverse magnetization due to the dephasing of 
protons in the transverse plane. Once the RF pulse is removed, the protons start to dephase. 
Although moments are still precessing, each of the magnetic moments is also generating its 
own magnetic field which will affect the neighbouring moments (spin spin interactions). 
This will mean that over time a given magnetic moment will drift out of phase with its 
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neighbours. Dephasing protons are therefore cancelled out with this resulting in a loss of 
magnetization in the transverse plane. We are effectively measuring the number of magnetic 
moments which are in phase with each other at a given time. Therefore T2 can be defined as 
the time taken for the magnetization to decay to 37% of its full value in the transverse plane 
(all moments in phase). T2
eff (effective) is measured by applying a series of pulses which act 
to reverse the effect of protons dephasing seen in T2 decay. This results in a significantly 
slower decay which can be measured more easily when the decay times in question are very 
short.  
 
2.8.4.2 In vitro MRI Dose Response Investigation 
The in vitro minimum visibility threshold for particle-labelled cells was investigated by re-
suspending varying cell doses of labelled cell populations in a 2 mg/ml rat tail type I collagen 
gel, 100 μl samples were then aliquoted into the customised 96 well plates and the gels 
allowed to set for 1 hr (37 oC) prior to MR imaging (MSME Table 2.3) 
 
2.8.4.2.1 hMSCs and Chondrocytes 
hMSCs and porcine chondrocytes were labelled in serum free media with 0, 1, 5, 10 and 100 
μgFe/ml of each particle (SiMAG, Lumirem, Nanomag and P904) and subsequently re-
suspended at varying cell doses, (5x105, 105 and 104) within a 2 mg/ml collagen gel 
suspension, prior MR imaging (MSME Table 2.3).  
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2.8.4.2.2 mMSCs 
Murine MSCs were labelled with 0, 1, 5 and 10 μgFe/ml of SiMAG in serum free media and 
re-suspended into the following cell densities; 5x105, 3x105, 105, 104 and 103 within a 2 
mg/ml collagen gel suspension, prior MR imaging (MSME Table 2.3) 
2.8.5 Ex Vivo MRI. 
2.8.5.1 Orthopaedic Tissues. 
The effects of various tissue structures on in vitro MRI visibility thresholds were investigated 
by re-suspending SiMAG labelled cells (hMSCs and chondrocytes) at different 
concentrations (0, 1, 5 and 10 μgFe/ml) in serum free media and injected (50 µl) at various 
cell densities (5x105, 1x105, 104) using a 21 G needle within key tissues associated with the 
knee (muscle, ligaments and patellar fat pad). Porcine legs were purchased from 
Staffordshire meat packers on the day of the experiments to prevent the need for freezing. 
The knee was identified and dissected from the rest of the leg using a surgical scalpel (21 
Blade). Once the knee had been isolated, the medial and collateral ligaments were identified 
and removed from the structure using a surgical scalpel and all the connective tissue carefully 
removed. The ligament tissue and patella fat tissues were then dissected into equal sized 
pieces and placed within a 24 well plate (n=3), as shown in figure 2.5. Similarly, 1 x 1 cm 
pieces of muscle were extracted from the quadricep femoris muscle and placed within a 24 
well plate (n=3), as shown in figure 2.5. Each well was fully submerged in water before 
injecting cells to prevent any air bubbles from being injected within the tissues. Plates were 
then MR imaged on Brucker 2.3 T animal scanner using MSME sequences stated in Table 
2.3.  
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Figure 2.5. Plate layout for ligament, muscle and fat prepared for MR imaging when 
injected with SiMAG labelled hMSCs and chondrocytes and prepared for ex vivo 
visibility threshold evaluation 
 
2.8.5.2 Porcine Knee Model 
A cadaveric porcine knee model of articular cartilage damage was created to assess the 
visibility threshold of SiMAG-labelled cells within a clinical relevant model.  All MR 
imaging related to this model were carried out at the MARIARC centre part of Liverpool 
University using the Siemens Symphony 1.5 T scanner.  Pig’s legs were purchased from 
Staffordshire meat packers (Staffordshire, UK) and processed to remove all surrounding 
tissue using a surgical scalpel (21 Blade). Once the knee had been isolated, the patella tendon 
was sliced and the patella pulled back revealing the articulating ends of the femur and tibia 
with the articular cartilage being clearly visible as shown in Figure 2.6. The knee was then 
bent to fully expose the upper condyles, and cartilage flaps were created (1.5 cm x 0.5 cm x 
1.5 cm) at various locations across the upper condyles of the knee. A maximum of two 
defects were created on each condyle (left and right) ensuring that defect were at least 0.5 
cm apart. In all experiments (sections 2.8.5.2.1, 2.8.5.2.2, 2.8.5.2.3) SiMAG-labelled 
chondrocytes were suspended in collagen type 1 gel (4.5 mg/ml) and injected within the 
defect while the knee was in the bent upright position. Care was taken to ensure that no 
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bubbles were created and that none of the collagen and cell suspension had leaked out. Once 
the gels had set (1 hr 37 oC) the leg was then straightened, the patella replaced and securely 
bandaged, to prevent excess movement. The leg was then stored at-20oC until MR imaged. 
The joint was defrosted 1 day prior to MR imaging. On the day of imaging, knees were 
transported to the MARIARC centre for scanning. During imaging knees were placed within 
a circularly polarised extremity coil and placed hip first into the scanner and Double Echo 
Steady State (DESS) sequences were applied (Table 2.4). These are common MRI scanning 
conditions implemented in the MR imaging and diagnosis of human knee pathologies. 
 
 
Figure 2.6. Dissected pigs knee with the patella pulled back exposing the upper condyle 
articulating the femur. 
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2.8.5.2.1 Porcine Knee Model Optimisation  
Optimisation experiment included the use of two cadaveric pig knee joints. In the first knee 
(Figure 2.7 A), two defects were created in each of the upper condyle; left condyle: cartilage 
flap was created  and injected with 100 μl volume of type 1 collagen gel (4.5 mg/ml), right 
condyle: the piece of cartilage was completely removed to expose the subchondral bone. The 
purpose of this was too evaluate defect appearances on an MRI image. It is important to 
establish that the defect created on the left condyle is suitable for further SPION-labelled 
cell experiments i.e the creation of the defect to not result in hypointenties when MR imaged 
that could encourage false positives with the implantation of SPION-labelled cells. In the 
second knee (Figure 2.7 B), only one defect was created in the upper left condyle and injected 
with 100 μl of 3x106 SiMAG-labelled chondrocytes in excess (concentration > 100 μg Fe/ml) 
suspended collagen type 1 gel (4.5 mg/ml collagen gel). The purpose of this was assess if 
SPION-labelled cells could be detected within the defect with standard pulse sequences 
while still evaluating knee anatomy.  
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Figure 2.7. Image highlighting the sites of artificially induced cartilage defects across 
the upper left and right condyle of 2 separate knee. (A) Knee 1; Cartilage flap filled 
with collagen (4.5 mg/ml), (B)  Knee 2; Cartilage completely removed C) Cartilage flap 
injected with 3x106 SiMAG-labelled chondrocytes (excess) re-suspended in 4.5 mg/ml 
collagen gel. 
 
2.8.5.2.2 Particle Concentration Investigation 
The effect of particle concentration on the visibility threshold within the clinically relevant 
model was assessed by implanting 5x105 chondrocytes labelled with SiMAG (0.1, 1, 10 
µgFe/ml) into the porcine model (Figure 2.8) and MR imaged as described in section 2.8.5.2 . 
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Figure 2.8. Particle concentration investigation. Schematic highlighting the 
implantation sites of 5x105 SiMAG-labelled chondrocytes: (A) 0.1 µgFe/ml, (B) 1 
µgFe/ml and (C) 10 µgFe/ml. 
 
 
2.8.5.2.3 Cell Dose Investigation  
Finally, the effect of cell densities on the visibility threshold was determined by implanting 
varying cell doses (104, 105 and 5x106) of SiMAG-labelled chondrocytes (5 µgFe/ml and 10 
µgFe/ml) into the porcine model (Figure 2.9 i and ii) and MR imaged as described in section 
2.8.5.  
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Figure 2.9. Cell dose investigation. Schematic highlighting the implantation sites of 
varying cell densities: (A) 104, (B) 105, (C) 5x105 of chondrocytes labelled with; (i) 10 
µgFe/ml and (ii) 5 µgFe/ml SiMAG.  
 
2.8.6 In vivo MRI 
2.8.6.1 Visibility Threshold: Animal Models 
The in vivo visibility threshold for both animal models (mouse and rat) was determined by 
injecting a 10 μl volume of cell suspension intra-articularly into each joint of healthy (non-
arthritic) mice (10 week old BALB/c mice) and rats (18 week old Wistar rats). SiMAG-
labelled mMSCs (1, 5 and 10 μgFe/ml) were re-suspended at the relevant cell dose (mouse; 
3x105, rat; 1x106 & 2x106) in serum free media prior to injection.   
 
Mice were placed face down into a purpose built holder (Figure 2.10) and inserted head first 
into the scanner. Rats were also positioned head first into the scanner, however, due to 
significantly larger size of the rats no holder was necessary. Mice were then MR imaged on 
Brucker 2.3 T animal scanner where whole body coronal slices were achieved for the mouse 
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while only sagittal knee focused imaged were possible for the rat. (MRI sequence; RARE 
Table 2.3).   
 
 
Figure 2.10. Mouse positioned in the customised holder prior to MR imaging thus 
ensuring that the knees were a suitable distance apart and positioned on an even plane.  
 
Data Analysis- Signal loss profiles 
Bruker files were first converted to Analyze files using Bru2Anz converter and subsequently 
processed using MRIcron. MRIcron allows for relative signal intensities of every point 
within the whole image to be obtained. Once the files were loaded, the slices were assessed 
to identify 3 slices where all the anatomical structures of the knee were in full form (Figure 
2.11; slice number 8, 9 and 10).  The signal intensity (SI) at 10 points of equal intervals 
across each knee of the mouse and 20 points of the rats were then measured. At all times the 
coordinates between slices were maintained. The average SI of the 3 slices were then 
averaged, plotted and compared.  
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Figure 2.11. Slice 1-16 of mouse MR imaged using Bruker 2.35T animal scanner using 
GEFI T2 weighted MR sequences and analysed using MRIcron. Slices outlined in red 
highlight slices whereby signal intensities (SI) profiles were taken.  
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2.8.6.2 In vivo MRI Tracking Studies.  
Once sacrificed (mice; days 3 & 7, rats at day 29) animals were transported to Nottingham 
Trent University to be MR imaged using Bruker 2.3 T animal scanner. Animals were 
positioned within the scanner as described in Section 2.8.6.1. Whole body coronal FLASH 
& RARE sequences (Table 2.3) were applied to image mice at the day 3 time point while 
GEFI & RARE sequences were used for day 7 (Table 2.3). Finally sagittal knee focused 
slices were implemented to MR image rats using MSME sequences day 29. Signal profiles 
were obtained as described in section 2.8.6.1. 
 
2.9. Animal Models 
 
2.9.1 CM-DiI Labelling 
Stock solution of the fluorescent cell-tracer CM-DiI (Molecular Probes, UK, Cat # C7000) 
was prepared in dimethyl sulfoxide (DMSO) at a concentration of 1 mg/ml. Cells were 
trypsinised, suspended in the CM-Dil working solution (2.5 µl of stock per 1 ml of PBS) and 
incubated for 5 mins at 37 ᵒ  C, and then for an additional 15 min at 4ᵒ C, in the dark. Unbound 
dye was removed by centrifugation at 300 g for 5 mins and washed twice using PBS. Finally, 
cells were resuspended in serum free media and maintained at 4 0C prior to injection 
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2.9.2 Rheumatoid Arthritis Model  
2.9.2.1 Animals 
Procedures were performed in accordance with Home Office-approved project licence. PPL 
40/3594 were approved by the Ethical Review Committee at Liverpool John Moores 
University UK, February 2012. Experiments were conducted in 10 week old male C57Bl/6 
mice (Harlan, Bicester UK) and carried out by Dr Oksana Kehoe.  
 
2.9.2.2 Induction of Murine Antigen-induced Arthritis (AIA) 
Murine AIA was induced as described by Nowell et al (180). Mice were subcutaneously 
immunised with 100 µl of 1 mg/ml of methylated BSA/PBS emulsified with an equal volume 
of Freund’s complete adjuvant into the right knee using 29 G insulin syringe (BD microfine 
0.5ml). 100 µl heat-inactivated Bordetella pertussis toxin (Sigma-Aldrich, Poole, UK) was 
then injected intraperitoneally. The immune response was boosted 1 week later by 
subcutaneously injecting 1 mg/ml of methylated BSA/PBS emulsified with an equal volume 
of Freund’s complete adjuvant. 21 days after the initial immunisation, murine AIA was 
induced (day 0) by intra-articular (IA) injection of 10 µl of 10 mg/ml BSA/PBS in the right 
knee joint. A left knee joint was treated as control by receiving 10 µl of PBS. 20 hours post 
arthritis induction, 10 μl of serum free media, containing 3x105 CM-DiL labelled mMSCs 
(either labelled with or without SiMAG (10 µgFe/ml) ) were injected intra-articularly into 
the right knee joint (day 1) and monitored for either 3 or 7 days. Experimental groups are 
descried in Table 2.5. Control animals were injected with only serum free CEM. Upon 
experiment termination, animals were sacrificed, MR imaged and joints were also collected 
for histological assessment (section 2.5.2). 
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Table 2.5. Explanations of experimental groups. 
 
Group Description Tracking period Study 
1 (n=6) SiMAG-labelled mMSCs  3 days MRI tracking study 
2 (n=5) SiMAG-labelled mMSCs 7 days MRI tracking study 
3 (n=6) Unlabelled mMSCs 3 days MRI tracking study 
4 (n=5) Unlabelled mMSCs 7 days  Pilot mMSCs study 
5 (n=6) Serum Free Media 3 days  Pilot mMSCs study 
6 (n=5) Serum Free Media 7 days MRI tracking study 
 
 
2.9.2.3 Joint Swelling Measurements.  
Animals were inspected daily for arthritic development by measuring knee joint diameters 
on days 0, 1, 2, 3, 5 and 7 using a digital micrometer (Kroeplin GmbH, Schlüchtern, 
Germany). The difference in joint diameter between the arthritic (right) and non-arthritic 
control (left) in each animal gave a quantitative measure of swelling (in mm). Statistical 
analysis was performed using unpaired t-test. 
 
2.9.3 Osteoarthritis Model  
2.9.3.1 Animals 
This study was carried out in accordance with UK Home Office Animals (Scientific 
Procedures Act 1986) and the guidelines of the International Association for the Study of 
Pain. Experiments were performed in 6 week old male Sprague Dawley Rats ranging in 
weight from 160-200 g obtained from Nottingham University animal house. Surgery was 
carried out by Dr Devi Sagar and Dr James Burston. 
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2.9.3.2 Induction of Osteoarthritis- Meniscal Transection Model (MNX)  
OA was induced by transecting the medial collateral ligament of the left knee of each 
anaesthetised rat and a full thickness cut made through the meniscus (day 0). Incisions were 
then closed using surgical staples. Weight gain, posture and behaviour were carefully 
monitored throughout the post-injury period.  14 days post-surgery, rats were stratified into 
groups (n=4) (Table 2.6) according to pain behavioural responses and prepared for cell 
implantation. Unfortunately, 1 rat did not survive the surgery and for this reason, only 3 rats 
were placed within the SiMAG-labelled group. A 10 μl solution containing 1.5x106 CM-DiL 
labelled mMSCs (either labelled with or without SiMAG (10 µgFe/ml) re-suspended in 
serum free media were then injected intra-articular through the infrapatellar ligament of the 
diseased knee.  
Table 2.6. Explanations of experimental groups. 
Group Description Tracking period 
1 (n=3) SiMAG-labelled mMSCs  29 days 
2 (n=4) Unlabelled mMSCs 29 days 
3 (n=4) Serum Free Media 29 days 
 
 
2.9.3.3 Pain Perception 
Behavioural tests assessing changes in weight-distribution and sensitivity to mechanical 
stimuli were performed for up to 42 days post-surgery by Dr Devi Sagar and Dr James 
Burston. Baseline measurements were taken immediately prior to intra-articular injection 
(day 0) and then from day 3 onwards.  
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2.9.3.3.1 Weight Bearing Asymmetry  
The effects of MNX surgery on the weight-distribution through the left and right knee was 
assessed using an incapacitance tester (Linton Instrumentation, UK) (Figure 2.12) and was 
assessed between post-operative days 3 to 42. The two hind-paws were placed on separate 
sensors and the force (in grams) exerted by each hind limb was calculated and averaged over 
a period of 3 seconds as described previously by Clayton et al and Elmes et al (181, 182).  
Each data point was taken as the mean of three 3 second readings and the weight bearing 
asymmetry calculated by applying the below equation 2.3. Statistical analysis performed by 
two way Anova with Bonferrioni post-test using GraphPad. 
Equation 2. 1 Equation used to calculate the weight bearing asymmetry of rats. This is 
the ratio of the forces placed on the treated (left) and untreated (right) hind legs. 
 
 
Figure 2.12. Incapacitance tester used to evaluate weight bearing asymmetry of rats. 
Rats are placed within a transparent box with hind legs placed on the sensor pads. 
 
2.9.3.3.2 Mechanical Allodynia 
The development of allodynia is commonly assessed using von Frey monofilaments 
(Semmes-Weinstein monofilaments) of bending forces 1, 1.4, 2, 4, 6, 8, 10 and 15 g (40) 
              Chapter 2 - Materials and Methods                                                                                           
   
106 | P a g e  
 
(Figure 2.13). Rats were placed in transparent plastic cubicles placed on a mesh floored table 
and allowed to acclimatize prior to testing.  Von Frey monofilaments were then applied, in 
ascending order of bending force, to the plantar surface of both hind-paws.  Each von Frey 
was applied for a 3 sec period.  Once a withdrawal reflex was established, the paw was re-
tested with the next descending von Frey monofilament until no response occurred. The 
lowest weight of monofilament which elicited a withdrawal reflex was noted as the paw 
withdrawal threshold. Statistical analysis performed by two way Anova with Bonferrioni 
post-test using GraphPad. 
 
Figure 2.13. Equipment used to measure paw withdrawal threshold. Rats are placed 
within the transparent cubicle shown in A) allowed to settle before assessing pain using 
a range of von Frey monofilaments shown in B.  
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3.1 Introduction 
 
The imaging and tracking of stem cell population in vivo requires the application of a contrast 
agent with the complementing imaging modality to distinguish the implanted cells against 
the biological tissue (84, 93, 183). MR imaging is a highly powerful, non-invasive technique 
benefiting from high spatial resolution, high tissue contrast and importantly, is available in 
most clinics today (93). Furthermore, the use of contrast agents in MR imaging improves the 
diagnostic power of this technique by enhancing the contrast between healthy and diseased 
tissues/organs and also improves image specificity. Of notable importance are the group of 
FDA approved SPION-based MRI contrast agents (119, 128). These are accepted T2 
weighted contrast agents (119, 128) and are commonly used to image the liver and spleen 
(130). Table 3.1 describes the range of commercially available T2 weighted MRI contrast 
agents, specifically focusing on their size and coating characteristics. Noticeably, dextran is 
the preferred coating of choice with a hydrodynamic diameter commonly ranging from 20 – 
150 nm in size.  
Table 3. 1. Commercial FDA approved T2-Weighted Contrast Agents.  
 
Brand Name Generic Name Target Hydrodynamic 
diameter (nm) 
Coating Reference 
Endorem (EU),  
Feridex (USA) 
Ferumoxide Reticulo-
endothelia 
system, 
Liver 
80-150 Dextran (184, 185) 
(186) (91) 
Rienso (EU), 
Feraheme (USA) 
Ferumoxytol Fe 
replacement 
20-30 Carboxyl -
methyldextran 
(91, 187) 
Resovist (EU, USA) Ferucarbotran Blood Pool 20 Carboxydextran (91, 188) 
Sinerem (EU) 
Combidex (USA) 
Ferumoxytol Blood Pool 15-30 Dextran (91, 189) 
(186) 
Lumirem (EU) 
Gastromark (USA) 
Ferumoxsil Liver, 
Blood pool 
300 Silica (91) 
  
The clinical approval of this range of contrast agents (Table 3.1) has encouraged the adoption 
of these particles by research communities working to image and track cells in vivo (83, 184, 
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187). Whilst still in seldom use,  Endorem,  Resovist and Sinerem have officially been off 
the commercial market since 2009 and are no longer available for purchase (91). Therefore, 
extensive efforts have been devoted to the development of novel SPIONs as imaging and 
tracking agents (91, 134). A commercial and literature search has revealed a vast and 
extensive range of SPIONs currently available, ranging in size, coating and functionalities. 
In general terms SPIONs are composed of either a magnetite (Fe3O4) or maghemite (γ-Fe2O3) 
core (125, 131) coated with a biocompatible polymer (121, 132); together defining the 
hydrodynamic diameter of the particle. Both maghemite and magnetite are ferrimagnetic in 
nature; however as their size decreases below 30 nm they lose their permanent magnetism 
and become superparamagnetic in nature (109). This has significant implications in the 
biological context as the superparamagnetic nature of the particles implies that the particles 
do not retain their magnetisation after the removal of the magnetic field. Therefore, will not 
be magnetically attracted to each other and so the risk of agglomeration in a medical setting 
is minimised (120, 129). The biocompatibility of the particle is attributed to the addition of 
the polymer coating preventing the biological entity from adverse effects as a result of being 
in direct contact with the iron core (121, 122). Silica, fibronectin and dextran are all examples 
of biocompatible polymer coatings, all of which can be further surface functionalised to 
enhance cell–SPION interactions (111,118,123). The nature of the polymer coating and the 
consequent modifications determine the ultimate physical and biological properties of the 
particles such as the size, charge, toxicity and degradability (91). 
SPION internalisation is a necessary prerequisite for the successful imaging and tracking of 
stem cell populations in vivo by MRI. Essentially, cells are encouraged to internalise SPIONs 
via various uptake mechanisms in order to accumulate within the cell cavity. When MR 
imaged, the SPIONs effectively alter the transverse relaxation properties of the water protons 
thus producing dark negative contrast providing an effective, simple and non-invasive means 
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of visualising cells against the background of a tissue as hypointense signal voids on MRI 
scans (91). 
Each of the particle characteristics (size, polymer coating and functionalities) have been 
reported to impact the rate and efficiency of SPION internalisation. In addition to the 
physical properties of the particle, cell type and rate of proliferation have also been known 
to affect this process (91, 118). Transfection agents (TA) can be implemented to promote 
SPION uptake (91, 106). A downfall of using TA is associated with unwanted toxic effects 
and impaired biological properties of the cells thus limiting the therapeutic potential of cells 
(91).  
There is no clear consensus as to the ideal set of SPION characteristic that would yield the 
greatest uptake while producing the best contrast. Figure 3.1 lists the criteria defining the 
ideal labelling agent. This includes efficient particle uptake, the ability to create T2 weighted 
contrast, biocompatible and the long term retention of particles to facilitate long term 
tracking.  
 
Figure 3.1. Basic criteria defining the ideal labelling agent for the in vivo imaging and 
tracking of implanted cells.  
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3.2 Aims and Objectives 
 
This chapter aims to investigate four commercially available SPIONs, namely SiMAG, 
Lumirem, Nanomag and P904 and their potential as tracking agents in arthritic stem cell 
based therapies. The criteria listed in Figure 3.1 will form the basic acceptance criteria 
according to which each particle will be assessed. However, this list has been modified 
(Figure 3.2) to increase the likeliness of clinical adoption. 
 
Figure 3.2. Modification of basic criteria defining the ideal labelling agent to increase 
likelihood of clinical adoption.   
 
Therefore, this chapter aims to assess a range of commercially available SPIONs on their 
potential application as in vivo tracking agents based on Figure 3.2. SPION internalisation 
will be assessed and subsequent effects on cell viability, proliferation and biological function 
of hMSCs and porcine chondrocytes will be further evaluated.  
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3.3 Materials and Methods 
 
The flow chart summarises key experimental aims of this chapter in dark blue with specific 
experimental parameters in light blue (Figure 3.3).  Further details can be found in Chapter 
2; Materials and Methods. 
 
Figure 3.3. Experimental plan for the selection of a labelling agent and the development 
of a labelling protocol for the use of SPIONs to track cell populations using MRI. 
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3.4 Results 
 
3.4.1 Cell Characterisation 
Bone marrow derived hMSCs reside within a heterogeneous population of cells within the 
bone marrow.  It is therefore essential to validate the specific characteristics of the isolated 
cells and confirm their identity as multipotent MSCs. hMSCs were characterised by applying 
the minimal criteria, set by the International Society for Cell Therapy (ISCT) (75). 
Similarly, it is necessary to characterise the porcine primary chondrocytes isolated from 
fresh articular knee cartilage. Primary chondrocytes can be characterised by their ability to 
secrete sulphated glycosaminoglycans (50). 
 
3.4.1.1 Human Mesenchymal Stem Cells (hMSCs) 
3.4.1.1.1 Plastic Adherence 
hMSCs were identified as those which after two weeks in culture had adhered to tissue 
culture plastic with a spindle shaped fibroblastic like appearance, as shown in Figure 3.4.   
 
Figure 3.4. hMSCs attached to tissue culture plastic at passage 1. Scale Bar = 100μm. 
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3.4.1.1.2 Cell Surface Marker Expression 
Flow cytometry was implemented to investigate the expression of cell surface markers 
typical to hMSCs and to validate the lack of hematopoietic markers as defined by Dominici 
et al (75). Flow cytometry analysis (Figure 3.5) demonstrated the positive expression of the 
MSC markers: CD 73, CD 90 and CD 105 while proving negative for the expression of 
CD14, CD 19, CD 31, CD 34, CD 45 and HLA-DR although the expression for CD14 was 
higher than expected. Percentage of positive expression of each of these cell markers are 
stated in Table 3.2.  
Table 3. 2. Positive expression of typical MSC Surface Markers. 
Cell Surface Marker % Positive 
CD14 13.50 
CD19 4.25 
CD31 5.60 
CD34 4.89 
CD45 4.66 
CD73 62.13 
CD90 74.57 
CD105 65.91 
HLA-DR 4.77 
 
 
Figure 3.5. Characterisation of the expression profile of typical hMSC surface markers 
(CD 105, CD 73, CD 90) and demonstrating the lack of hematopoietic markers (CD34, 
CD 45, CD 14, CD 19, CD 31 and HLA-DR) using flow cytometry.  
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3.4.1.1.3 Multi-lineage Differentiation of hMSCs 
The multipotent differentiation capacity of bone marrow derived hMSCs was investigated 
by inducing differentiation towards osteogenic, adipogenic and chondrogenic lineages. 
hMSCs underwent successful differentiation towards all three lineages (adipogenic, 
chondrogenic and osteogenic) after 21 days in culture with relevant differentiation media. 
Adipogenesis was confirmed by the presence of lipid and triglyceride droplets stained 
positive with oil red O after 21 days cultured with adipogenic differentiation media (Figure 
3.6 A). Calcium deposition was stained positive by alizarin red for samples receiving 
osteogenic differentiation media, thus confirming osteogenesis (Figure 3.6 B).  Alcian Blue 
stain was used to identify the secretion of sulphated gycosaminoglycans by cells which had 
undergone chondrogenic differentiation (Figure 3.6 C). No positive staining was observed 
in control groups receiving basic proliferation media for all cases nor at day 0 (image not 
shown). This study confirms the multipotency of isolated hMSCs as well as their 
differentiation capacity.  
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Figure 3.6. Multi-lineage differentiation of hMSCs. Images represent differentiation of hMSCs towards (A) Adipogeneic, (B) Osteogenic 
and (C) Chondrogenic lineages with time at days 14 and 21 days. Scale Bar = 100 μm. 
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3.4.1.2 Chondrocytes 
Chondrocyte morphology appeared rounded upon isolation at Passage 0 while at P1, 
chondrocytes appeared to be flatter and more spread out (Figure 3.7). 
 
Figure 3.7. Chondrocyte morphology at passages 0 and 1. Scale Bar = 100 μm  
 
3.4.1.2.1 Alcian Blue Staining 
Porcine chondrocytes (P3) were characterised by their ability to secrete sulphated 
glyosaminoglycans (GAGs) when cultured in monolayer in either standard proliferation 
media or in chondrogenic differentiation media. Alicia blue staining highlights secreted 
sulphated GAGs as blue. Secreted GAGs were detected for chondrocytes cultured in both 
proliferation media and chondrogenic media while the use of chondrogenic media resulted 
in the increased secretion of sulphated GAGS over a 21 day culturing period (Figure 3.8). 
This confirms the identity of chondrocytes.  
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Figure 3.8. Alcian Blue staining of chondrocytes highlighting the secretion of sulphated 
GAGs as blue areas when cultured in chondrogenic media or basic proliferation media 
at day 21. Secreted sulphated GAGS are depicted by blue s. Scale Bar= 100 μm 
 
3.4.2 Particle Characterisation 
The physiochemical properties of the each particle (SiMAG, Lumirem Nanomag and P904) 
were assessed in terms of particle size, particle charge and Fe content. Nanoparticle 
fabrication can be a highly variable process. It is therefore essential to validate the 
information given by the manufacturers, as these parameters can affect the uptake of 
particles by the cells.  
 
3.4.2.1 Size  
The principal of dynamic light scattering was applied to measure and validate the reported 
hydrodynamic diameter (HD) of each particle (SiMAG, Lumirem, Nanomag and P904). 
Particles were characterised under standard cell culturing conditions. Nanoparticles were re-
suspended in either serum free media (SFM) or serum containing media (SCM) and 
incubated for 24 hrs at 37 oC and 5 % CO2  in order to mimic cell labelling conditions. 
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The HD of SiMAG as reported by Chemicell is 1000 nm. The addition of serum to culture 
media (SCM) resulted in a statistically significant decrease in the HD of SiMAG when 
compared to SFM at the same time point (0 hrs) (SFM; 1.23 ± 0.103 μm vs SCM: 0.97 
± 0.041 μm with P < 0.001). This difference became insignificant over the 24 hr incubation 
period time where similar HD sizes were measured for SiMAG when incubated in SFM and 
SM for 24 hrs (SFM 1.19 ± 0.228 μm vs SCM, 1.09 ± 0.178 μm). The effect of  incubation 
time on the HD of SiMAG when incubated in either SFM or SCM resulted in a non-
statistically significant difference in HD over the 24 hr period (SFM: 0 hrs; 1.23 ± 0.103 
μm vs 24 hrs; 1.19 ± 0.228 μm; SCM: 0 hrs 0.97 ± 0.041 μm; vs 24 hrs, 1.09 ± 0.178 μm). 
In all cases, the HD of SiMAG falls approximately within the 1 μm range roughly validating 
the manufacture`s report (Figure 3.9 A).  
The incubation of Lumirem with either SCM or SFM resulted in a marked increase in HD at 
either of the two time points (0 hrs and 24 hrs) when compared to the reported value of 300 
nm. Further to this, the addition of serum and the effect of incubation time had no significant 
impact on the HD of Lumirem (SFM: 0 hrs; 1271± 221 nm, 24 hrs; 1208± 216 nm; SCM: 
0hrs; 1329 ± 168 nm, 24 hrs; 1401 ± 152). (Figure 3.9 B). 
A HD ranging between 50-75 nm has been reported for Nanomag. In this case, the effect of 
serum had a significant effect on the HD of Nanomag whilst the effect of incubation time 
had no effect on this parameter. The addition of serum resulted in a significant (P<0.0001) 
decrease in the HD of Nanomag when compared to SFM at both time points (0 hrs: SFM; 
76.4 ± 2.9 nm vs SCM 48.3 ± 2.8 nm and 24 hrs: SFM 78.5 ± 2.6 nm vs SCM 49.2 ± 1.48 
nm). Both sets of values fall within the reported range highlighting the effect of serum on 
the HD of Nanomag (Figure 3.9 C). 
Chapter 3- Labelling 
120 | P a g e  
 
Finally, the addition of serum and the effect of incubation time had no statistically significant 
impact on the HD of P904 with values falling in very close to the reported value of 22 nm 
(SFM: 0 hrs; 23.9 ± 1.68 nm, 24 hrs; 24.7 ± 1.01 nm, SCM: 0 hrs; 22.3 ± 1.44 nm, and 24 
hrs 22.1 ±1.21 nm) (Figure 3.9 D). 
 
Figure 3.9. Dynamic light scattering analysis of particle size to investigate the effect of 
SCM (serum containing media), SFM (serum free media) and incubation time on the 
hydrodynamic diameter (HD) of each particle: (A) SiMAG, (B) Lumirem, (C) 
Nanomag and (D) P904 when compared to the equivalent particles in water and the 
reported manufactures value.  Data = mean HD ± SD, n=3. Statistical significance 
levels represented by * where p < 0.05, ** is p < 0.01 and *** is p<0.001.  
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A poly dispersity value is produced by the Malvern H3000 zetasizer to complement the DLS 
data. This is a measure of the size distribution of particles within a suspension. This is a 
dimensionless value ranging from 0-1 and scaled such that the lower range of values are 
representative of monodispersed solutions. Values greater than 0.7 are indicative of a particle 
solution with a highly broad size distribution. Table 3.3 highlights the polydispersity values 
at each condition (SFM or SCM) and time point (0 hrs and 24 hrs) for each particle (SiMAG, 
Nanomag, Lumirem, P904) when measuring HD by DLS. The maximum polydispersity 
value of 1 was reported for Lumirem at all conditions and is thus characterised as being a 
solution with a highly broad size distribution of particles. SiMAG is considered the next 
broadly dispersed solution amongst the group of particles with polydispersity values of 
0.51 ± 0.11 and 0.53 ± 0.28 reported at 0 hrs for both SFM and SCM respectively. This 
value then increases to 0.75 ± 0.28 and 0.78 ± 0.23 for SFM and SCM respectively after the 
24 hr incubation period. This is followed by Nanomag. A lower polydispersity index is 
noticed for Nanomag incubated in SFM at either time point (SFM 0 hrs; 0.29 ± 0.004, 24 
hrs; 0.33 ± 0.004). However, the polydispersity index for Nanomag appeared to increase to 
0.7± 0.006 and 0.74 ± 0.007 when incubated in SCM at either 0 hrs or 24 hrs respectively. 
The lowest range of polydispersity values was observed for P904 with a noticeable trend 
similar to Nanomag.  The polydispersity of P904 was higher when incubated with SCM than 
in SFM at either time point (SFM: 0 hrs; 0.19 ± 0.03, 24 hrs; 0.2± 0.06, SCM: 0 hrs; 0.4 ± 
0.007, 24 hrs; 0.36  ±  0.02). Polydispersity values for all particles (SiMAG, Lumirem, 
Nanomag and P904) in different conditions (SFM vs SCM) are summarised in Table 3.3. 
Furthermore, a schematic diagram illustrating the relative size differences between all four 
particles and the cells used in this study (hMSCs and chondrocytes) under different 
conditions and time points (Figure 3.10). This set of results imply that SiMAG, Nanomag 
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and P904 do not cluster and aggregate in the presence of either SFM or SCM media with the 
measured HD values hovering closely similar to the reported value.  
Table 3.3. Polydispersity values of SiMAG, Lumirem, Nanomag and P904 when 
incubated in serum free and serum containing media at either 0 hrs or 24 hrs. Values 
are expressed as mean ± SD (n=3) 
 
Particle Serum Free Media Serum Containing Media 
 0 hrs 24 hrs 0 hrs 24 hrs 
SiMAG 0.51 ± 0.11 0.75 ± 0.28 0.53 ± 0.17 0.78 ± 0.23 
Lumirem 1 ± 0 1  ± 0 1 ± 0 1 ± 0 
Nanomag 0.29 ± 0.04 0.33 ± 0.04 0.70 ± 0.06 0.74 ± 0.07 
P904 0.19 ± 0.03 0.2 ± 0.06 0.40 ± 0.07 0.36 ± 0.02 
 
 
Figure 3.10. Schematic representing the relative size difference between the four 
selected particles: SiMAG, Lumirem, Nanomag and P904 under various incubation 
conditions (SFM, SCM, for either 0 hrs or 24 hrs) in comparison to the manufactures 
reported value and to a hypothetical hMSCs (20 μm) and Chondrocytes (10 μm) size. 
Scale bar = 5μm 
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3.4.2.2 Charge – Zeta Potential 
The zeta potential (ζ) is defined as the degree of electrostatic repulsion or attraction between 
particles and is an essential parameter dictating stability of a particle suspension (colloidal 
suspension) (179). SiMAG and Lumirem were discovered to be negatively charged but 
stable (-34.6 ± 0.4 and -61.4 ± 0.8 mV respectively), whilst P904 and Nanomag were both 
found to be positively charged with a lower degree of stability (1.8 ± 3.4 and 2.7± 0.4 mV 
respectively) in comparison to SiMAG and Lumerim, as shown in Table 3.4. 
 
Table 3.4. Zeta potential values for each particle. Values are expressed as a mean ± SD 
(n=5). kCPs refers to the count rate;  Mob refers to the electrophoretic mobility. 
 
Particle kCPs Mob Zeta Potential ζ (mV) 
SiMAG 6765 ± 217 -2.74 ± 0.03 -34.6 ± 0.4 
Lumirem 2980 ± 105 -5.09 ± 0.065 -61.4 ± 0.8 
Nanomag 2383 ± 3.8 0.24 ± 0.031 2.7 ±  0.4 
P904 2380 ± 15 0.14 ± 0.27 1.8 ± 3.4 
 
 
3.4.2.3 Particle Relaxivity 
The relaxivity of a given particle is a measure of its ability to form contrast when MR imaged. 
Figure 3.11 demonstrates the comparative R2 relaxivity of each particle (SiMAG, Lumirem, 
Nanomag and P904) with R2 being defined by the gradient of the slope. Under these imaging 
conditions, Lumirem appears to have the greatest potential to form contrast with an R2 value 
of 0.019 ms-1 in comparison to SiMAG (0.011 ms-1) Lumirem (0.007 ms-1) and finally P904 
(0.0005 ms-1).  
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Figure 3.11. Particle relaxivity (R2) of SiMAG, Lumirem, Nanomag and P904. MR 
imaging of each particle at varying concentrations (5-40 μg Fe/ml; T2 weighted MSME 
sequences) used to determine R2 measurements. Data shown represents the inverse of 
T2 measurements at each concentration with the slope signifying the R2 value.  
  
3.4.3 Assessing Particle Uptake 
3.4.3.1 Prussian Blue Staining 
The visual assessment of particle internalisation following a passive incubation period of 24 
hrs was assessed by Prussian blue staining (Figure 3.12 & 3.13). hMSCs and chondrocytes 
were labelled with SiMAG, Lumirem, Nanomag and P904 ranging in Fe concentration 0, 1, 
5, 0 and 100 μgFe/ml.  The hydrochloric acid component of the stain was used to degrade 
the particle thus exposing the iron core which then reacts with the potassium ferrocyanide 
component. The reaction results in the formation of a blue stain of the iron particles when 
visualized by light microscopy. Prussian blue staining revealed the presence of SiMAG 
within the cell membrane of hMSCs and chondrocytes when labelled with 1, 5, and 10 
μgFe/ml. Particle content was noticed to increase within increasing SiMAG concentration 
1-10 μgFe/ml for both hMSCs and chondrocytes (Figure 3.12 & 3.13). It is obvious that the 
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addition of 100 μgFe/ml of SiMAG is in significant excess, as SiMAG particles are observed 
to almost completely cover the bottom of the well and appear to sit on top of the cells 
(hMSCs and chondrocytes) (Figure 3.12 & 3.13). Further to this, considerably fewer stained 
particles could be detected within hMSCs when labelled with 5, 10 and 100 μgFe/ml 
Lumirem, shown by white arrow in Figure 3.12. No Lumirem particles could be detected at 
either concentration (1, 5, 10 and 100 μgFe/ml) for chondrocytes (Figure 3.13). Furthermore 
no particles could be detected in either cell type when labelled with Lumirem (1 μgFe/ml), 
Nanomag (1, 5, 10 and 100 μgFe/ml), P904 (1, 5, 10 and 100 μgFe/ml) appearing similar to 
unlabelled cells.  
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Figure 3.12. hMSCs stained with Prussian Blue. Light microscopy images (24 hrs post 
labelling) of Prussian blue stained SPION-labelled hMSCs (SiMAG, Lumirem, 
Nanomag & P904; 1, 5, 10, 100 μgFe/ml ). SPION are stained blue and shown by white 
arrow Scale bar = 100 µm.  
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Figure 3.13. Porcine chondrocytes stained with Prussian Blue. Light microscopy 
images (24 hrs post labelling) of Prussian blue stained SPION-labelled chondrocytes 
(SiMAG, Lumirem, Nanomag & P904; 1, 5, 10, 100 μgFe/ml ). SPION are stained blue 
shown by the white arrows. Scale bar = 100 µm 24hrs 
 
3.4.3.2 ICP–OES  
ICP-OES was used to determine the intracellular Fe content of hMSCs and chondrocytes 
when labelled with 10 μgFe/ml of SiMAG, Lumirem, Nanomag, and P904 in either serum 
free (SFM) or serum containing media (SCM). In general, the use of serum free labelling 
media facilitated improved uptake efficiencies for both hMSCs and chondrocytes when 
compared to the use of serum containing labelling media for all particles apart from P904 
and Lumirem labelled chondrocytes. Furthermore, SiMAG was most efficiently internalised 
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by both hMSCs and chondrocytes, corroborating Prussian blue results. Similar uptake trends 
were obtained for hMSCs and chondrocytes when labelled with either SiMAG, Nanomag or 
P904, this however was not the case for Lumirem. (Figure 3.14 & 3.15 E).   
The use of SCM resulted in very similar uptake efficiencies for hMSCs (58 % ± 3.29) and 
for chondrocytes (55 % ± 6.08) (Figure 3.15 A) when labelled with 10 μgFe/ml SiMAG 
resulting in 16±0.7 pgFe/hMSC and 14 ±0.9 pgFe/chondrocyte (Figure 3.14 A). The 
labelling of hMSCs and chondrocytes in SFM resulted in a significant increase in the uptake 
of SiMAG by both hMSCs (p<0.001) and chondrocytes (p<0.01) when compared to SCM 
media, equating to 22 ± 0.41 pgFe/hMSC and 20 ± 0.46 pgFe/chondrocyte (Figure 3.14 A). 
Lumirem labelling (Figure 3.14 and 3.15 B) resulted in significantly greater amount of Fe 
uptake in hMSCs when compared to chondrocytes in both media types (SFM and SCM). 
The labelling of hMSCs with Lumirem in SCM resulted in approximately 11 % of the 
Lumirem being taken up with this equating to 2.4 ± 0.46 pgFe/hMSC. This is a significant 
(p<0.001) increase over chondrocytes where only 0.63 % uptake being detected under 
similar conditions (SCM) equating to 10 times less Fe per cell (0.2  ± 0.13 
pgFe/chondrocyte). Furthermore, there was an insignificant increase in the uptake of 
Lumirem in SFM over SCM for chondrocytes resulting in 1.39 ± 0.35 pgFe/chondrocyte. In 
comparison, there was a statistically significant increase in the uptake of Lumirem in the 
presence of SFM over SCM for hMSCs resulting in 4.8 ± 0.5 pgFe/hMSC (p<0.0001) which 
is also a significant increase over chondrocytes under the same conditions (SFM) (0.45±0.34 
pgFe/chondrocyte p<0.0001). 
Nanomag (Figure 3.14 & 3.15 C) did not demonstrate the ability to be significantly taken up 
for either of the cell types (hMSCs and chondrocytes) with only 0.8 % of the Fe being 
internalised by hMSCs and 1.19 % for chondrocytes when labelled with SCM translating to 
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0.2 ± 0.3 pgFe/hMSC and 0.34 ±  0.2 pgFe/chondrocyte. The uptake efficiency then 
significantly increased in SFM to 4 % for hMSCs (p<0.05) and 4.23 % for chondrocytes 
(p<0.001) which was equivalent to 1 ± 0.3 pgFe/hMSC and 1.3 ± 0.35 pgFe/chondrocyte. 
Over 95 % of the Fe associated with Nanomag was detected in the media (SFM and SCM). 
No significant differences were observed between cell types while the presence of SFM 
resulted in a significant increase in particle uptake over SCM for both cell types. 
Overall, the labelling of chondrocytes with P904 resulted in significantly greater levels of 
Fe per cell than for hMSCs in both types of labelling media (Figure 3.14 & 3.15 E). 
Furthermore, choice of labelling media did not appear to influence uptake. Under SCM 
2.3±0.34 pgFe/chondrocyte were detected. This was just over double the amount found in 
hMSCs under the same conditions (1.3 ± 0.35 pgFe/hMSC; p<0.0001). Significantly greater 
Fe levels were also detected under SFM for chondrocytes (1.7 ± 0.07 pgFe/cell) than hMSCs 
(0.65 ± 0.16 pgFe/cell; p<0.0001). 
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Figure 3.14. ICP-OES quantification and comparison of total Fe content per cell 
(hMSCs and chondrocytes) post particle labelling in either serum free media (SFM) or 
serum containing media (SCM) for: (A) SiMAG, (B) Lumirem, (C) Nanomag and (D) 
P904 labelled with 10μgFe/ml. (E) Shows a comparative graph comparing the total iron 
content for each particle per cell type and media condition. Data = mean Fe ± SD, n=3.  
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Figure 3.15. Percentage Fe uptake and comparison of Fe in media and cells (hMSCs 
and chondrocytes) post particle labelling in either serum free media (SFM) or serum 
containing media (SCM) for: (A) SiMAG, (B) Lumirem, (C) Nanomag and (D) P904. 
E) Shows a comparative graph comparing the total iron content for each particle per 
cell type and media condition. Data = mean ± SD (n=3). 
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3.4.4.3 Particle uptake efficiency 
Prussian blue staining and ICP-OES analysis confirmed the efficient internalisation of 
SiMAG by both hMSCs and chondrocytes. The labelling efficiency was then investigated at 
varying SiMAG concentrations (1, 5 and 10 μgFe/ml) in SFM. Prussian blue staining 
revealed approximately 95% of cells to have internalised SiMAG when labelled with 5 
(hMSC; 94±2% & chondrocytes 94±5%) and 10 μgFe/ml (hMSC; 95±3% & chondrocytes 
95±2%) while fewer cells appeared to be labelled with 1 μgFe/ml (hMSC; 10±1.5% & 
chondrocytes 14±4%) SiMAG (Figure 3.16). As expected, the amount of Fe per cell 
significantly increased (p<0.0001) with increasing SiMAG concentration between each 
condition for both cell types hMSCs; (1 μgFe/ml; 0.22  ± 0.09 pgFe/cell, 5 μgFe/ml; 
14.29  ± 0.59 pgFe/cell and 10 μgFe/ml; 21.88  ± 0.4 pgFe/cell) and chondrocytes; (1 
μgFe/ml; 0.33 ± 0.36 pgFe/cell, 5 μgFe/ml; 13 ± 0.54 pgFe/cell and 10 μgFe/ml; 20 ± 0.3 
pg Fe/cell) (Figure 3.17). 
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Figure 3.16. Prussian blue staining to investigate particle uptake efficiency 24 hrs post labelling. Light microscopy images of Prussian 
blue stained SiMAG-labelled hMSCs (1, 5, & 10 μgFe/ml). SPION are stained blue. Scale bar = 100 µm  
Chapter 3- Labelling 
134 | P a g e  
 
 
Figure 3.17. ICP-OES quantification of internalised Fe as a result of increasing SiMAG 
concentration (1, 5, & 10 μgFe/ml) (n=3). Data = mean 𝑭𝒆 ±SD. Statistical significance 
levels represented by *** where is p<0.001 unless otherwise stated 
 
3.4.4 Cell Viability and Proliferation Assessment 
The effect of particle labelling (SiMAG, Lumirem, Nanomag and P904) on the viability and 
proliferative capacity of hMSCs and chondrocytes was investigated at 24 hrs and 7 days 
when labelled with 10 and 100 μgFe/ml of each particle. This investigated the effect of 
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particle dose and exposure time on the viability of cells. An MTT assay and a double staining 
live dead assay were implemented in this study.   
 
3.4.4.1 MTT Assay  
This a measure of mitochondrial activity and is a standard means of assessing cell viability 
and proliferation (109). Normalised MTT data allows for comparisons between the two cell 
types to be made. MTT analysis revealed no diminished viability for either cell type (hMSCs 
and chondrocytes) when labelled with 10 μgFe/ml of the relevant particle (SiMAG, Lumirem, 
Nanomag and P904) after a 24 hr incubation period when compared to untreated cells 
(Figure 3.18 A & B). A marked increase in optical density (OD) was observed between all 
groups incubated with 10 μgFe/ml of each particle (apart from chondrocytes labelled with 
10 μgFe/ml SiMAG) from 24 hours with those tested at 7 days. When compared to untreated 
cells, no impaired viability could be detected in hMSCs incubated with 10 μgFe/ml of either 
particle type after 7 days exposure.  This represents the proliferative abilities of labelled cells 
with results indicating that labelled hMSCs populations retain their ability to proliferate. 
Conversely, there is a significant reduction in OD for chondrocytes labelled with 10 μgFe/ml 
SiMAG after 7 days exposure. This signifies a reduction in metabolic activity (Figure 3.18 
B).  
As demonstrated in Figure 3.18 the effect of a higher particle dose (100 μgFe/ml) did not 
appear to affect viability and proliferation of hMSCs (Figure 3.18 A) and chondrocytes 
(Figure 3.18 B) labelled with Lumirem, Nanomag and P904 at either time point (24 hrs and 
7 days) when compared to untreated groups. However, for hMSCs and chondrocytes labelled 
with 100 μgFe/ml SiMAG a significantly low OD is measured similar to the negative control 
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(dead cells) and is thus indicative of cell death or reduced metabolic activity at both time 
points. 
 
Figure 3.18. Normalised MTT analysis (A) hMSCs and (B) chondrocytes labelled with 
10 and 100 μgFe/ml and left to culture for 24 hrs and 7 days. Data = mean OD ± SD, 
n=3; Statistical significance levels represented by * where p < 0.05, ** is p < 0.01 and 
*** is p<0.001 
  
Chapter 3- Labelling 
137 | P a g e  
 
3.4.4.2 Live Dead Assay  
This is a simple and visual means of assessing cell viability and is based on a double staining 
protocol where live cells, showing intact cell membranes are stained fluorescent green while 
cells with impaired viability and compromised cell membranes are stained fluorescent red. 
A greater number of viable cells (hMSCs and chondrocytes), appearing in green were 
observed in all groups (SiMAG, Lumirem, Nanomag and P904) treated with 10 µgFe/ml in 
comparison to dead cells (red) and displaying similar patterns to the untreated controls 
(Figure 3.19 - 3.21). Furthermore, it was also revealed that there was an increase in the 
overall number of cells (hMSCs and chondrocytes) in these groups after 7 days in culture 
similar to the untreated controls (Figure 3.19-3.21). This demonstrates the proliferative 
abilities of these groups apart from SiMAG-labelled chondrocytes where the proliferation 
activity is clearly demonstrated to be limited as can be seen by the insignificant increase in 
the number of green cells.  
A higher dose (100 μgFe/ml) did not seem to affect the viability and proliferation of hMSCs 
and chondrocytes labelled with Lumirem, Nanomag and P904 at either time point (24 hrs 
and 7 days) when compared to untreated groups, as shown in Figure 3.19 and 3.20. However, 
only a few stained cells (hMSCs and chondrocytes) were visible when exposed to 100 μg 
Fe/ml SiMAG over 24 hrs and 7 days. This is likely due to the excessive amount of particles 
(as depicted by Prussian blue staining (Figure 3.12 & 3.13) preventing the dyes from 
penetrating the majority of the cells.  
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Figure 3.19. Live Dead staining of hMSCs labelled with 10 μgFe/ml and 100 μgFe/ml 
SiMAG, Lumirem, Nanimag and P904 cultured for 24 hrs and 7 days. Green stained 
cells represent live, viable cells whereas red stained cells represent dead, non-viable 
cells. Scale bar = 100 μm. 
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Figure 3.20. Live Dead staining of chondrocytes labelled with 10 μgFe/ml and 100 
μgFe/ml SiMAG, Lumirem, Nanimag and P904 cultured for 24 hrs and 7 days. Green 
stained cells represent live, viable cells whereas red stained cells highlight dead, non-
viable cells. Scale bar = 100 μm. 
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Figure 3.21. Live Dead stain controls. Untreated positive control and DMSO treated 
negative control hMSCs and chondrocytes after 24 hrs and 7 days in culture. Scale 
bar= 100 μm. 
 
3.4.5 Cell Characterisation Post SiMAG labelling. 
The relatively high doses of Fe found in SiMAG-labelled cells (hMSCs and chondrocytes) 
encouraged further investigation into the influence of SiMAG labelling on cell function and 
characteristics. Therefore cells were characterised to ensure cell populations remained robust 
in culture after particle uptake and that biological properties remained intact (75). 
 
3.4.5.1 hMSCs 
3.4.5.1.1 Cell Surface Marker Expression 
Flow cytometry was implemented to investigate the effect of SiMAG labelling (10 μgFe/ml) 
on the expression of standard cell surface markers typical to hMSCs. It demonstrates the 
positive expression of typical mesenchymal markers: CD 73, CD 90 and CD 105 while 
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proving negative for the expression of CD 14, CD 19, CD 31, CD 34, CD 45 and HLA-DR 
as expected (Figure 3.22). Positive expression (%) of each of these cell markers are stated in 
Table 3.7. These values appear similar to values seen in section 3.4.1.1.2 for unlabelled 
hMSCs and can thus be deduced that SiMAG labelling does not influence marker expression. 
Table 3 5. Positive expression of typical mesenchymal cell surface markers in hMSCs 
treated with SiMAG (10 µgFe/ml). 
 
 
  
 
 
  
 
 
Figure 3.22. Characterisation of hMSC surface markers using FACS. hMSCs labelled 
with SiMAG at 10 µgFe/ml for 24 hrs in serum-free conditions. 
 
Cell Surface Marker %Positive 
CD14 22.22 
CD19 5.91 
CD31 6.97 
CD34 4.53 
CD45 5.72 
CD73 77.1 
CD90 80.93 
CD105 73.54 
HLA-DR 5.40 
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3.4.5.1.2 Multi-lineage Differentiation 
SiMAG-labelled hMSCs (10 μgFe/ml) were tested for their differentiation capacity into 
adipocytes, chondrocytes and osteocytes. Labelled cells were incubated for a period of 21 
days in the relevant differentiation medias. Similar to unlabelled hMSCs (Figure 3.6) 
SiMAG-labelled hMSCs underwent successful differentiation towards all three lineages 
(adipogenic, chondrogenic and osteogenic) after 21 days in culture. Adipogenesis was 
confirmed by the presence of lipid and triglyceride droplets stained positive with oil red O 
after 21 days in samples treated with adipogenic differentiation media (Figure 3.23 A). 
Calcium deposition was stained positive by alizarin red for samples cultured in osteogenic 
differentiation media confirming osteogenesis (Figure 3.23 B).  Alcian Blue stain was used 
to identify the secretion of GAGs by cells which had undergone chondrogenic differentiation 
(Figure 3.23 C). No staining was observed in control groups cultured under basic 
proliferation media for all cases (Adipogenesis, Chondrogensis and Osteogenesis) and to the 
day 0 control.  
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Figure 3.23. Multi-lineage differentiation of SiMAG-labelled hMSCs. Multi-lineage differentiation of hMSCs. Images represent 
differentiation of hMSCs towards (A) Adipogeneic, (B) Osteogenic and (C) Chondrogenic lineages with time at days 14 and 21 days. 
Scale Bar = 100 μm. 
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3.4.5.2 Chondrocytes 
SiMAG-labelled chondrocytes (10 μgFe/ml) maintained the ability to secrete sulphated 
GAGs when cultured under standard proliferation media for 21 days. In comparison to day 
0, increased levels of secreted GAGs can be noticed (Figure 3.24) 
 
Figure 3.24. Alician Blue staining of SiMAG-labelled chondrocytes at day 0 and day 
21. Secreted GAGs are shown by blue staining. Scale Bar = 100 μm. 
 
3.4.6 Particle retention 
hMSCs and chondrocytes were labelled with 10 μgFe/ml SiMAG and the retention of 
SiMAG within the cells was monitored over 28 days. Analysis was performed quantitatively 
using ICP-OES and visually using Prussian blue staining on days 1, 7, 14, 21 and 28.  
The amount of Fe associated with SiMAG-labelled hMSCs and chondrocytes over 28 days 
was quantified by ICP-OES. Fe content remained largely stable from day 1 until day 21 for 
both hMSCs and chondrocytes at approximately 20 pgFe/ cell up until day 21. This value 
was seen to significantly decrease to 12 ± 2.8 pgFe/hMSC at day 28 in comparison to days 
1 (p <0.008), days 7 (p<0.008), day 14 (p<0.0116) and day 21 (p<0.0018) (Figure 3.25 A). 
Similarly, the value for SiMAG-labelled chondrocyte was also seen to significantly decrease 
to 6 ±  4.6 pgFe/chondrocytes at day 28 in comparison to day 1 (p<0.0129), days 7 
(p<0.0037), day 14 (p<0.0032) and day 21 (p<0.005) (Figure 3.25 B). 
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Prussian blue staining confirmed the retention of internalised SiMAG by chondrocytes 
(Figure 3.26) for the duration of the study. However, hMSC in comparison a network of 
particles appeared to have developed and it is unclear whether this network was interacting 
with the network of cells (Figure 3.26).   
 
Figure 3.25. ICP-OES quantification of Fe content: (A) hMSC and (B) chondrocytes 
labelled with 10 μgFe/ml SiMAG and cultured for 1, 7, 14, 21 and 28 days post labelling. 
Data point = mean ±SD (n=3); where*p < 0.05, **p < 0.01, ***p < 0.001.   
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Figure 3.26. Prussian blue staining of SiMAG-labelled hMSCs and chondrocytes for 1, 7, 14, 21 and 28 days post labelling.
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3.5 Discussion 
 
Studies by Clift et al and Mairano et al have shown that the exposure of SPIONs to a solution 
containing serum can significantly impact the rate and efficiencies of particle uptake. The 
presence of various proteins in FBS may account for this effect by either causing the 
aggregation of particle or the development of the protein corona (190-192). This theory was 
validated here, where ICP-OES analysis revealed enhanced uptake efficiencies for both 
hMSCs and chondrocytes when labelled with SIMAG, Lumirem and Nanomag in the 
presence of serum free media (SFM) over serum containing media (SCM). The dynamic 
light scattering data (measuring hydrodynamic diameter) did not account for any significant 
SPIONs aggregation with regards to SiMAG, Nanomag and P904 when incubated in either 
SFM or SCM. Although variations in the HD of Nanomag were observed between SFM and 
SCM this is not believed to be a result aggregation but rather an effect of the dextran coating 
and is expected. The measurements of Lumirem (±1200 nm) however resulted in HD 
values far greater than the reported manufacturer’s value (300 nm). This is potentially due 
to the overall application of Lumirem as an oral contrast agent requiring the addition of 
various additives and preservative (and even orange flavouring) to enable its use. Lumirem 
is therefore not a pure SPION solution but has extra additions prohibiting accurate 
measurement of the actual particle size.  Unfortunately, statistical comparison of the 
measured HD of each particle could not be made with the manufacturer’s value due to the 
lack of reported errors. However the measured values are similar to the manufacturers 
reported value and thus assuming a realistic error for all SPIONs, these values can be 
considered acceptable.  
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It is unlikely that the lower uptake levels in SCM media are a result of particle aggregating. 
The theory of the development of the protein corona may better account for these results. 
This theory takes the interaction of the protein in the media as well as the surface of the 
SPION. It is thought that proteins interact with the particle to form a complex layer of 
molecules over the SPION. This biological layer is termed as “corona” (190, 193). The 
physical and chemical properties of SPION (size, surface coating and functionalization) 
dictates the binding of molecules to the particles resulting in either a hard or weak corona 
which is significantly different to that of the surface of the particle (190, 193). This affects 
the initial interaction of the cell with the particle as the cell`s first point of contact is with the 
corona and not the surface of the particle (193). In turn, this dictates subsequent cellular and 
tissue responses, thus the presence of the protein corona may impede particle uptake in serum 
containing conditions (190).   
The greatest amount of Fe was detected in cells (hMSCs and chondrocytes) labelled with 
SiMAG, where approximately 20 pgFe/cell was detected in serum free conditions. Less Fe 
was detected in cells labelled with Lumirem and in particular Nanomag and P904 under the 
same conditions. Detected levels, are however comparable to other studies where internal Fe 
content ranged from 1-30 pg of Fe/cell in comparison to a value of 0.1 pg of Fe/cell for 
unlabelled cells (146, 152).  However, it cannot be assumed that the increased Fe content 
detected in SiMAG-labelled cells is a result of enhanced uptake efficiency when compared 
to the other three particles but rather as a result of its size. In general, larger SPIONs have a 
greater Fe content per particle than smaller SPIONs, therefore, fewer larger SPIONs need to 
be internalised to result in significant Fe measurements (194, 195).  To compare SiMAG and 
Nanomag for example; SiMAG is 20 times larger than Nanomag, assuming each SiMAG 
particle has 20 times more Fe than a single Nanomag particle; then cells would need to 
internalise 20 times more Nanomag particles to achieve similar values to SiMAG. Therefore, 
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without counting individual particle within each cell, conclusions of the comparative uptake 
efficiency between the four particles cannot be made. This observation has significant 
implications for non-phagocytic cells being labelled without the use of TA with intended 
MRI applications implying that the application of micron-sized SPIONs may be beneficial 
for non-phagocytic cells such as stem cells, as each cell would need to internalise fewer 
particles than it would if smaller SPIONs were applied to create contrast. This also implies 
that smaller particles may be required at higher concentrations to facilitate sufficient uptake 
(194). No conclusive comments could be made about the uptake efficiency between SPIONs 
of varying sizes in this study.  
The significantly higher levels of Fe (measured by ICP and visually confirmed using 
Prussian blue staining) for Lumirem between hMSCs and chondrocytes can be explained by 
the concept of  “cell vision” presented by Laurent et al,  (196). This refers to the contact 
point between a particle and the cell membrane, which is characterised by surface molecules 
i.e. proteins, sugars and phospholipid composition. The binding of particles to these 
structures may be different for different cell types and explains how individual cell types 
‘‘see’’ the particle.  As a result, the binding of exogenous objects like SPIONs to these 
structures may cause different responses and influence uptake and metabolism depending on 
the cell type (196, 197). The fact that these results are only seen for Lumirem and not for 
other particles may be accounted for by the variations in polymer coatings between the other 
SPIONs.  Alternatively, residual Lumirem solution may have not been washed off properly, 
as Lumirem is a viscous solution which has proved to be difficult to handle.  
A particular limitation associated with ICP-OES is the inability to distinguish between 
intracellular and extracellular Fe.  Multiple wash steps were performed to try and mitigate 
this issue by removing all extracellular SPIONs. Histological Prussian blue staining is a more 
conclusive method of establishing SPION and cell association. Although, there are increased 
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levels of difficulty in seeing smaller particles which may account for the lack of visual 
evidence for Nanomag and P904.  
Ideally, to strategically determine the effect of any one physiochemical parameter 
(hydrodynamic diameter, polymer coating, surface charge and functionalisation) on 
internalisation of particles, all parameter will need to be maintained while varying the 
parameter in question. This is no easy task as physiochemical properties of SPIONs are 
strongly interconnected  thus altering one parameter may subsequently have effects on other 
parameters (198).  
A vast number of studies have reported stem cells tagged with SPIONs to have little or no 
effect on the proliferation and viability of cells (91, 146, 152, 199).  It is still necessary 
however to address the issue of toxicity in a case by case fashion.  Laurent et al demonstrated 
the same concentration of SPIONs caused significant toxicity on neuronal and glial cells 
whilst displaying little toxicity on other cell types like heart and kidney cells (196, 197). In 
general, a combination of factors can influence SPION toxicity. These factors include; 
particle core material, SPION size, polymer coating and also the immediate in vitro (culture 
media) environment (91, 198).  Toxicity may arise from the leaching of ions from metal core 
and the biodegradation polymer coating; processes that are heavily reliant on the physical 
environment of the particles (198).  At the cellular level, oxidative stress is thought to be the 
main cause of toxicity by SPIONs (156). Oxidative stress arises when there is an imbalance 
between damaging oxidants also referred to as reactive oxygen species (ROS) such as; 
hydrogen peroxide, hydroxyl radicals and the protective anti-oxidants of which vitamin C 
and glutathione are examples. ROS are primarily formed by the incomplete reduction of 
oxygen (200). The accumulation of oxidants eventually leads to the destruction of cellular 
proteins, enzymes, lipids and nucleic acids and as a consequence the normal cellular 
processes become impaired (121, 129, 156, 200). ROS can be generated from the surface of 
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SPIONs, the leaching of metal ions from the core or release of oxidants by enzymatic 
degradation of the SPIONs (109). It has been reported that dissociated iron oxide can 
promote the formation of ROS and hydroxyl radicals and as a result may lead to cellular 
toxicity along with impaired cell metabolism and increases in apoptosis (123). 
Even though Fe is a naturally occurring element in the human body with the body adapted 
to metabolise Fe (88, 98, 105, 120, 136, 147), the potential risk of toxicity associated with 
iron based particles is low but does still need to be assessed. It is important to further 
remember that in high quantities, Fe can possibly impair cell viability by damaging cell 
membranes, proteins and DNA, impeding normal cell function (91, 105, 147). Therefore, it 
is important to obtain a balance between Fe incorporation (concentration) for the required 
role and cell function (105). Particle concentration ranging from 2.8- 400 μg/ml have been 
reportedly used in in vivo tracking (83, 104-107). The particle concentration chosen for this 
study were purposely chosen to primarily lie within the lower range of this range. However, 
the problem lies with studies not generally offering enough information of their labelling 
protocols and generally being vague in terms of concentration specifics. For example, it is 
unclear as to what 50 μg/ml of a certain particle refers too; e.g the level of Fe or cell/SPION 
ratio. There is a significant difference between the addition of 50 μg/ml to 105 cells and to 
106 cells.  Therefore, although a concentration of 400 μg/ml seems high, it really does depend 
on the number of cells that are being labelled to properly put this into perspective. For this 
reason the labelling protocol in this study clearly stipulated all of these parameters. In this 
study, SPION concentration (in terms of Fe) ranging from 1-100 μgFe/ml has been 
investigated. The exposure of hMSCs and chondrocytes to 10 μgFe/ml to either of the 
particles (SIMAG Lumirem, Nanomag and P904 had no significant implication on the 
viability of these cell. A slight reduction in metabolic activity however is observed for 
hMSCs labelled with either of the 4 particles (SiMAG, Lumirem, Nanomag and P904) 
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during the first 24 hrs of labelling. This is most likely attributed to resources being directed 
to physically endocytosing SPIONs therefore resulting in reduced cell metabolism. 7 days 
post labelling metabolic activity restored to levels observed by untreated cells.  The exposure 
of hMSCs and chondrocytes to 100 μgFe/ml SIMAG appeared to significantly impact the 
cell viability of both cells. This was not the case for Lumirem, Nanomag and P904. The 
SiMAG result may not be true, however; based on the Prussian blue staining highlighting 
the obvious excess of particle and the inability of the live dead stain to reach the cells, it may 
be possible that the MTT reagent was not able to come into contact with the cell. In any case, 
further investigation of this needs to be explored. Impaired proliferation capacity was only 
identified for SiMAG-labelled chondrocytes labelled with 10 μgFe/ml SiMAG. This may be 
attributed to the development of ROS which have shown to impair biological activities.  
The ability to potentially track cells over time in in vivo is unfortunately limited by the 
dilution of SPIONs with the proliferation of the cell and exocytosis of the particles by the 
cells. It has been reported that exocytosis is size dependent and smaller particles are 
exocytosed at a faster rate than larger particles. Chondrocytes appeared to fully retain 
SiMAG after 28 days in culture whilst this was not as obvious in the case of hMSCs.  
Furthermore, it became obvious that chondrocyte morphology remained consistent 
throughout the 28 day culture period while hMSCs became elongated with confluency with 
hMSCs appearing to be closely packed from day 7 onwards. Prussian blue staining revealed 
the presence of Fe amongst this cell population. Contrary to chondrocytes (where particles 
are clearly observed within the cell), the particles linked to hMSCs formed chains throughout 
this network of cells. This may indicate that the arrangement of the particles within hMSCs 
is altered with cell shape with particles therefore appearing to form network. The conflicting 
hMSCs and chondrocyte results may be explained by referring to the high proliferation rate 
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of hMSCs in comparison to chondrocytes where proliferative rates of chondrocytes were 
found to be impaired with SiMAG labelling.  
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3.6 Conclusion 
 
This chapter investigated the potential of 4 commercially available SPIONs (SiMAG, 
Lumirem, Nanomag, and P904) as possible cell tracking agents when used in conjunction 
with MRI. Labelling condition revealed optimal uptake in serum free media. A range of 
particle doses were further investigated (1-100 μgFe/ml) revealing the greatest measure of 
intracellular Fe content by SiMAG (for both cell types). Furthermore, at optimal 
concentrations (10 μgFe/ml) no diminished viability or proliferative capacity was 
demonstrated by SiMAG, Lumirem, Nanomag and P904 labelled cell population, although 
the presence of SiMAG appeared to impair the proliferation of labelled chondrocytes (10 
μgFe/ml). SiMAG-labelled hMSCs (10 μgFe/ml) successfully underwent differentiation 
down mesodermal lineages whilst maintaining immunophenotypical profiles post labelling.  
The findings from this chapter highlight the potential application of the investigated SPIONs 
(SiMAG, Lumirem, Nanomag and P904) as possible contrast agents given the observation 
of Fe present within both cell types with no impaired cellular function. It can be concluded 
that these SPIONs largely meet the prerequisites presented in Figure 3.2 defining the ideal 
in vivo cell tracking agent. This chapter however failed to assess the contrast forming ability 
of these particles therefore to make a definitive decision regarding these particles this will 
need to be evaluated. With this, chapter 4 has been design to assess the MRI contrast forming 
potential of SPION-labelled cell population.  
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Chapter 4 
MR-Imaging of SPION-labelled Cell 
Populations  
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4.1 Introduction 
 
SPION and MRI based technologies have been identified as a practical and non-invasive 
means of generating data linked cell fate in vivo. The internalisation of SPIONs by cells 
allows for the location of SPION-labelled cell populations to be identified in vivo by MR 
imaging as hypointense areas of signal loss. The successful imaging and tracking of 
implanted cell populations in vivo using SPIONs and MRI based technologies requires the 
synergistic and optimised relationship between cell labelling (SPIONs) and subsequent in 
vivo cell imaging (MRI). Chapter 3 describes the investigation of SPION-labelling protocols 
for four commercially available SPIONs (SiMAG, Lumirem, Nanomag and P904) by 
hMSCs and chondrocytes. This chapter therefore aims to evaluate the MR imaging 
component of this strategy and assess the ability of SPION-labelled cells to create contrast 
using clinically relevant MRI scanners.  
It is important to have a firm understanding of the MRI detection limits of the system to be 
able to fully exploit the technology in gathering data for stem cell therapy evaluation. 
Furthermore, understanding key parameters affecting visibility threshold is useful in 
optimising the labelling and tracking strategy for maximum results.  The MRI detection 
limits of SPION-labelled cells is dependent on a range of factors including; 
a) The total SPION concentration for a population of cells. This is governed by the SPION 
uptake efficiency and the total number of labelled cells.  
b) The relaxivity properties of the labelling SPION (91). 
c) MRI parameters e.g sequence choice and magnet strength (134, 159).  
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The ability for a contrast agent to successfully create contrast depends on longitudinal (R1) 
and transverse relaxivities (R2) properties of agent itself. Relaxivities can be defined as the 
inverse of the relevant relaxation times;  R1=
1
𝑇1
 and R2=
1
𝑇2
  (159). Table 4.1 highlights the 
relaxivities of some of the commercially available FDA approved contrast agents.  
Table 4.1 Relaxivity measurements for various positive and negative contrast agents 
when assessed at 1.5T and 37 oC. 
Brand Name Type of 
contrast 
agent 
Magnetic 
material 
Relaxivity 
R1 (s-1mM-1) 
Relaxivity R2 
(s-1mM-1) 
Reference 
Endorem  Negative Fe 10.1 120 (159) 
Resovist  Negative Fe 9.7 189 (159) 
Magnevist Positive Gd 3.3 3.9 (159) 
Dotarem Positive Gd 2.9 3.2 (159) 
 
SPIONs have generally been the preferred contrast agent for cell labelling and tracking 
purposes. Gadolinium contrast agents tend to be extracellular compounds and unlike 
SPIONs are not easily internalised by cells. This not only limits the amount of contrast agent 
that can be associated with the cell but the significantly lower particle relaxivity of 
gadolinium compounds in comparison to SPION compounds (Table 4.1) implies that much 
higher concentrations of the gadolinium compound are required to achieve the same level of 
contrast for cell detection (130).  In addition, gadolinium is not biocompatible and has been 
associated with toxic outcomes when used to label cells in vitro (97). SPIONs on the other 
hand have improved biocompatibility as they are composed of biodegradable iron which can 
be incorporated into normal iron metabolism in addition to having increased contrast 
potential.  
Understanding the relaxivity characteristics of SPIONs used in cell labelling and tracking is 
highly advantageous. Selecting particles with high relaxivities implies that contrast can be 
created in at low particle concentration. This is particularly beneficial to cells with low 
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degree of phagocytosis as fewer particles need to be internalised. Furthermore risk of 
toxicities are minimised with lower particle concentration (186)  
Investigating MRI detection limits or visibility thresholds is a necessary step in the 
development of all cell based therapies and is primarily investigated in vitro by re-
suspending labelled cell populations (varying in cell doses and particle concentrations) 
within a gel e.g collagen, agarose and agar to be MR imaged.   
To our knowledge, no studies have taken this further to investigate the detection limits of 
labelled cell populations in various tissues. Given the varying T1 and T2 properties of tissues 
we hypothesise the visibility threshold or detection limits to be influenced by the host tissue.  
We believe this to be an important consideration in tracking cell in vivo in particularly for 
stem cell based therapies reliant on the ability of cells to migrate towards the injured tissue 
and integrate with the tissue. It is important to be able to recognise the implanted cells at the 
given doses against your tissue of interest in order to investigate parameters such as cell 
integration and migration. This is especially important in the knee where there are a number 
of tissues with which cells can integrate in addition to cartilage. These include the patella fat 
pad, patella tendons and the various stabilising ligaments.  
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4.2 Aims and Objectives 
 
 To investigate the contrast forming potential and consequent MRI visibility threshold 
of SPION (SiMAG, Lumirem, Nanomag and P904) labelled hMSCs and 
chondrocytes with relation to particle concentration and cell dosage when visualised 
in vitro. 
 Investigate how the minimum in vitro visibility thresholds are affected by various 
orthopaedic tissue adipose tissue, ligament and muscle  
 Establish an ex vivo model of articular cartilage damage to investigate the minimum 
visibility threshold in a clinically relevant animal model and MRI scanner.   
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4.3 Materials and Methods 
 
4.3.1 Chapter Experimental Plan 
To address the specific chapter aims and objectives, a series of experiments shown in Figure 
4.1 were implemented. More elaborate details of experimental procedures can be found in 
chapter 2; Materials and Methods.   
 
Figure 4.1. Experimental plan for MR-imaging of SPION-labelled cell populations 
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4.3.2 Interpretation of MRI data. 
The presence of SPIONs results in a decrease in signal or a shortening of T2 and is portrayed 
visually by an increase in hypointensity (progression from high signal to low signal). The 
colours are such that blue areas (on colour images) and black areas (on grey scale images) 
are significant of low signal conditions and are referred to as hypointense regions or areas 
of short T2 (Figure 4.2). Areas of high signal are seen as lighter, brighter areas with red areas 
representing areas of the highest signal or longest T2 (Figure 4.2). A decrease in signal 
implies that the likeness of that particular set of conditions to create contrast is improved (0-
1000 ms). The colours produced by the signal offer an indication as to the signal intensity 
range. The specific T2 value can differ within this range. For this reason, the T2
eff is quantified 
as a more accurate means of comparing various conditions and how these could possibly 
affect the visibility threshold. For short values of T2 the signal rapidly decays into the noise 
level. We therefore define the visibility threshold of this particular system as any condition 
(particle concentration and cell dose) which produces a T2
eff value below 75 ms as below 
this value signal cannot be significantly differentiated from the noise thus making it highly 
likely that contrast will be generated within a tissue at those conditions. T2
eff values are taken 
from the periphery of each well as the SI in the center of each well (where the gel dips) 
presents with greater hypointensity.  
 
Figure 4.2. Signal map. Colour range related to signal strength. High signal (red or 
white) representing a long T2 while blue or black areas are significant of low signal and 
short T2 implying that these areas will create contrast.  
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4.4 Results 
 
4.4.1 In vitro MRI visibility threshold. 
4.4.1.1 In vitro MRI dose response optimisation. 
4.4.1.1.1 MRI sequences 
A selection of MRI sequences were investigated and optimised in order to establish a set of 
conditions that will accurately and reproducibly allow for variations in contrast to be 
detected. In this study, hMSCs were labelled with 1, 5 and 10 μgFe/ml SiMAG and re-
suspended within a collagen gel (2mg/ml) at varying cell doses (103, 104, 105, 3x105, 5x105).  
In this set of experiments T2 MSME (Multi Slice Multi Spin Echo) imaging sequences were 
applied in the first instance. Using standard T2 weighted sequences, signal was seen to decay 
rapidly thus making it difficult to obtain values. For this reason it was decided to apply a 
refocusing pulse to delay signal decay allowing for signal to be detected easier. Therefore 
T2
eff was measured in all cases. T1 and T2
eff relaxation parameters were obtained by varying 
repetition times from 100-5000 ms. Figure 4.3 is a graphical interpretation of the effect of 
SiMAG concentration and hMSC cell dose on T1 and T2
eff measurements. As expected T1 is 
not affected by the presence of SiMAG with just a slight variation observed around 1 s at 
each condition (Figure 4.3 B). On the other hand, T2
eff is seen to be greatly affected by 
SiMAG (Figure 4.3 A). T2
eff was found to decrease for increasing numbers of labelled cells 
(from 103 to 5x105) with this further decreasing with increasing SiMAG concentration from 
1 μgFe/ml to 10 μgFe/ml. The T2eff at 1000 cells labelled with 1 μgFe\ml resulted in a lower 
value than anticipated (0.175 ms). This is likely due to poor distribution of the small number 
of cells. With this, it was decided to limit MRI scans to MSEM T2
eff weighted imaging 
sequences with a repetition time 1000 ms.  
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Figure 4.3. Relationship between SiMAG concentration (1, 5 and 10 μgFe/ml) and cell 
dose (104, 105, 3x105, 5x105) on A) T2eff and B) T1. 
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4.4.1.1.2 Collagen Gel Concentration.   
SPION-labelled cells will be re-suspended within a collagen gel when investigating the 
effect of cell dose and SPION concentration on the in vitro MRI visibility threshold. The 
collagen gel serves as a means of providing a physiologically relevant environment while 
retaining cells in suspension and preventing SPION-labelled cells from settling during 
imaging. In this study, varying collagen concentrations (0.5, 2, 5 and 9 mg/ml) were MR 
imaged using the established T2
eff MSME imaging sequence (section 4.4.2.1.1). These values 
were then compared to the T2
eff of water (Figure 4.4 A). Little variation in the T2
eff is 
observed between water and 0.5 mg/ml and 2 mg/ml gels while a significant drop 
(p<0.000053) in T2
eff is observed between water and 5 mg/ml and 9 mg/ml gels.  The 
corresponding T2
eff maps (Figure 4.4 B) appears to be similar in appearance across all 
concentration ranges being bright red/yellow in appearance significant of high signal apart 
from the 9 mg/ml sample where the presence of an air bubble is noticed (arrow Figure 4.4). 
From this experiment, it was decided that 2 mg/ml gel would be used in subsequent 
experiments. This implies that a concentration of 2 mg/ml will not influence the T2
eff 
measurement of SPION-labelled cell populations in subsequent in vitro experiments while 
still preventing the settling of particles during imaging.   
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Figure 4.4. T2eff comparison of varying collagen gel concentration and corresponding 
T2eff map. Arrow represents air bubble shown as hypointense (blue). Data=mean±SD 
(n=6) where *** is significant of p<0.005. 
 
4.4.1.2 In vitro MRI visibility threshold assessment. 
To investigate the minimum visibility threshold, hMSCs and chondrocytes were labelled 
with varying concentrations (1, 5, 10, 100 μgFe/ml) of each particle (SIMAG, Lumirem, 
Nanomag and P904), re-suspended at varying cell density (104, 105 and 5x105) within 2 
mg/ml of a type 1 collagen gel and MR imaged using the Bruker 2.3T MRI scanner with 
optimised MSME T2
eff weighted sequences (section 4.4.2.1.1). For each particle, a T2
eff map 
was produced comprising of the T2
eff image at each condition (particle concentration and cell 
dose) with the corresponding T2
eff value building the T2
eff plot (n=3). This was carried out 
for each cell type (hMSC and chondrocyte) in addition to an acellular control. Together this 
set of results offers a qualitative and quantitative means of determining the minimum 
visibility threshold. The acellular control represents a scenario whereby 100 % of the 
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particles would hypothetically be taken up by each cell type and how this would set the 
visibility threshold. 
a) Unlabelled cells 
T2
eff images (Figure 4.5 A) appear to be bright (yellow/red) in colour across all cell doses 
for both cell types similar to that exhibited by water. The bright colours (Figure 4.5 A) are 
representative of long T2 values and can be verified by the high T2
eff values in Figure 4.5 B. 
 
Figure 4.5. A) T2eff map and B) corresponding T2eff plot of unlabelled hMSCs and 
chondrocytes at varying cell doses (5x105, 104, 103)  
 
b) SiMAG 
Hypointense regions of signal voids (blue areas) highlight the presence of SiMAG-labelled 
cells. Hypointensity is seen to increase with increasing SiMAG concentrations (from 1 
μgFe/ml to 100 μgFe/ml) and increasing cell dose (104 – 5x105). This is significant of signal 
loss while progressing from low concentrations of SiMAG (1 μgFe/ml) towards the higher 
concentrations (100 μgFe/ml) and from lower cell densities (104) towards high cells densities 
(5x105). This trend is clearly observed in the T2
eff plots where a clear relationship is observed 
between the number of labelled cells at each concentration and T2
eff (Figure 4.6) 
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A complete loss of signal is experienced when 5x105 and 105 cells are labelled with 100 
μgFe/ml while the colour is seen to transform to a lighter blue (representing increasing signal) 
when 104 cells are labelled with 100 μgFe/ml (Figure 4.6 Ai and Bi). This effect becomes 
less pronounced with decreasing SiMAG concentration where a complete loss in signal is 
experienced only when 5x105 cells are labelled with 10 μgFe/ml while 104 and 105 are 
represented by a lighter blue area again significant of increasing signal.  Continuing with 
this trend, relatively dark blue area seen when 5x105 cells are labelled with 5 μgFe/ml while 
1x104 labelled with 5 μgFe/ml is represented by bright yellow/red areas significant of high 
signal. Similar trends are observed for hMSCs and chondrocytes alike (Figure 4.6 B). In this 
case, the minimum visibility threshold for SiMAG-labelled hMSCs and chondrocytes will 
be set at 5 μgFe/ml (5x105 labelled cells) (hMSCs; T2eff = 41.92 ms and chondrocytes; T2eff 
= 41.66 ms) in terms of minimum particle concentration and 104 cells (100 μgFe/ml) (hMSCs; 
T2
eff = 73.66 ms and chondrocytes; T2
eff = 65.32 ms).   
The acellular control represents a scenario whereby 100% of the particles would 
hypothetically be taken up by each cell type and how this would set the visibility threshold 
(Figure 4.6 C). Under these conditions, the minimum visibility threshold for SiMAG-
labelled hMSCs and Chondrocytes assuming that all the particles were internalised increased 
to 1 μgFe/ml (5x105 labelled cells)( T2eff = 22.3 ms) and 104 labelled cells (10 μgFe/ml)( T2eff 
= 50 ms). Noticeably, the T2
eff for 104 labelled with 5 μgFe/ml and 104 and 105 (1 μgFe/ml) 
is measured to be longer (Figure 4.6 C ii) than those measured for hMSC and chondrocytes 
(Figure 4.6 A and B ii).  
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Figure 4.6. In vitro dose response; SiMAG. Investigating the relationship between 
SiMAG concentration (1, 5, 10 and 100 μgFe/ml) and cell dose (104, 105, 5x105) on the 
MR visibility threshold for 2 cell types A) hMSCs and B) Chondrocytes while C) 
represents the acellular control. Data is presented as i) T2eff map and ii) corresponding 
T2eff plot. Red line indicated visibility threshold 75 ms. 
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c)  Lumirem   
Greatest signal loss is noticed for hMSCs labelled with 100 μgFe/ml of Lumirem with T2eff 
increasing with decreasing cell doses from when 5x105 to 104 at this concentration (100 
μgFe/ml). However, only 5x105 hMSCs labelled with 100 μgFe/ml Lumirem created enough 
contrast to fall below the minimal visibility threshold (75 ms) (T2
eff = 56.43ms) (Figure 4.7 
A ii).  Further trends are evident where T2
eff is seen to increase with decreasing Lumirem 
concentration, however, this was only significant of 5x105 Lumirem-labelled hMSCs across 
all concentrations. All other conditions appeared to be bright and yellow in appearance with 
high T2
eff values. (Figure 4.7 A) 
Lumirem-labelled chondrocytes did not appear to follow the trends displayed by Lumirem-
labelled hMSCs. Despite this, 5x105 chondrocytes labelled with 100 μgFe/ml of Lumirem 
still appeared to cause the greatest loss of signal (similar to hMSCs). Although this drop was 
not as intense as that of hMSCs and did not fall below the visibility threshold. All other 
conditions resulted in bright red/yellow areas and supported by the long T2
eff values (Figure 
4.7 Bi & ii). Therefore, the visibility threshold for Lumirem can bet set at 5x105 chondrocytes 
labelled with 100 μgFe/ml and 105 hMSCs labelled with 100 μgFe/ml. 
The acellular control demonstrating the potential signal profiles when total internalisation of 
Lumirem is achieved, sets the minimal visibility threshold at a minimal particle 
concentration of 5 μgFe/ml (5x105) (T2eff = 74.33 ms) and a minimal cell dose of 104 cells 
labelled with 100 μgFe/ml (T2eff = 74.89 ms) (Figure 4.7 C) 
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Figure 4.7. In vitro dose response; Lumirem. Investigating the relationship between 
SiMAG concentration (1, 5, 10 and 100 μgFe/ml) and cell dose (104, 105, 5x105) on the 
MR visibility threshold for 2 cell types A) hMSCs and B) Chondrocytes while C) 
represents the acellular control. Data is presented as i) T2eff map and ii) corresponding 
T2eff plot. Red line indicated visibility threshold 75 ms. 
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d) Nanomag 
The labelling of hMSCs and chondrocytes by Nanomag did not result in significant contrast 
with long T2
eff values being measured for all conditions (1, 5, 10 and 100 μgFe/ml; 104, 105 
and 5x105 cells) for both hMSCs and chondrocytes (Figure 4.8 Aii and Bii) with no condition 
resulting in a T2
eff below 75 ms. Corresponding T2
eff maps (Figures 4.8 Ai and Bi) were all 
bright and red/yellow in appearance corroborating high T2
eff signal intensities.   
 Significant signal loss was demonstrated by the acellular control with areas of hypointensity 
seen to increase with increasing Nanomag concentrations (from 1 μgFe/ml to 100 μgFe/ml) 
and increasing cell dose (104–5x105). Under conditions facilitating 100% internalisation of 
Nanomag by either hMSCs or chondrocytes, the visibility threshold would be set to a 
minimum of 1 μgFe/ml (labelled with 105) (T2eff = 75.33 ms) in terms of minimum particle 
concentration and 104 cells when labelled with 10 μgFe/ml (T2eff = 72.83 ms) in terms of 
minimal cell dose (Figure 4.8 C). 
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Figure 4.8. In vitro dose response; Nanomag. Investigating the relationship between 
SiMAG concentration (1, 5, 10 and 100 μgFe/ml) and cell dose (104, 105, 5x105) on the 
MR visibility threshold for 2 cell types A) hMSCs and B) Chondrocytes while C) 
represents the acellular control. Data is presented as i) T2eff map and ii) corresponding 
T2eff plot. Red line indicated visibility threshold 75 ms. 
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e)  P904 
Similar to Nanomag neither hMSCs nor chondrocytes resulted in significant hypointensity 
when labelled by P904. Bright, yellow/red areas are noticed at every condition in the P904 
T2
eff map (Figure 4.9A and B i). This is further confirmed by the T2
eff  plots highlighting long 
T2
eff values at each condition. (Figure 4.9A and B ii) 
Shortening of T2
eff was demonstrated by the acellular control with areas of hypointensity 
seen to increase with increasing P904 concentrations (from 1 μgFe/ml to 100 μgFe/ml) and 
increasing cell dose (104–5x105).  Under these conditions the visibility threshold would be 
set to a minimum of 5x105 cells labelled with 1 μgFe/ml (T2eff = 16.30ms) or 104 cells when 
labelled with 10 μgFe/ml in terms of minimal cell dose (T2eff = 40.00ms) (Figure 4.9 C) 
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Figure 4.9. In vitro dose response; P904. Investigating the relationship between SiMAG 
concentration (1, 5, 10 and 100 μgFe/ml) and cell dose (104, 105, 5x105) on the MR 
visibility threshold for 2 cell types A) hMSCs and B) Chondrocytes while C) represents 
the acellular control. Data is presented as i) T2eff map and ii) corresponding T2eff plot. 
Red line indicated visibility threshold 75 ms. 
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From the above set of data (section 4.4.2.2) it is clear that only SiMAG is internalised by 
hMSCs and chondrocytes to a degree to significantly influence T2
eff (particle and cell dose 
dependant). For this reason, only SiMAG was carried forward from here onwards. 
 
4.4.2 Ex vivo MRI dose response 
The ability to create contrast within a tissue and the effect of tissue type on the perceived 
contrast of SiMAG-labelled cells was investigated. Muscle and fat specimens were isolate 
from the knee joint of a pig, and injected with hMSCs and chondrocytes labelled with 0, 1, 
5, and 10 μgFe/ml at varying cell doses (1x104, 1x105, and 5x105). Ligament was only 
investigated for SIMAG-labelled hMSCs. Specimens were then MR imaged using MSME 
sequences (n=3). In this set of experiments, hypointense areas of signal void (implying the 
presence of SiMAG) are represented by black areas. Comparing the MR images of untreated 
samples of ligament, muscle and fat (Figure 4.10 C) clear differences are noticed in the 
appearance of ligament when compared to that of muscle and fat. Ligament appeared be 
completely black in form creating significant contrast with the surround water in the wells 
of the plate. Conversely, fat and muscle were brighter in appearance, with fat being brighter 
than muscle (similar to that of the surrounding water). No contrast was detected between 
SiMAG-labelled hMSCs and ligament specimens (Figure 4.10 A). The same result is 
expected for SiMAG-labelled chondrocytes when MR imaged against ligament tissue. 
Further to this, implantation of SiMAG-labelled hMSCs and chondrocytes appeared to create 
contrast against both muscle and fat in particular when 105 and 5x105 cells labelled with 5 
and 10 μgFe/ml.  The minimum visibility threshold is set at 105 labelled with 5 μgFe/ml 
(Figure 4.10 A & B).  These results are summarised in Table 4.2. 
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Figure 4.10. Ex vivo MR images of ligament, muscle and fat injected with A) hMSCs 
and B) chondrocytes when labelled with 1, 5, and 10 μgFe/ml SiMAG at varying cell 
doses (104, 105, and 5x105). C) Represent specimens of untreated samples. Red arrows 
represent hypointense regions.  
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Table 4.2. Table summarising results obtained from ex vivo visibility threshold 
investigation emphasising conditions where contrast was created between tissue and 
SiMAG-labelled cells. 
 
 
4.4.3 Porcine Knee Model  
A cadaveric model of cartilage damage in a pigs knees was established with the primary aim 
of translating the established labelling protocol to a clinically relevant scenario. Knees were 
MR imaged using the Symphony 1.5 T clinical canner with a T2/T1 DESS (double echo 
steady state) imaging sequence as this is commonly used for looking at knee cartilage in 
humans to differentiate between cartilage and synovial fluid. It also has a strong T2 weighting 
which is preferential for identifying the presences of particle labelled cells. 
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4.4.3.1 Porcine Knee Model optimisation  
A preliminary study was performed to assess the suitability of the cadaveric model in this 
context. Figure 4.11 highlights the key features of the porcine knee when MR imaged. In the 
first instance, a cartilage flap was created on the upper left condyle while another piece of 
articular cartilage was completely removed in the upper right condyles of the same knee 
(Figure 4.12 i). Figure 4.12 ii demonstrates the coronal MRI view of the knee highlighting 
the appearance of full cartilage thickness in the left condyle (A). The small black marks are 
significant of the cuts made to create the cartilage flap and is more clearly shown in Figure 
4.12 iii). The cartilage of the right condyle is shown to not be intact with a disturbance in the 
articular cartilage (Figure 4.12 i B & iv) 
 
Figure 4.11. Diagram highlighting key anatomical structures of the knee when in A) 
flexion and B) in extension.  
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Figure 4.12. Assessing the suitability of the cadaveric porcine model. From left to right, 
(i) Anatomical schematic highlighting defect sites A) Flap B) Excision ii) DESS MR 
image coronal view highlighting both sites (A & B) of the defect on each of the upper 
condyle iii) Sagittal view highlighting defect site A iv) Sagittal view highlighting defect 
site B  
 
To validate the use of the DESS sequence and its applicability in assessing knee anatomy in 
conjunction with identifying the presence of the labelled cells, 3 million chondrocytes 
labelled with SiMAG in excess were implanted within a cartilage defect and scanned using 
the Symphony 1.5T. Exaggerated hypointensity are observed in areas corresponding to the 
implantation site (upper left condyle) implying that the presence of particle labelled cells can 
be detected with this system (Figure 4.13).  
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Figure 4.13. Hypointense areas of signal void corresponding to implantation of 3 
million chondrocytes implanted on the upper left condyle of each knee, imaged with 
Siemens Symphony 1.5T (double steady state image; DESS). Region of interest (ROI), 
highlighted by cross hairs (red lines).  
 
4.4.3.2 Particle Concentration Investigation 
Here, 5x105 SiMAG-labelled (0.1 µgFe/ml, 1 µgFe/ml and 10 µgFe/ml) were implanted in 
series across the upper condyles within the same knee, as illustrated in Figure 4.14 A. 
Hypointense areas of signal loss are observed only in areas corresponding to the implantation 
site of 10 µgFe/ml SiMAG. All anatomical features of the knee are clearly visible in 
particular the bright white articular cartilage with the implanted cells.  
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Figure 4.14. Particle concentration assessment: A) Schematic highlighting 
implantation sites of 5x105 chondrocytes labelled with 0.1, 1 and 10 µgFe/ml SiMAG B) 
Corresponding coronal DESS image when imaged with Siemens Symphony 1.5T. 
Region of interest (ROI), highlighted by cross-hairs (red lines).  
 
4.4.3.3 Cell dose investigation 
In a similar study chondrocytes labelled with 5 and 10 µgFe/ml SiMAG were implanted at 
varying cell doses (104, 105 and 5x105) in series across the upper condyles within the same 
knee, as illustrated in Figure 4.15 A. Hypointense regions of signal loss were only observed 
in the location corresponding to the implantation site of 5x105 chondrocytes labelled with 5 
µgFe/ml SiMAG (upper right condyle) (Figure 4.15 Bii) with no hypointense regions are 
observed in the left condyle corresponding to the implantation site of 104, 105. chondrocytes 
labelled with 5 µgFe/ml (Figure 4.15 Bii). While hypointense regions are observed (Figure 
4.15 Ci) and ii) in both the right and the left condyles when varying cell doses of 
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chondrocytes labelled with 10 µgFe/ml are implanted. This corresponds to 5x105 and 1x104 
cells.   
 
Figure 4.15. Cell dose investigation: A) Schematic highlighting implantation sites of 
104, 105 and 5x105 SiMAG-labelled chondrocytes B) Corresponding coronal DESS 
image (Siemens Symphony 1.5 T MRI Scanner) for each particle concentration  i) 5 
µgFe/ml ii) 10 µgFe/ml SiMAG. Region of interest (ROI), highlighted by cross-hairs 
(red lines).   
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4.5 Discussion 
 
SPIONs form a group of negative MRI contrast agents designed to overcome the inherent 
low sensitivity associated with MRI (97, 130, 164). They are particularly beneficial in the 
identification of implanted cell populations, in vivo (84, 93, 183). The Fe component of these 
particles disrupts the local magnetic field causing a shortening of T2, therefore allowing for 
SPION-labelled cells to be visualised as signal voids or hypointense areas when imaged with 
T2 weighted MRI pulse sequences. T1 weighed MRI pulse sequences typically have a 
reduced sensitivity to SPIONs (159, 164). This is because T1 is a parameter determined by 
the physical and chemical structure of the sample whilst T2 is strongly affected by local 
changes in the magnetic field such as those caused by the presence of SPIONs. Therefore a 
SPIONs ability to create contrast is dependent on the interactions or communication of the 
magnetic moments associated with the particle and those associated with the neighbouring 
water protons and is appropriately governed by the magnetization of the particles, strength 
of the MRI scanner and proton density of the tissue (97)(14). 
Based on this principle, the ability to detect implanted cell populations (detection limits) by 
MRI is dependent on a number of interconnected factors. These include;  a) the relaxivity 
properties of the particles (contrast forming ability) (97), b) concentration of contrast agent 
(130) (in the case of in vivo MRI imaging and tracking, this refers to the cumulative Fe, 
which is the intracellular Fe content and cell dose relationship), c) magnet strength, d) 
diffusivity of protons within the sample and finally e) MRI pulse sequences.  
For cell imaging and tracking applications, particles with high relaxivity properties are 
extremely beneficial as this implies that relatively lower labelling concentration are required 
to generate contrast in comparison to particles with lower relaxivity properties. However, 
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this would only prove beneficial with the ability to be internalised by cells in appropriate 
doses. An ideal scenario would be the application of a particle with high particle relaxivity 
potential and high cell uptake efficiency. It is equally important to optimise these parameters 
to clinical systems to encourage clinical adoption of such techniques.  
The relaxivity of a SPION is a measure of contrast efficiency and is governed by the 
physiochemical properties of the particles such as: core material, coating thickness and 
crystallinity (91, 162, 201). Furthermore, it is important to understand that relaxivities are 
field dependant and therefore it is difficult to directly compare values between systems. This 
is clearly shown by Hinds et al where the R2 of Feridex was found to be 240 mM
-1s-1 when 
measured using a 4.7 T with this value increasing to 498 mM-1s-1when measured using a 
11.7 T (186). As a general indication, particles with large magnetization and stronger 
magnetic field enhances this effect and so creates better contrast with increased sensitivity 
in tissues. However, this is often at the expense of obscuring underlying pathology at the 
higher range of values (known as blooming) (97). The properties of the coating (material 
and thickness) have been reported to further affect relaxivity. Yu et al successfully 
demonstrated the ability to tune particle relaxivity by maintaining core properties but altering 
the thickness of the monodisperse mesoporous silica coating (162). Preliminary relaxivity 
data (Chapter 3 section 3.4.2.3) for particles used in this study (SiMAG, Lumirem, Nanomag 
and P904) indicate greatest transverse relaxivity (R2) for Lumirem closely followed by 
SiMAG, Nanomag and P904. This is not unexpected given that Lumirem is purposely 
designed to be an MRI contrast agent and therefore should have high contrast potential.  
Despite the high potential of Lumirem to generate contrast (highest R2 in comparison to the 
other particles), little contrast was observed by Lumirem labelled hMSC and chondrocyte 
populations. This could be attributed to the limited uptake of Lumirem by hMSCs and 
chondrocytes, which resulted in far less intracellular Fe than SIMAG. It has been reported 
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that as little as 1.4-3.0 pgFe/cell is capable of generating contrast when MR imaged (97, 
202). The intracellular iron values measured by ICP-OES (chapter 3) were significantly 
greater for SiMAG-labelled cell types (hMSCs and chondrocytes; ± 20 pgFe/cell) when 
compared to Lumirem, Nanomag and P904 which ranged from 1.05 pg/cell (Nanomag; 
hMSCs) to a maximum of 4.8 pg/cell (Lumirem; hMSCs). This implies that although these 
values were lower than SiMAG, contrast could still be generated. However, this was not the 
case with these MRI parameter. The discrepancies observed between the reported data in 
this chapter and literature may be accounted for by considering that MRI pulse sequences 
can influence potential contrast (97)(134). The effect of MRI pulse sequences on the contrast 
potential and in vitro visibility threshold was demonstrated by Li et al, where 1x106 labelled 
cells (25 pgFe/cell) demonstrated significant contrast with the application of GRET2*W 
(Gradient Echo T2* weighted sequence), whilst the use of FSET2W (Fast Spin Echo T2 
weighted sequence) failed to generate any contrast at these cell doses with the same strength 
MRI scanner (1.5 T). This demonstrates how the chosen parameters of the MRI sequences 
can influence contrast potential (83, 97, 134) and may account for the lack of contrast 
observed by hMSCs and chondrocytes labelled with Lumirem, Nanomag and P904 at these 
Fe doses and MRI parameters (2.35 T; MSME sequences) in comparison to published studies 
(3 T; FIESTA sequences). This also highlights the difficulty in making direct comparisons 
between studies and the need to optimise visibility threshold in a case by case manner.  
By considering conditions mimicking 100 % particle uptake (Lumirem, Nanomag and P904), 
significant shortening of T2 was observed at each condition. Therefore, it can be deduced 
that the lack of contrast generated by these SPION-labelled cell populations is likely to be 
due to the limited intracellular Fe content either as a result of limited uptake or low labelling 
concentrations. Labelling protocols could therefore benefit from increased labelling 
concentrations or perhaps the application of transfection agents to facilitate better particle 
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uptake. This highlights the importance of designing a SPION-based labelling agent with 
specific physiochemical properties to not only generate contrast but also be efficiently 
internalised.  
It is essential to establish MRI visibility thresholds in terms of particle concentration and 
cell number in vitro and to understand the limits of the tracking study. Labelled cell 
populations were re-suspended in a collagen type I gel (a substrate highly applicable in 
cartilage tissue engineering) (203) and MR imaged using specific T2 weighted sequences. 
This study demonstrated the ability of only SiMAG-labelled hMSCs and chondrocytes to 
form significant dose dependant contrast when MR imaged. As expected, T2
eff was seen to 
decrease with increasing cell numbers and particle concentrations corresponding to the 
increasing Fe content. A minimum in vitro visibility threshold of 5 μgFe/ml (5x105 labelled 
cells) in terms of minimum particle concentration and 105 cells (10 μgFe/ml) in terms of cells 
dose for SiMAG-labelled hMSCs and chondrocytes was set with this system as it is believed 
that these conditions can potentially generate contrast with a host tissue. These values are 
considered to be highly acceptable as similar published studies have reported values ranging 
from a single cell when labelled with micron sized particles (11.7T) (97, 183) to 1x106 
labelled with 12 μg/ml (3T) (101).  
The ability to detect a single cell in vivo may be a highly attractive prospect in specific 
clinical applications especially those focused on the imaging and tracking of implanted cells 
within soft tissue such as liver and brain. However, the availability of high field strength 
scanners in a clinical setting is not realistic as 1.5 and 3 T scanners are primarily found in 
clinical practise today. High strength scanner (4.7 T, 7 T and 11.7 T) are currently limited to 
research application (130, 135, 199). This implies the use of this technology to track a single 
cell in the clinical evaluation of cell based therapies, is not translatable to clinic as yet and 
is thus limited to research application. It is therefore important to design and optimise 
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imaging and tracking protocols in terms of cell number and particle concentration to 
clinically relevant scanners 1.5 and 3 T (130) justifying the use of the 2.35 T scanner in this 
study.  
 
The knee is a complex structure made up of a variety of interconnected tissues such as 
ligaments, adipose tissues, articular cartilage and bone all interacting with synovial fluid. It 
is therefore not unreasonable to question the contrast created with SPION-labelled cell 
populations against these tissues given the migratory ability of especially hMSCs in terms 
of injectable therapies (non-scaffold assisted approaches) and the tissue integration potential. 
For this reason, the visibility threshold established in vitro for SiMAG were further evaluated 
ex vivo within relevant tissue associated with the knee; ligament, adipose tissue in addition 
to skeletal muscle. To our knowledge this has not been evaluated in other similar studies 
before.   
MRI imaging is sensitive to the hydration of the tissue (proton density) and the structure of 
the tissue (204). These factors govern the magnetic susceptibility (extent to which a tissue 
becomes magnetized) of each tissue and is affected by tissue microstructure, relative blood 
volume and the range of induced magnetization (97). Tissues are categorised by their 
magnetic susceptibility and appropriately referred to as; a) fluids e.g. cerebrospinal fluid, 
synovial fluid and oedema, b) fat-based tissues e.g. fat and bone marrow and c) water-based 
tissues e.g. muscle, brain, cartilage and ligaments. Fat is considered to have high magnetic 
susceptibility, (accounting for the high water and lipid content) followed by water based 
tissue. On the other hand, bone has the lowest of all susceptibility generating similar contrast 
to air, in MRI images (130). Tissues of high magnetic susceptibility appear to be brightest 
associated with highest signal intensity where brightness is then observed to decrease with 
decreasing magnetic susceptibility characteristic of low signal intensity such as that seen in 
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bone (dark) (130). The images generated of the native untreated tissues follow this theory 
where adipose tissue appeared to be brighter than muscles under the same scanning 
parameters. Despite ligament being a water based tissue, the characteristic bright “high 
signal” image was not observed, instead the ligament appeared to be dark (low signal 
intensity). This is a common problem associated with the imaging of tendons and ligamnets 
and is as a consequence of the anisotropic diffusion of water within the tightly packed fibre 
structure. Under routine MRI scans, the ligament is commonly positioned parallel to the 
main magnetic field instead of perpendicular due to human physiology. However, by 
adjusting the ligaments to be positioned at the magic angle of 54.7o ligaments appear as 
bright areas of high signal which can be useful diagnostically (205, 206).  
The in vitro visibility threshold of SiMAG labelled cells was found to create contrast against 
muscle and fat with the visibility threshold being slightly different. The in vitro visibility 
threshold for hMSCs and chondrocytes labelled with SiMAG re-suspended within a collagen 
gel was set at a minimum concentration of 5 μgFe/ml (5x105 cells) and a minimal cell dose 
of 105 (when labelled with 10 μgFe/ml) (100 μgFe/ml SiMAG excluded). Within the 
environment of a tissue, this threshold changes to a minimum of 105 cells labelled with 5 
μgFe/ml with no variations observed between adipose tissue and muscle. This implies that 
within these tissues there is increased sensitivity which could be beneficial as less 
concentration is needed to create contrast.  No contrast was generated with SiMAG-labelled 
cell population and the ligament tissue.  
 
The use of MRI in the imaging and tracking of implanted cell population for arthritic cell 
based therapies bares a dual purpose. Not only can it be used to image and track implanted 
cells, but its ability to distinguish between cartilage and bone (99) can be used to assess the 
defect and determine the extent of cartilage repair. The amount of fill in the image could 
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reflect the extent of repair while comparing the signal of the new graft with surrounding 
tissue could indicate the maturity of the graft (207). For this reason, it was important to 
develop a realistic model of articular damage to assess the clinical potential of this imaging 
and tracking protocol. This goes further to analyse the extent to which implanted cell 
population could be detected within a clinical system in relation to the anatomical structures. 
The clinical system applied in this study was a Siemens 1.5 T Symphony Scanner, a knee 
extremity coil and DESS pulse sequences. This is common practise in the diagnosis of 
pathology in the knee. The application of a porcine knee is significant in that the dimensions 
of the knee are similar to that of a human. In addition, the visibility threshold of SiMAG-
labelled cells was further assessed using this system (Siemens 1.5 T Symphony scanner) and 
found to be similar to the ex vivo thresholds established (105 cells labelled with 5 or 10 
μgFe/ml). The implantation of SiMAG-labelled cells generated significant contrast within 
this system and could be clearly detected against anatomical structure. This study encourages 
the clinical translation in therapies such as ACI of the tracking protocol with confidence that 
implanted cell populations can be detected and the extent of tissue repair could be evaluated.  
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4.6 Conclusion 
 
This study has demonstrated the ability of SiMAG-labelled hMSCs and chondrocytes to 
create particle and cell dose dependant contrast in vitro when MR imaged using T2 specific 
MRI sequences (Bruker 2.35 T animal scanner). No significant contrast was generated for 
either cell type when labelled with Lumirem, Nanomag and P904. Enhanced MRI contrast 
efficiency of SiMAG was related to the superior cell uptake intracellular Fe content. 
Minimal in vitro visibility thresholds were set at 5 μgFe/ml (5x105 labelled cells) in terms 
of minimum SiMAG concentration and 105 cells (10 μgFe/ml) in terms of minimal cell dose. 
In vitro visibility threshold was found to be influenced by the presence of fat muscle and 
ligament tissue resulting in a shift in visibility thresholds to 105 cells labelled with 5 μgFe/ml 
with no variation between fat and muscle tissue, whilst no contrast was generated in ligament 
tissue. The development of a clinically relevant cadaveric porcine model of articular 
cartilage damage allowed all anatomical features of the knee to be detected simultaneously 
with the implanted labelled cells when MR imaged using Siemens 1.5 T MRI scanner whilst 
maintaining visibility ex vivo threshold. This study further confirms the applicability of 
SiMAG as a potential tracking agent.  
This study suggests the potential application of SiMAG as a possible tracking agent will 
therefore be implemented in small animal tracking studies. 
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- Labelled mMSCs in Arthritic Animal 
Models 
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5.1 Introduction 
 
Arthritis can be defined as a set of musculoskeletal disorders responsible for the 
inflammation and destruction of the synovial joint (24). It can be classed as either 
degenerative/mechanical arthritis in the case of OA (osteoarthritis) or as 
inflammatory/autoimmune arthritis in the case of RA (rheumatoid arthritis) (30). The names 
offer some insight as to the broad mechanism of damage with OA generally being classified 
as a wear and tear disease, and affects approximately 8 million people in the UK. RA is 
considered an autoimmune disease and is known to affect approximately 400 000 people in 
the UK every year (30). In both cases, the quality of life for patients is greatly reduced due 
to pain and loss of join function with disease progression (24).  
Regardless of the mechanism of destruction, arthritis treatments involve a combination of 
drug regiments to alleviate symptoms such as pain and inflammation to maintain quality of 
life for the patient. Pain killers such as paracetamol, and non-steroidal anti-inflammatory 
(NSAIDs) drugs are typically prescribed. These approaches however do not target the 
disease process itself (6, 24, 208) thus allowing the disease to progress in severity with most 
individuals continuing to experience pain even at rest (209). In fact, pain is often considered 
the worst symptom by patients, often having severe implications on simple every day 
activities. Therefore, pain relief is clearly of clinically importance and currently is an unmet 
need (210). Current pain treatments have limited efficacies, hence alternative means of 
treating pain have to be investigated (40, 211). Arthroplasty (joint replacement) is often 
recommended in extreme cases of OA (24). However, this technique is not suitable for 
patients under the age of 55 due to the limited life span of the prosthesis (24).  
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In recent years, cell therapy approaches have been applied in an effort to regenerate damaged 
joint tissues (articular cartilage) in order to restore function, ultimately improving quality of 
life (24). These approaches aim to produce a tissue comparable to that of native cartilage, 
which would act to replace and or repair the damaged cartilage (13). Microfracture, 
Mosaicplasty, and Autologous Chondrocyte Implantation (ACI) are examples of cartilage 
regeneration techniques and have shown varying degrees of success (44). The chronic 
inflammatory environment of the rheumatic arthritic joint renders these techniques 
ineffective, as similarly to original native cartilage, newly formed cartilage would again 
undergo destruction within the hostile environment (6). Therefore the above mentioned 
approaches are limited to the damage caused by osteoarthritis and trauma (6). 
Mesenchymal stem cells (MSCs) have been identified as suitable candidates in treating both 
OA and RA (6, 78, 79, 184). They can be implemented to address not only structural 
destruction but also the inflammatory aspects of the disease (24). This potential is a direct 
result of the properties demonstrated by MSCs; these include the ability to home to the site 
of tissue injury and their immunosuppressive and immune-privileged properties. Therefore 
cell therapy approaches involving the implantation of MSCs either encompassed within a 
biodegradable scaffold or simply injected directly into the synovial cavity have been 
investigated (31). The use of small and large animal models are primarily implemented to 
gather data related to the in vivo events occurring post transplantation. This is a vital step in 
understanding and optimising any therapy. Animal models closely resembling the human 
form of RA and OA have been established (212). These models allow for the progressive 
degeneration of articular cartilage with histopathologically accurate features and bare 
significant importance in understanding pathogenesis and evaluating potential treatments for 
these diseases (213, 214). Studies have investigated the effects of MSCs within AIA 
(Antigen Induced Arthritis) models of RA in mice. Here, Kehoe et al demonstrated the 
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significant reduction in inflammation, joint swelling and cartilage destruction in response to 
MSC delivery (article under review). Other studies have demonstrated the significant 
reduction of OA progression and improved healing capacity in both the MIA (Monosodium 
Iodoacetate) (215) and the MXN (Meniscal Transection) (31) models of OA when treated 
with MSCs.   
To investigate aspects linked to the mechanisms of repair (cell migration, tissue integration 
and rate of repair) in vivo, histological analysis has traditionally been performed on the 
animal models. This tends to be very labour intensive and highly invasive as it requires the 
euthanization of the test animal and the processing of all tissues. For these reasons, the recent 
initiative proposed by the NC3R (National Centre for the Replacement Refinement and 
Reduction of Animals in Research) further aims to reduce, refine and replace the number of 
animal models used in scientific experiments today. This initiative has driven the 
development of alternative, non-invasive techniques to evaluate in vivo experiments. Having 
a practical and non-invasive means of identifying and subsequently optimising key 
parameters linked to the therapeutic potential of implanted cells (cell migration, tissue 
integration, rate of repair and mechanism of action) is an extremely powerful tool to have 
and will contribute to the optimisation and eventual clinical adoption of such therapies.  
The combined use of SPIONs and MRI has been proposed as one such technique. Extensive 
in vitro work has been carried out to demonstrate the feasibility of using SPIONs to label 
various cell populations. A range of cell types (fibroblasts, stem cells,  lung cells, liver cells, 
kidney cells, macrophages, nerve cells, endothelial cells and various cancer cells lines) have 
been labelled with a wide variety of SPIONs (Endorem, Feraheme) and optimised towards 
different strength MRI scanners (1.5 T, 4 T, 11.7 T) (109). In recent years these strategies 
have been applied to in vivo animal models of disease processes. Song et al  demonstrated 
the ability to track  human neural stem cells labelled with Endorem (150 nm particle size) 
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within a rat model of focal cerebral brain ischemia over a period of 4 weeks using a 1.5 T 
scanner (216).  Jackon et al  implemented a 9.7 T MR scanner to track USPION labelled 
MSCs within a preclinical rat modal of Parkinson’s for six weeks while studying the 
functional recovery of the rats with behavioural soring methods (217). Furthermore, MRI 
allows for real time correlation of cell localisation with corresponding, measurable 
physiological outcomes (141).  
More relevantly, studies have focused on the development of strategies to image and track 
stem cells within the articular joint for articular cartilage regeneration cell-based therapies.  
Henning et al compared the use of transfection agents to label hMSCs with Endorem. 
Labelled cells were seeded onto agarose scaffolds and implanted within a surgically induced 
osteochondral defect within the distal femur (rats knee) to mimic the MASI approach of 
articular cartilage regeneration. Animals were monitored for 12 weeks using a 3T MR 
scanner. However, Endorem has recently been taken off the market and replaced with 
Feraheme (20-30 nm) instead (184). The study was repeated by the same group later using 
Feraheme, (187). Here, adipose derived MSC labelled with Feraheme (with a transfection 
agent) transfection agent) were seeded within an agarose and gel implanted within an 
osteochondral defect. These cells were monitored in vivo for 4 weeks using a 7 T MR scanner 
(187). Further studies can be found in Table 5.1 which have also demonstrated the ability to 
track particles within animal models.  
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Table 5.1. Tracking studies in arthritic animal models 
 
Cell type Animal 
model 
Particles MRI 
scanner 
Transfection 
agents 
Scaffold Tracking 
period 
Ref 
Chondrocytes Osteochondral 
defects. 
Mini pigs 
Ferric oxide 
nano-
composites 
(79nm) 
3 T None Collagen 
type II gel 
12 weeks (101) 
MSCs Trochlear 
cartilage 
defects.  
Rabbits 
Endorem 
150nm 
1.5 T Protamine 
sulphate 
CGP gel 12 weeks (83) 
Rabbit MSC Ex vivo knee 
model OA. 
Bovine 
Commercial 
1.63μm 
3T None Puramatric None (103) 
 
From these studies, it is evident that SPION based tracking studies have focused on the use 
of scaffold driven approaches to tackle articular cartilage damage in small animal models 
such as in the case of OA. It is evident that SPIONs ranging in size between 30- 150 nm 
(diameter) have primarily been implemented for in vivo studies. It is fair to mention that the 
application of micron sized particles in small animal models such as articular cartilage 
defects has not been widely investigated. Finally, the end point of these studies (Table 5.1) 
assessed the extent and quality of cartilage regeneration while no studies were found which 
investigated any functional outcomes as a result of these approaches.  
To our knowledge, the following gaps have been identified in the literature: 
1. There are no published studies which have adopted the rheumatoid arthritis model to 
track cells in this manner. 
2. There are no studies which inject cells within the joint cavity without the aid of a 
scaffold in order to localise cells within a specific area to be tracked. 
3. Micron sized SPIONs have not been used in the live tracking of cells in arthritic cell 
based therapies. 
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4. Clinically relevant functional outcomes are yet to be assessed in conjunction with 
tracking studies aimed at cartilage regeneration focused cell based therapies. In 
particular the effect of MSC treatment on pain outcomes in OA models.  
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5.2 Aims and Objectives 
 
The work presented in previous chapters suggests the use of SiMAG (a micron sized particle) 
to be implemented to image and track murine mesenchymal stem cells (mMSCs) within two 
separate animal models (RA and OA) to monitor the long and short term bio-distribution of 
implanted stem cells in vivo. In addition, clinically relevant functional outcomes of the 
disease models will also be assessed. Specifically, this chapter aims to investigate the 
relationship between the location of implanted mMSCs and: 
 Joint swelling and inflammation to histopathological features of RA. 
 Pain and histopathological features of OA.  
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5.2 Materials and Methods 
 
5.2.1 Overall Experimental Plan 
A mouse model of RA and a rat model of OA have been selected to evaluate the feasibility 
of the devised protocol (SiMAG, 24hr incubation, SFM) for in vivo tracking of cell 
populations for the treatment of arthritis (OA and RA). Therefore, the protocol will initially 
be optimized to assess the in vitro and in vivo visibility thresholds for SiMAG-labelled 
mMSCs within a mouse and rat model prior to the tracking study. Details of the optimizing 
stages are shown in Figure 5.1. 
 
Figure 5.1. Optimisation and adaption of established labelling protocol for applications 
in tracking.   
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5.2.2 Animal Model Experimental Plan.  
Murine mesenchymal stem cells (mMSCs) were tracked for a total time period of 7 days 
when applied in a RA mouse model and 29 days when applied to an OA model. Figure 5.2 
highlights the general schema applied in the animal studies. In general, experimental groups 
consisted of animals treated either with; SiMAG-labelled mMSCs, unlabeled mMSCs or 
serum free media (Table 5.2 & 5.3). All cells were pre-labeled with a fluorescent tracker; 
CM-DiI prior to implantation. This allows for the therapeutic potential of MSCs to be 
evaluated post SiMAG-labelling but also offers the opportunity to correlate the location of 
implanted cells as deciphered by MRI to histological assessment.  
 
Figure 5.2. Overall experimental plan for the two animal studies: (1) Mouse model of 
RA and (2) Rat model of OA. 
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Rheumatoid Arthritis 
The short term bio-distribution of implanted mMSCs population (SiMAG-labelled and 
unlabelled mMSCs) was assessed over 7 days in a mouse model of RA by MRI. In addition 
the effects of mMSC administration on the progression of RA was assessed in parallel to the 
tracking aspects of the study. Upon RA induction, 3x105 CM-DiI labelled mMSCs (SiMAG-
labelled or unlabelled) were implanted within the joint of arthritic mice and joint swelling 
monitored throughout the experiment. Upon termination of the experiment, animals were 
sacrificed and MR imaged (Days 3 and 7 post implantation). A description of the 
experimental groups is shown in Table 5.2 while key experimental time points are shown in 
Figure 5.3.  
 
Table 5.2. Description of experimental groups; RA. 
Group Description Tracking period Study 
1 (n=6) SiMAG-labelled mMSCs  3 days MRI tracking study 
2 (n=5) SiMAG-labelled mMSCs 7 days MRI tracking study 
3 (n=6) Unlabelled mMSCs 3 days MRI tracking study 
4 (n=5) Unlabelled mMSCs 7 days  Pilot mMSCs study 
5 (n=6) No cells + No Particles  (control) 3 days  Pilot mMSCs study 
6 (n=5) No cells + No Particles  (control) 7 days MRI tracking study 
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Figure 5.3. Experimental timeline for the RA tracking study. Coloured boxes highlight 
days where joint swelling was measured. 
 
Osteoarthritis 
A MNX model of OA was implemented to evaluate the long term tracking of SiMAG-
labelled and unlabelled mMSCs in a rat model of OA. This experiment further serves as a 
short pilot study to investigate the effect of MSC administration and the potential 
antinoceptive abilities of MSCs. To our knowledge, this is the first study of its kind where 
the potential of mMSCs to influence pain are assessed. This has implication in MSC 
therapies for both OA and RA. In this study, 1.5x106 CM-DII-labelled mMSCs (SiMAG-
labelled or unlabelled) were implanted via intra-articular injection within diseased joints and 
pain behavioural assessment (paw withdrawal threshold and weight bearing asymmetry) 
performed throughout the study. Animals were sacrificed and MR imaged 29 days post 
implantation. A description of the experimental groups is shown in Table 5.3 while key 
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experimental time points are shown in Figure 5.4 Description of experimental groups for 
OA 
Table 5.3. Description of experimental groups for OA 
Group Description Tracking period Study 
1 (n=3) SiMAG-labelled mMSCs  29 days MRI tracking study 
2 (n=4) Unlabelled mMSCs 29 days MRI tracking study 
3 (n=4) Serum free media 29 days MRI tracking study 
 
 
 
Figure 5.4. Experimental timeline for the OA tracking study. Coloured boxes highlight 
days where behavioural outcomes were assessed in terms of weight baring asymmetry 
and hind paw withdrawal threshold. 
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5.3 Results 
 
5.3.1 In vitro Assessment.  
5.3.1.1 Particle uptake 
Particle uptake following a 24 hr passive incubation period of SiMAG (10 μgFe/ml) with 
mMSCs was confirmed by Prussian blue staining (Figure 5.5). Internalised particles were 
stained blue and were visible within the cell. Intracellular Fe content was measured by ICP 
as 20.64 ± 1.34 pg/cell. Cells retained morphology post labelling  
 
Figure 5.5. Particle uptake and cell morphology evaluation post 24 hr SiMAG-labelling 
of mMSCs. (A) Unlabelled mMSCs, B) SiMAG-labelled mMSCs, C) Prussian blue stain 
of SiMAG-labelled cells; (i) x 20 magnification, (ii) x 40 magnification. Scale bar = 
100μm.   
 
5.3.1.2 Viability and Proliferation. 
Live dead (Figure 5.6) and MTT (Figure 5.7) analysis revealed no diminished viability and 
proliferation capacity for SiMAG-labelled mMSCs (10 μgFe/ml) when compared to 
unlabelled mMSCs.  Figure 5.6 visually highlights the relative increase in the number of live 
cells (stained green) from 24 hrs to 7 days in culture with no obvious differences observed 
between SiMAG-labelled and unlabelled groups either at 24 hrs or day 7.  
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Live dead results were further validated quantitatively by MTT analysis demonstrating a 
significantly higher OD (Optical density; p < 0.001) (function of metabolic activity) between 
SiMAG-labelled and unlabelled groups at either time point (24 hrs and day 7) when 
compared to the negative control (dead). Additionally, no significant differences in OD was 
observed between SiMAG-labelled and unlabelled groups at either 24 hrs or day 7. The 
significant increase (p <0.001) in metabolic activity from 24 hrs to 7 days as exhibited by 
both groups highlights the proliferative capabilities of SiMAG-labelled and unlabelled 
mMSCs. These results suggest that mMSCs are able to tolerate the internalisation of SiMAG 
(10 μgFe/ml) with no measured impairment to viability and proliferation.  
 
 
Figure 5.6. Cell viability analysis. Live/dead staining of SiMAG-labelled (10 μgFe/ml) 
and unlabelled mMSCs characterised at 24 hrs and 7 days. Scale bar = 100 μm. 
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Figure 5.7. MTT analysis. SiMAG-labelled (10 μgFe/ml) and unlabelled mMSCs 
characterised at 24 hrs and 7 days. Data expressed as mean ± SD *** Indicates p <0.001. 
 
5.3.1.3 Expression of mMSC Surface Markers pre and post SiMAG-labelling.  
Flow cytometry (Fluorescence activated cell sorting; FACS) analysis was implemented to 
validate the expression of specific cell surface markers associated with mMSCs and then to 
further confirm the retention of these markers post SiMAG-labelling (10 μgFe/ml). FACS 
analysis revealed the lack of hematopoietic markers CD 11b and CD 45 and endothelial cell 
marker CD 31 (PECAM) on both SiMAG-labelled and unlabelled mMSCs (Figure 5.8). 
Furthermore, positive expression was revealed of key mesenchymal markers (CD44 and CD 
105), including the stem cell marker Sca-1 for SiMAG-labelled and unlabelled mMSCs. PI 
(Propidium Iodine) staining confirmed a cell viability of >95 % for both SiMAG-labelled 
and unlabelled cell populations. Similar profiles are observed for SiMAG-labelled and 
unlabelled mMSCs with no significant differences in the percentage of positive expression 
of each of these cell markers (Table 5.4). This data confirmed that the labelling of mMSCs 
with SiMAG did not affect the immunophenotype profile of mMSCs.  
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Figure 5.8. Characterisation of mMSC Surface Markers.  SiMAG-labelled (10 
μgFe/ml) and unlabelled mMSCs showed no variation in immunopheotypical markers 
profiles.  
  
Table 5.3. Positive Expression of key mMSC Surface Markers. 
 
Cell Surface Markers  Positive (%) 
 Unlabelled mMSCs SiMAG-labelled mMSCs 
CD11b 7.71 5.53 
CD31 7.71 1.47 
CD34 22.36 25.38 
CD44 99.47 98.75 
CD45 6.75 5.98 
CD105 88.14 83.57 
SCA -1 99.42 97.87 
 
 
5.3.1.4 Multi-lineage Differentiation Capacity of mMSCs pre and post SiMAG-
labelling. 
SiMAG-labelled (10 µgFe/ml) and unlabelled mMSCs were assessed for their ability to 
undergo differentiation down the mesenchymal lineage (osteogeneic, adipogenic and 
chondrogenic lineages). Both SiMAG-labelled (10 µgFe/ml) and unlabelled mMSCs 
demonstrated successful differentiation towards osteogenic and adipogenic lineages after 21 
days in culture with relevant differentiation media. Calcium deposition was stained positive 
by alizarin red in both labelled and unlabelled cells receiving osteogenic differentiation 
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media confirming osteogenesis (Figure 5.9).  Adipogenesis was confirmed by the presence 
of lipid and triglyceride droplets stained positive with oil red O after 21 days for SiMAG-
labelled and unlabelled cells treated with adipogenic differentiation media (Figure 5.10).  No 
staining was observed in control groups receiving basic expansion media and at day 0.   
mMSCs (either labelled with or without SiMAG) were unable to undergo chondrogenic 
differentiation when performed in 2D monolayer or in 3D micro mass pellet form (data not 
available). This study confirms that the internalisation of SiMAG does not hinder the ability 
of mMSCs to differentiate towards osteogenic and adipogenic lineages.  
 
Figure 5.9. Osteogenic differentiation. SiMAG-labelled mMSCs (10 μgFe/ml) and 
unlabelled mMSCs cultured in osteogenic media for 21 days. Successful differentiation 
demonstrated by alizarin red stained calcium deposits (red). Scale Bar = 100μm 
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Figure 5.10. Adipogenic differentiation. SiMAG-labelled mMSCs (10 μgFe/ml) and 
unlabelled mMSCs cultured in adipogenic media for 21 days. Successful differentiation 
demonstrated by oil red “O” stained oil droplets (red). Scale bar = 100μm 
 
 
5.3.1.5 Evaluating Minimum Visibility Threshold by MRI 
Figure 5.11 demonstrates the relationship between SiMAG concentration and cell number 
(mMSCs) in terms of MRI signal loss or hypointensity (highlighted by blue areas). 
Hypointense regions of signal loss highlight the presence of SiMAG-labelled cells. As 
expected, hypointensity increases with cell number and SiMAG concentration (Figure 
5.11A).  T2
eff was found to be shorter for higher numbers of labelled cells with this further 
decreasing with increasing SiMAG concentration from 1 μgFe/ml to 10 μgFe/ml (Figure 
5.11B). MRI detection thresholds correspond to a minimum SiMAG concentration of 5 
μgFe/ml (3x105 cells) (T2eff =69.38ms) and a minimum cell dose of 105 cells (10 μgFe/ml) 
(T2
eff =75.81ms). In essence, any cell:particle combination that results in a T2
eff value of 75 
ms or below would be visible by MRI.  
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Figure 5.11. In vitro dose response: (A) T2eff map for 103,  104, 105, 3x105, 5x105 mMSCs 
labelled with 1, 5 and 10 μgFe/ml SiMAG, re-suspended in collagen gels (2 mg/ml) and 
MR imaged using MSME sequences. Hypointense areas of low signal (Blue) highlight 
the presence of SiMAG-labelled cells. (B) Corresponding T2eff measurements at each 
particle concentration (1-10 μgFe/ml) and cell dose (103, 104, 105, 3x105, 5x105). Red line 
indicates visibility threshold (75ms). Data = mean T2eff ± SD (n=6).  
 
5.3.2 Rheumatoid Arthritis Model  
5.3.2.1 In vivo Dose Response  
In vivo dose response was assessed by intra-articular delivery of 3x105 SiMAG-labelled 
mMSCs (0, 1, 5 and 10 μgFe/ml) into each knee (left and right) of a mouse (n=2). Mice were 
MR imaged immediately post-delivery and signal profiles across treated knees compared.  
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Figure 5.12 indicates the key features of a mouse when MR imaged. MR images demonstrate 
good contrast (visualised as hypointense regions of signal losses or black areas over right 
knees, shown by the white arrow in Figure 5.13) in mice receiving mMSCs labelled with 10 
μgFe/ml (Figure 5.13 iii) and 5 μgFe/ml (Figure 5.13 iv) SiMAG in both knees. This was 
not the case for mice receiving doses of 1 μgFe/ml SiMAG (Figure 5.13 ii) and the untreated 
mouse (Figure 5.13 i) where no hypointense regions could be visualised over the treated 
knees. Similar results are seen for the left knee however data is not shown here.   
This was further validated by evaluating and comparing the signal intensity (SI) across the 
treated knees in all groups (Figure 5.14). A greater loss in signal over a greater area was 
observed in mice injected with 5 and 10 μgFe/ml SiMAG in both knees (Figure 5.14 A&B 
(i), A&B (ii)) whilst a less obvious drop in SI was observed for mice injected with 1μgFe/ml 
(SiMAG) (Figure 5.14 A&B (iii)) when compared to the control mouse (untreated) (Figure 
5.14 A&B (iv)). The comparative signal profile clearly highlights differences in signal 
intensities between groups (Figure 5.15).  
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Figure 5.12. Diagram of a mouse: (A) within the customised holder and (B) 
corresponding GEFI MR Image depicting the key structural features of the mouse and 
the relative dimensions.  
 
Figure 5.13. In vivo dose response. GEFI MR Images relating to mMSCs labelled with 
(i) 0 μgFe/ml, (ii) 1 μgFe/ml, (iii) 5 μgFe/ml & (iv) 10 μgFe/ml of SiMAG and implanted 
within the right knee of each mouse. Red line highlights area across which SI was 
measured. 
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Figure 5.14. In vivo dose response. Signal intensity of 10 points measured across both 
the (A) right and (B) left knees relating to delivery of mMSCs labelled with (i) 10 
μgFe/ml, (ii) 5 μgFe /ml, (iii) 1 μgFe/ml & (iv) untreated knees to give a signal profile.  
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Figure 5.15. Comparative signal profile. Comparing the averaged SI of the left and 
right knees as measured over 10 points across the knee for mice treated with 10 
μgFe/ml, 5 μgFe /ml, 1 μgFe/ml & 0 μgFe/ml (untreated knees) SiMAG. Data = average 
of left and right knee.  
 
 5.3.2.2 RA Progression (Joint Swelling)  
A model of antigen induced arthritis (AIA) was applied to investigate the therapeutic effects 
of mMSCs in arthritic mice by measuring joint swelling (mm) as a clinical indication of joint 
inflammation. Upon RA induction (day 0), knee swelling increased approximately 1.5 (3 
day study) and 1.1 (7 day study) times that of the control knee (left). Intra-articular 
administration of mMSCs (SiMAG labelled and unlabelled) on day 1 resulted in an 
immediate decrease in joint swelling in both studies. A significant drop in swelling measured 
on day 2, in the 3 day study (Figure 5.16 A) (SiMAG-labelled; 0.8± 0.09 mm , unlabelled 
mMSCs; 0.8 ± 0.05 mm vs. control group; 1.23 ± 0.07mm p=0.0104) and day 3 of the 7 day 
study (Figure 5.16 B) (SiMAG-labelled; 0.46 ± 0.06 mm p=0.040, unlabelled mMSCs; 0.45 
±0.07mm p=0.026 vs control group; 0.78±0.07mm). This trend continued in the 3 day study 
(SiMAG-labelled; 0.6± 0.11mm, p=0.044 unlabelled mMSCs; 0.5 ± 0.07mm p= 0.0309 vs. 
control group; 0.9 ± 0.08mm) and ultimately in the 7 day study (SiMAG-labelled; 
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0.12 ± 0.05 mm p= 0.0064, unlabelled mMSCs; 0.18 ± 0.07 mm p= 0.0342 vs. control 
group; 0.45 ± 0.08mm). The joint swelling in the control groups of the 7 day study was seen 
to increase in from 0.3± 0.085 mm on day 5 to 0.45± 0.08mm on day 7 (Figure 5.16).  
 
 
Figure 5.16. Joint swelling measurements (mm) as an indication of inflammation and 
RA progression. Comparing joint swelling between SiMAG-labelled mMSCs, 
unlabelled mMSCs and control groups (SFM) over A) 3 days and B) 7 days. Data 
expressed as mean ± SEM Significant levels ** Indicates p<0.01 and * indicates p<0.05. 
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5.3.2.3 In vivo tracking - MRI 
Sacrificed mice were MR imaged at day 3 and 7 using FLASH and GEFI sequences 
respectively. Hypointense areas of signal voids were observed over the diseased knee (right) 
of every mouse in group 1 (+ mMSCs, + SiMAG; day 3; Figure 5.17 A) and group 2 (+ 
mMSCs, + SiMAG; day 7; Figure 5.17 C). This is attributed to the presence of intracellular 
Fe as a result of SiMAG-labelled mMSCs. No signal voids or hypointense regions could be 
detected over the diseased knee in group 3 (+ mMSCs, – SiMAG; day 3; Figure 5.17 B) and 
group 6 (- mMSCs, +SiMAG; day 7; Figure 5.17 D) nor in any of the untreated knees (Left 
knees; Groups 1, 2, 3, 6) as expected.  
This was further validated graphically by plotting signal loss profiles across each knee and 
comparing the signal of the right (diseased and treated joint) (Figure 5.18 i & Figure 5.19 i) 
to the corresponding left (healthy and untreated joint) (Figure 5.18 ii & Figure 5.19 ii). 
Comparative signal loss profiles demonstrated a drop in signal over SiMAG-labelled 
mMSCs treated knees (groups 1 and 2) when compared to untreated knees (Figure 5.18 A 
iii and Figure 5.19 A iii). Similar high-signal profiles are shown for both the right (diseased 
joint) and left (untreated joint) in (groups 3 and 6) (Figure 5.18 B iii and Figure 5.19 B iii). 
These results confirm the ability to identify the presence of SiMAG-labelled cells up to day 
7 post implantation using MRI.  
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Figure 5.17. Whole body coronal MRI images for RA tracking study. (A) Group 1 (+ mMSCs, + SiMAG, Day 3, GEFI sequence), (B) 
Group 3 (+ mMSCs, - SiMAG, Day 3, Flash Sequence), (C) Group 2 (+ mMSCs, + SiMAG, Day 7, GEFI sequence), (D) Group 6 (- 
mMSCs, - SiMAG, Day 7, FLASH sequence). Orange ring represents hypointense areas of signal void highlighting location of SiMAG 
labelled cells.  
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Figure 5.18. Signal loss profiles for RA tracking study. (A) group 1 (+ mMSCs, + 
SiMAG, n=6), (B) group 3 (+ mMSCs, - SiMAG, n=6) where: (i) treated knee (right), 
(ii) untreated knee (left) and (iii) average comparative signal profile. 
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Figure 5.19. Signal loss profiles for RA tracking study. (A) group 2 (+ mMSCs, + 
SiMAG; n=5), (B) group 6 (-mMSCs, -SiMAG; n=5) where: (i) treated knee (right), (ii) 
untreated knee (left) and (iii) average comparative signal profile. 
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5.3.2.4 Histological Evaluation 
Hematoxylin and Eosin Stain (H&E) 
H&E staining was used to identify key structural features of the mouse knee joint shown in 
Figure 5.20. Nuclear material was stained dark purple (hematoxylin) whilst the cytoplasmic 
material, connective tissue and collagen was stained pink (Eosin) (16). H&E staining offers 
a qualitative means of analysing the cellular content within the synovial joint. A greater 
number of cells were noticed within the synovial cavity of the right knee (AIA induced joint) 
of all groups (Figure 5.21 A i, B i, C i, D i, E i, F i) when compared to the left control joint 
knee (Figure 5.21 A ii, B ii, C ii, D ii, E ii, F ii). This was likely due to the influx of immune 
cells (macrophages, neutrophils) as a result of RA induction. No obvious differences 
between days 3 and day 7 studies can be observed. 
 
Figure 5.20. Sagittal H&E section of mouse knee joint (post RA induction) highlighting 
the key structures of the joint. The curvy epiphyseal line denotes the femur while the 
straighter epiphyseal line highlights the tibia. Nuclear material is stained purple while 
connective tissue such as collagen is shown as pink. Scale bar =100μm
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Figure 5.21. H&E stained sagittal sections of mice synovial joints:  (A)  group 1 (+mMSCs + SiMAG; day 3; n=6), (B) group 2 (+mMSCs 
+ SiMAG; day 7; n=5), (C)  group 3 (+mMSCs – SiMAG; day 3; n=6),  (D) group 4  (+mMSCs, – SiMAG; day 7; n=5), (E) group 5  (- 
mMSCs, – SiMAG; day 3 ; n=6) and (F) group 6 (- mMSCs, -  SiMAG; day 7; n=5). Nuclear material stained dark purple whilst 
connective tissue is stained pink. Increase in cellular content in the right knees of groups 1-6 is shown by arrow. Scale bar = 100 μm.
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Fluorescence  
Both SiMAG-labelled and unlabelled mMSCs were stained with a cell tracking dye (CM- 
DiI), prior to intra-articular delivery to allow the identification of implanted cells post 
implantation. All sections were counterstained with DAPI (a fluorescent nuclear marker; 
blue) and analysed using fluorescent microscopy under the TRITC and DAPI filter.  CM-
DiI labelled cells (indicated in red) were clearly visible within the synovium (seen in the 
x4 images) up to 7 days post implantation in the right joint of groups receiving mMSC 
treatments (groups 1, 2, 3 and 4) as shown in Figure 5.22 A-D (i,iii). No CM-DiI labelled 
cells could be detected in the untreated joints (left) Figure 5.22 A-D (ii, iv) and in either 
acellular control joints Figure 5.22 E&F (i,- iv). 
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Figure 5. 22. Fluorescent evaluation of the synovial joint (CM-DiI (red) and DAPI (blue). CM- DiI labelled cells visualised in the 
synovium of the right (treated) joints of:  (A) group 1 (+mMSCs, + SiMAG; day 3), (B) group 2 (+mMSCs, + SiMAG; day 7), group 3 
(+mMSCs, – SiMAG; day 3) and group 4 (+ mMSCs, - SiMAG; day 7). No CM-DiI labelled cells were detected in the control (left) 
joints and groups 5 and 6 (-mMSCs, – SiMAG; days 3 and 7 respectively).  Key anatomical structures are labelled in each image 
namely the  meniscus (M),   Femur (F),  Synovium (S)  and the Tibia (T)  . Scale bar = 100μm.
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Prussian Blue 
Prussian blue staining was performed on joint sections to identify the location of SiMAG - 
labelled mMSCs. Prussian blue staining successfully revealed the presence of iron oxide 
particles (stained blue) within the synovium (marked x on the accompanying H&E section; 
Figure 5.23). These areas were found to overlap with the location of CM-DiI labelled 
mMSCs in the treated joints (right) of groups 1 (+ mMSCs, + SiMAG; day 3; Figure 5.23 
Ai, ii) and 2 (+ mMSCs, + SiMAG; day 7; Figure 5.23 Bi, ii). Conversely, no blue staining 
was observed anywhere in the treated joint of group 3 (+ mMSCs, – SiMAG; day 3; Figure 
5.23 C ii) and group 4 (+ mMSCs, – SiMAG; day 7; Figure 5.23 D ii); neither in any of the 
control joints (left joint Figure 5.23 E) in all groups. 
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Figure 5.23. Prussian blue staining of joint sections with corresponding H&E and fluorescent sections. Blue staining highlights the 
presence of iron oxide particles (SiMAG) in the synovium of groups 1 (+ mMSCs, + SiMAG; day 3) and group 2 (+ mMSCs, + SiMAG; 
day 7) corresponding to the location of CM-DiI labelled mMSCs (X). No blue staining was detected for groups 3 (+ mMSCs, - SiMAG; 
day 7) and group 4 (+ mMSCs, - SiMAG; day 7), or for the control joint (left). (M) Meniscus, (T) Tibia and (F) Femur. Scale bar = 
100μm
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Toluidine Blue 
Toluidine blue primarily stains acidic proteoglycans found in articular cartilage deep purple. 
Cartilage depletion is a key characteristic in the AIA model and is significant of 
proteoglycans losses on the articular surface. Therefore toluidine blue staining is an 
applicable stain to assess cartilage depletion in arthritis. Proteoglycan losses are depicted by 
a change in colour from a deeper blue to lighter blue. Proteoglycan loss is clearly visible in 
the treated (right) joint of control groups 5 and 6 receiving SFM (Figure 5.24 E, F arrow). 
No proteoglycan loss can be visualised in groups 1-4 receiving mMSC treatments at either 
day 3 or day 7 (Figure 5.24 A, B, C, D). As expected, the untreated left joint (Figure 5.24 G) 
for the same animals show no cartilage depletion.    
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Figure 5.24. Toluidine staining to demonstrate cartilage depletion within treated joint 
sections for; A) group 1 (+ mMSCs, + SiMAG; day 3), B) group 2 (+ mMSCs, + 
SiMAG; day 7), C) group 3 (+ mMSCs, - SiMAG; day 3), D) group 4 (+ mMSCs, - 
SiMAG; day 7), E) group 5 (− mMSCs, - SiMAG; day 3), F)  group 6 (− mMSCs, - 
SiMAG; day 3). G) Representative left untreated joint. Bars = 100 μm
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5.3.3 OA model  
5.3.3.1 In vivo Dose Response  
Figure 5.25 illustrates the key features of a rat’s hind leg when MR imaged. By comparing 
the sagittal MR images of the untreated (Figure 5.26 D) and the PBS treated joints (Figure 
5.26 C) to all the treated joints (Figure 5.26 A (i,-iii), B (i-iii), obvious variations in 
hypointensities (exaggerated black marks) are clearly observed. The delivery of 1x106 
mMSCs labelled with 5 and 10 μgFe/ml of SiMAG and 2x106 mMSCs labelled with 1, 5 and 
10 μgFe/ml of SiMAG resulted in obvious hypointense areas of signal loss (circled in red, 
Figure 5.26 A (ii, iii), B (i-iii)) in the region of the synovial joint. However, less obvious 
areas of hypointensities could be identified in joints receiving 1x106 mMSCs labelled with 
1 μgFe/ml of SiMAG (Figure 5.26 Ai). As expected, no hypointense regions observed in the 
control groups (untreated and PBS treated joints) when MR imaged (Figure 5.26 C&D). The 
visibility threshold in this system could therefore be set at a minimal cell dose of 1x106 (when 
labelled with 5 μgFe/ml) and minimal particle concentration of 1 μg Fe/ml (2x106 implanted 
cells).  
 
Figure 5.25. Sagittal MR image of a rat’s hind leg highlighting key structural features.  
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Figure 5.26. In vivo dose response: Sagittal GEFI MR images relating to the 
implantation of: (A) 1x106 and (B) 2x106 mMSCs when labelled with: (i) 1 μgFe/ml, (ii) 
5 μgFe/ml and (iii) 10 μgFe/ml SiMAG. Red circles highlight hypointense areas of signal 
loss. (C) PBS treated (D) Untreated. Red line highlights area across which SI was 
measured. 
 
Further assessment of the in vivo dose response was performed by analysing the signal 
profiles produced when 1x106 and 2x106 mMSCs labelled with 0, 1, 5 and 10 μgFe/ml 
SiMAG were injected within the synovial cavity of a rat (Figure 5.27). Similar signal profiles 
were generated for groups receiving 1x106 mMSCs labelled with 5 and 10 μgFe/ml SiMAG 
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(Figure 5.27 Bi, ii) and 2x106 mMSCs labelled with 1, 5 and 10 μgFe/ml SiMAG (Figure 
5.27 A (i-iii)) with no obvious variations between these groups. The signal profile generated 
when 1x106 mMSCs were labelled with 1 μgFe/ml (Figure 5.27 B iii) was overall greater 
and similar to the control groups (Figure 5.27 C&D).  
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Figure 5.27. In vivo dose response: Signal profiles generated by measuring signal 
intensity across 20 points of the rats knee when injected with: (A) 2x106 and (B) 1x106 
mMSCs labelled with: (i) 10 μgF /ml, (ii) 5 μgFe/ml and (iii) 1 μgFe/ml SiMAG C) PBS 
and D) Untreated. 
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5.3.3.2 Pain Perception  
The perception of pain by osteoarthritic rats was assessed by monitoring the weight-bearing 
asymmetry (Figure 5.28 A) and the paw withdrawal threshold (as a measure of mechanical 
allodia) (Figure 5.28 B) for each rat. Following MNX surgery, rats developed a 16 % 
increase in weight-bearing asymmetry from the pre-surgery assessment on day 0 (pre-
surgery) (+mMSCs, + SiMAG; 0.26 ±2.89 %, +mMSCs, - SiMAG; 2.2 ±2.30 %, -mMSCs, 
- SiMAG; -0.2 ±1.84 %) to the pre implantation measurements on day 14 (+mMSCs, + 
SiMAG; 16.3 ±5.70 %, + mMSCs, - SiMAG; 16.3 ±1.17 % -mMSCs, - SiMAG; 16.29 
±3.08 %) in all experimental groups 1-3. Rats receiving an intra-articular injection of SFM 
showed a gradual increase in weight-bearing asymmetry over the 29 days resulting in a final 
measurement of 19.50 ± 0.59 % (at day 42). Intra-articular injection of mMSCs (labelled 
with or without SiMAG) prevented any further increase in weight-bearing asymmetry 
resulting in a significant decrease in the weight-bearing asymmetry of SiMAG-labelled 
mMSC treated animals (group 1; 4.8 % decrease to 12.60 ±4.80 % p<0.05) and unlabelled 
mMSCs (group 2; 8.7 % decrease, to 7.23 ±4.25 % p <0.001) by day 29 when compared to 
SFM treated animals (19.50 ±0.59 %).  
Rats developed a decrease in paw withdrawal threshold in treated (L-left) (Figure 5.28 B) 
paws over 3 days directly following MNX surgery compared to pre-surgery baseline values 
at day 0 (mMSCs with and without SiMAG (L) 15 ±0 g and no mMSCs and SiMAG (L) 
13.75 ±1.15 g). These trends persisted until day 14 at which point mMSCs were implanted 
(+mMSCs, + SiMAG; (L) 7.35 ±1.76 g, +mMSCs, - SiMAG; (L) 7.75 ±2.46 g, -mMSCs - 
SiMAG; (L) 6.65 ±2.06 g). Intra-articular injection of SiMAG-labelled mMSCs resulted in 
no significant increase in the paw withdrawal threshold over 29 days (+mMSCs, + SiMAG; 
(L) 7.6 ±3.60 g,) whereas a further significant decrease in paw withdrawal for unlabelled 
Chapter 5 - Tracking 
233 | P a g e  
 
MSCs and SFM was measured (+mMSCs, - SiMAG; (L) 3 ±0.57 g –mMSCs, - SiMAG; (L) 
2.85 ± 0.67 g p<0.005).  
 
 
Figure 5.28. Pain assessment by monitoring the development of: (A) weight-bearing 
asymmetry and (B) mechanical paw withdrawal thresholds (Allodynia) in the MNX 
model of OA in response to the intra-articular implantation of SiMAG-labelled (10μl) 
(n=3) and unlabelled mMSCs (n=4) and serum free media (n=4) over 42 days. Data is 
expressed as mean ± SEM.  Significant levels *** indicates p<0.001** Indicates p<0.01 
and * indicates p<0.05. 
 
5.3.3.3 In vivo Tracking – MRI  
Increased areas of hypointensity are observed in the synovial cavity of each rat treated with 
SiMAG-labelled mMSCs (Group 1) 29 days post implantation (Figure 5.29 Bi). This 
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represents the presence of SiMAG and is further validated by the signal profile plots, (Figure 
5.29 Ai) a significant loss in signal is detected over the synovial joint. As expected, this was 
not the case for rats in groups 2 (+ mMSCs, – SiMAG) & 3 (-mMSCs, –SiMAG) where MRI 
images (Figure 5.29 Bii & iii) and signal loss profiles (Figure 5.29 Aii and iii) generated 
appear to be similar in appearance to untreated joint (Figure 5.26 D) with the relatively high 
signal across the joint.   
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Figure 5.29. MRI tracking of mMSCs in a MNX rat model of OA 29 days post 
implantation. (A) Signal profile and (B) corresponding sagittal MSME MR images: (i) 
SiMAG-labelled mMSCs (10 μgFe/ml), (ii) unlabelled mMSCs and (iii) SFM.  
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5.3.3.4 Histological Evaluation 
Hematoxylin and Eosin Stain (H&E) and Fluorescence (DAPI) 
H&E staining was used to identify key structural features of the knee joint (rat) whilst 
identifying the location of fluorescent imaging (marked by X on H&E images) (Figure 5.30). 
DiI labelled mMSCs (stained red) were identified in the synovium in the treated (left) knee 
of animals in groups 1 (+mMSCs, + SiMAG) and 2 (+ mMSCs, – SiMAG), and can be seen 
in the fluorescent images (Figure 5.30 A & Biv) and corresponding H&E image (Figure 5.30 
A & Bii, Marked as X).  No labelled cells were visible in any of the untreated knees (right) 
(Figure 5.30 A, B & C iii) or in the treated knee of group 3 (+ mMSCs, + SiMAG) (Figure 
5.30 C iv).  
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Figure 5.30. H&E and fluorescent stained sagittal sections of rat synovial joints for: (A) group 1 ( + mMSCs,  +  SiMAG; 3 days. n=3),  
B) group 2 ( + mMSCs, +  SiMAG; 7 days. n=4),  C) group 3 (+ mMSCs, - SiMAG; 3 days. n=4). Fluorescent images correspond to 
location marked X on H&E images.  Nuclear material such as cells is depicted by dark purple staining while connective tissue such as 
collagen is stained pink in H&E staining. CM- DiI (red) and DAPI (blue). Left knees are the treated knees while the right knee was used 
as a control. Bars = 100μm 
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5.4 Discussion  
 
Despite the extraordinary medical advances made to tackle RA and OA, these disease remain 
to be a significant burden on society today. Medicine has reached the point where pain and 
inflammation can be treated effectively. However, till now no cures for OA and RA have 
been developed where the damage made to the synovial joint can be reversed giving patients 
full function of their joint. The development of stem cell-based therapies however, aim to 
address this need and has the potential to challenge current gold standard treatments. MSCs 
in particular hold the most promise in achieving this goal. The use of enabling technologies 
such as those described in this thesis may be used to evaluate such therapies to assess risks 
and successes thereby enabling the clinical translation of such therapies. This chapter 
therefore aims to implement the established labelling protocol (1-10 μgFe/ml SiMAG, 24 hr 
passive incubation, serum free media) to track implanted murine MSCs in a mouse model of 
RA and also a rat model of OA with time whilst also assessing clinically relevant functional 
outcomes.   
 
Previous chapters (chapter 3 and 4) have clearly demonstrated the ability of hMSCs and 
chondrocytes to passively and efficiently internalising SiMAG, (a commercially available 1 
μm silica coated SPION) with labelled populations successfully creating dose dependant 
contrast when MR imaged using a Bruker 2.35 T animal scanner. This data has encouraged 
the progression from in vitro experiments to small animal in vivo tracking studies in order to 
explore the potential application of this strategy to track implanted cell populations in 
arthritic cell-based therapies.  
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The implementation of any SPION and MRI based tracking protocol to a new system (cell 
type and animal model), calls for the interaction between the cell type and the tracking agent 
(in this case SiMAG) to be evaluated. It is necessary to assess the effect of cell type on the 
labelling efficiency and consequent visibility threshold for the particular system as well as 
the effect of labelling on the cellular function (viability, proliferation and potency). Failing 
to run these preliminary experiments can impact on the full potential of the established 
imaging protocol and limit the therapeutic efficiency of the cells. Hence, a series of in vitro 
experiments were performed to assess the uptake of SiMAG by mMSCs and the subsequent 
effect of internalisation on hMSCs (cell viability, proliferation and potency).  
Prussian blue staining successfully revealed the presence of SiMAG (stained blue) within 
the cell membrane of mMSCs labelled with 10 μgFe/ml (SiMAG), thus positively 
confirming internalisation with a total iron content of 20.64 ± 1.34 pg/cell. This value is 
comparable to the values detected for hMSC (21.8 ± 0.4 pg) and chondrocytes (20 ±0.3 pg 
of Fe) in chapter 3 when labelled under similar conditions.  
Toxicity and safety is a major concern in the implementation of nano-materials in any cell 
based therapy and can be a major hurdle in the adoption of SPION based tracking protocol 
(117). The application of SPIONs should in no way inhibit the therapeutic potential of the 
cells or should the SPIONs trigger any toxic events either on the cells during the labelling 
stage or evoke an immune response once implanted within the body (198). In vitro cell 
viability assays revealed no diminished cell viability and proliferation capacity on SiMAG-
labelled mMSC populations implying the optimised dose and exposure period was not 
harmful. The in vivo toxicity of SiMAG was not investigated at this time but no abnormal 
behavioural or immune reactions were observed by any of the animals receiving SiMAG-
labelled mMSCs over the duration of either studies. However, the in vivo toxicity should be 
strategically tested in longer term studies.  
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Currently, there is a debate regarding the differentiation ability of MSCs once they have been 
labelled with SPIONs (199). Generally, studies have found that the osteogenic and 
apidogenic potential of MSCs was maintained post SPION labelling whilst there are 
conflicting reviews reported for the differentiation of SPION labelled MSCs to chondrocytes 
(147, 199). Studies have shown that stem cells labelled with Feridex (an FDA approved 
contrast agent), inhibited their differentiation towards the chondrogenic lineage but not for 
osteogenic and adipogenic lineages (105, 143, 199). Kostura et al found that the presence of 
Feridex interfered with the signalling pathways responsible for driving chondrogenic 
differentiation (143). In contrast, Jasmin et al reported that MCSs labelled with Feridex 
underwent successful differentiation down all three lineages (adipogenesis, chondrogenesis 
and osteogenesis) (136). In a study by Henning et al, it was revealed that the differentiation 
of SPION-labelled MSCs to chondrocytes was dependant of the dose of the particle which 
may explain the contrasting results (147). Henning et al, also suggested that the use of a 
transfection agent could mitigate this effect by encouraging the internalisation of particles 
via alternative mechanism and further compartmentalization which might cause less 
interaction with differentiation associated intracellular substrates (147). In this study, it was 
not possible to demonstrate the differentiation of BALB/c mMSCs to chondrocytes labelled 
either with or without SiMAG. In a study by Chamberlain et al. BALB/c derived mMSCs 
were shown to differentiate down osteogenic and adipogenic, but not chondrogenic, lineages 
(175). It may therefore be the case that a lack of chondrogenic potential does not stem from 
the presence of SiMAG but to properties of the cells themselves.  Importantly, we have 
shown that mMSCs labelled with 10 μgFe/ml of SiMAG retain their capability to 
successfully differentiate down osteogenic and adipogenic lineages. 
 
A key aspect of using SPIONs in this context involves establishing and optimising minimal 
doses which achieve best resolution and contrast. Investigating the minimal in vitro MRI 
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visibility thresholds in terms of particle concentration and cell number offers some insight 
as to the optimal doses to be used in subsequent tracking studies. In vitro MRI threshold 
assessment resulted in a minimal cell dose of 105 mMSCs when labelled with 10 μgFe/ml 
SiMAG and a minimal SiMAG concentration of 5 μgFe/ml with 3x105 labelled mMSCs. 
These are considered highly acceptable values as similar studies by Jing et al reported a 
minimal cell dose (5x105) MSCs when labelled with 25 μgFe/ml of Feridex aided by the 
transfection agent protamine sulphate (83). This implies that SiMAG labelling offers 
potentially greater resolution and higher sensitivity in tracking studies. Based on this set of 
results and supported by current literature where therapeutic doses of MSCs ranging from 
3x105 – 106 have been implemented with successful outcomes in similar RA studies (218, 
219), 3x105 SiMAG-labelled MSCs were carried forward to the RA mouse tracking study. 
With regards to the OA model, positive therapeutic effects have previously been reported 
with much higher MSC doses ranging from 1x106 to 10 x106  (31, 215, 220). Therefore, cell 
doses at the lower end of this range (1x106 and 2x106) were chosen for the OA study in an 
effort to mitigate the effects of excessive accumulated Fe content associated with higher cell 
doses in MR imaging such as the blooming effect. The magnetic susceptibility of an 
individual particle results in a blooming artefact which extends beyond the size of the 
individual particles allowing for small injections of particles to be amplified beyond the 
actual location. This makes for practical identification of implanted cells but consequently 
becomes challenging to assess anatomical features in that vicinity (152, 155). 
Detection thresholds and cell doses were consequently validated in vivo for both the mouse 
model and rat model. In this study, 3x105  mMSCs labelled with 1, 5, 10 μgFe/ml SiMAG 
were implanted within mouse joints, whereas 1x106 and 2x106 mMSCs labelled with 1, 5, 
10 μgFe/ml SiMAG were implanted within a rat joint. To my knowledge similar studies have 
not assessed the effect of the in vivo biological environment on the MRI visibility threshold 
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prior to in vivo tracking studies. It is important to understand that the surrounding tissues can 
affect the MR contrast and therefore influence the visibility threshold. Unfortunately, 
relaxivity measurements could not be taken due to the inhomogeneities associated with 
biological tissue and for this reason, the signal intensity across the hypointense regions of 
the knee were read, plotted and compared to each other and  untreated joints.  Mice injected 
with mMSCs labelled with SiMAG (5 and 10 μgFe/ml) revealed a significant loss in signal 
over a substantial area; however, this signal loss was experienced over a greater area in the 
mice injected with 10 μgFe/ml than in 5 μgFe/ml. A less obvious drop in signal intensity 
was observed for mice injected with 1 μgFe/ml when compared to the control mouse. This 
revealed that the minimal visibility threshold for the mouse model was therefore 3x105 cells 
labelled with 5 μgFe/ml. Resultant signal loss profiles of the rat assessment appeared similar 
in form with a significant signal loss (attributed to the presence of SiMAG) when 1x106 
SiMAG-labelled mMSCs (5 & 10 μgFe/ml) and 2x106 SiMAG-labelled mMSCs (1, 5 & 10 
μgFe/ml of SiMAG) were implanted within the synovial cavity of a rat. This implied that 
either one of the mentioned conditions would be suitable for implementation in the OA 
tracking study.  
SiMAG concentration appeared to have a greater influence on the signal profiles created 
within the mouse model as opposed to the rat model where less variations was detected in 
the signal profiles in response to varying cell dose and SiMAG concentration. This is likely 
due to overall greater accumulated Fe content in the rat model causing the blooming to 
saturate at 1x106 mMSCs (5 μgFe/ml). Given the prolonged duration of the OA rat study and 
the unknown in vivo dilution rate of SiMAG-labelled mMSCs, it was decided that 1.5x106 
mMSCs labelled with 10 μgFe/ml would be implemented. This assumes that particle labelled 
cells would still be visible even after a hypothetical 10 fold dilution which is a reasonable 
rate after 4 weeks (97).  
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Generally, MRI images associated with the rat study resulted in greater anatomical details 
of the area of interest (knee) in comparison to the mouse where only whole body images 
were possible. This was expected and is a direct consequence of the overall larger size of the 
rat in comparison to the mouse; an observation also made by Burtea et al highlighting the 
general preferential use of rats in small animal MRI tracking studies for this reason (159). 
As mentioned earlier, the presence of a SPION are amplified beyond their exact location, a 
phenomenon known as the blooming effect. Although the blooming effect can be a useful 
means of identifying the general location of implanted cells, it makes it difficult to 
specifically identify the exact location of the cells with relation to the rest of the anatomical 
features of the knee. This was particularly evident in this study and in tracking within the 
knee in general given the complexity of the knee joint. The application of a purposely 
designed MRI knee transmitter coil (similar to those routinely used clinically in the diagnosis 
of knee pathology (130) in this system would have allowed for better resolution and 
sensitivity allowing for greater anatomical features in conjunction with particle location 
particularly in the rat (130, 158). Alternatively higher field strength MRI scanners (4.7, 7, 
11.7T) could have also improve image resolution (159) however these scanners are limited 
to research applications and therefore do not translate well into clinic. 
The chosen OA and RA animal models have been shown to develop similar pathology to 
human disease and is thus suitable for predicating the efficacy and appropriateness of MSC 
therapy in humans (213). It must be noted that the rodent version of this disease progresses 
at a faster rate than that of the human version (212). The chosen duration of the RA tracking 
study is significant in terms of the acute nature of joint swelling. Based on unpublished 
studies by Kehoe et al, MSC treatment was found to have the greatest effect on joint swelling 
in the first 3-7 days in a study monitoring joint swelling over 28 days. This suggests that 
cells are most active within this time frame and for this reason implemented in this short 
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term tracking study. These time points comply with the current literature where SPION – 
labelled cells could be detect with similar arthritic cell based MR tracking studies as long as 
12 weeks post implantation (101, 184).   
MR imaging revealed the presence of SiMAG-labelled cells which were identified within 
the synovial joint up to 7 days post implantation in the mouse model of RA and 29 days post 
implantation in the rat model of OA. The exact location of SiMAG-labelled and unlabelled 
cells was further verified via histological analysis where Dill-labelled cells were clearly 
identified along the synovial lining in both studies at the final time point (7 day; mouse RA,  
29 days; rat OA) in the treated knees of all groups receiving MSC treatment. No integration 
with the articular cartilage was observed. Henning et al successfully detected the 
transplanted hMSCs (SPION labelled and unlabelled) within the defect site over 12 weeks 
by MRI (184). Similar results were found in the study by Chen et al where the implantation 
of autologous chondrocyte seeded onto a collagen II hydrogel into a surgically induced 
defect (mini-pig) resulted in the persistence of hypointense signal voids up to 12 week post-
surgery within the defect. This implies that the cells had remained within the defect and was 
later confirmed by  histology (101). The use of biological scaffolds may account for the 
conflicting engraftment sites of the cells with the scaffold acting to localise transplanted cells 
within the defect site. This theory is supported by work carried by Murphy et al where 
evidence of cell engraftment in several tissues ( synovial capsule, fat pad, and lateral 
meniscus) in the joint were observed while no cell engraftment in the cartilage was observed 
post intra-articular implantation of MSCs (scaffold free) in an MNX model of OA in goats 
(31). 
This study was able to link the presence of mMSCs (SiMAG-labelled and unlabelled) within 
the synovium to the various clinically relevant functional outcomes; pain and inflammation. 
Pain is caused by multiple mechanisms and results in increased nociceptive inputs via 
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various pain processing pathways linked to the peripheral or central nervous system (40, 
211). In this study, progression in pain was monitored by weight bearing asymmetry and 
paw withdrawal evaluations and are commonly implemented the evaluation of 
pharmaceutical interventions in pain research. Weight bearing asymmetry is a standard 
behavioural correlate of hyperalgesia (increased sensitivity to pain) and is believed be 
initiated from the peripheral system (40). Paw withdrawal threshold on the other hand is 
indicative of mechanical allodeniya (pain due to a stimulus which does not normally provoke 
pain) and is associated with pain stemming from the central nervous system (40) 
Prior to OA induction, animals are able to place equal force on each hind leg when standing 
i.e it can be said that animal have little variation their weight bearing asymmetry. With OA 
induction in one leg, more force will naturally be place on the healthy leg as opposed to the 
injured leg which is experiencing pain. therefore there is an increase in the difference in 
force placed between each leg i.e increase in weight bearing asymmetry. This trend was 
clearly observed in this study where weight bearing asymmetry significantly increased upon 
OA induction and is indicative of pain. The administration of mMSCs (SiMAG labelled and 
unlabelled) was seen to mitigate the development of weight bearing asymmetry in rats with 
established OA. This implies that upon MSCs administration, rats were able to more evenly 
distribute their weight over both legs, significant of alleviated pain. 
Mechanical allodynia describes a scenario whereby pain is initiated by a stimulus what 
would not normally provoke pain. In healthy animals (Pre-OA induction) a large localised 
force would need to be implemented on the hind leg of the rat to provoke the withdrawal of 
their paw as a result of the stimulus. Upon OA induction, rats become more sensitive to this 
pain and therefore, low forces are required to generate a result. There was no effect of 
unlabelled mMSC (unlabelled) on the development of mechanical Allodynia while the 
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administration of SiMAG labelled mMSCs appeared to significantly influence the 
progression of mechanical allodynia.  
Collectively, this set of data indicates that the administration of MSCs may be able to alter 
peripherally-driven pain, but possibly not centrally-mediated pain in established OA. Finally, 
this data may offer insights into the mechanisms of underlying pain in OA.   
The effects of MSC treatment on inflammation in RA were monitored by assessing acute 
inflammation (macrophage, lymphocyte and neutrophil infiltration) in terms of joint 
swelling (99, 213). As expected, a significant decrease in joint swelling was measured upon 
mMSC administration. In a similar way the administration of SiMAG-labelled mMSC also 
resulted in a significant decrease in joint swelling with no statistical difference between 
mMSC groups. This suggests that the immunomodulating properties of mMSC labelled with 
SiMAG was maintained. Biological variation between mice within groups accounted for the 
conflicting rates of joint swelling progression between the two studies where a significant 
drop in joint swelling found on day 2 for the 3 day study, but only on day 3 for the 7 day 
study.  
Toluidine blue staining demonstrated far less cartilage depletion in groups receiving either 
SiMAG-labelled or unlabelled mMSC when compared to control groups. This suggests that 
the therapeutic potential of mMSCs is not affected by SiMAG-labelling. Although the 
mechanism of action is unknown, it can be hypothesised that the implanted cells are not 
differentiating into chondrocytes and repopulating the damaged area as no fluorescently 
labelled cells could be detected within the articular cartilage (corroborating findings by 
Kehoe et al). This suggests that mechanism of repair is attributed to a paracrine effect 
whereby the early MSC treatment acts to prevent proteoglycan loss possibly via the secretion 
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of factors influencing the activity of ADAMTS enzyme, an enzyme responsible for the 
cleaving of aggrecan (an abundant proteoglycan in articular cartilage) (221) 
The presence of SiMAG particles within the synovial lining was identified via Prussian blue 
staining at 7 days in the RA study. It is difficult to ascertain whether this staining was related 
to internalised SiMAG-labelled cells or to the particle dilution effect at this point. Particle 
dilution refers to the loss of particle from labelled cells as a result of either exocytosis or the 
division and proliferation of implanted cells. Released particles may then either be removed 
by the reticuloendothelial system (159)  or taken up neighbouring cells (97). This effectively 
limits the extent of tracking introducing the concerns of false positive where particles are 
being tracked instead of the cells. This becomes an increasing concern with longer tracking 
studies as is the case rat OA and warrants further investigations. (97).  
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5.5 Conclusion 
 
This chapter confirms the potential application of SiMAG as a feasible tracking agent in cell 
based therapies. In vivo MRI scans demonstrated good contrast and the identification of 
SiMAG-labelled populations within the synovial joint up to 7 days (mouse study) and 29 
days (rat OA) post implantation. Furthermore, it has been demonstrated that the presence of 
SiMAG does not affect the therapeutic potential of mMSCs when applied in small animal in 
vivo studies. The presence of mMSCs (SiMAG-labelled or unlabelled ) resulted in a marked 
decrease joint swelling over 7 days in the RA tracking study implying that SiMAG-labelled 
mMSCs maintained their anti-inflammatory and immunosuppressive property. Finally for 
the first time we demonstrate the potential antinociceptive properties of mMSCs as shown 
in the rat OA study.  
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6.1 Overriding Discussion 
 
In response to the lack of effective osteoarthritis and rheumatoid arthritis treatments, cell-
therapies have been developed offering new opportunities in tackling these diseases. 
Mesenchymal stem cells have been identified as ideal candidates in the development of 
arthritic cell-based therapies.  Their specific self-renewal, multipotent differentiation ability, 
migratory, anti-inflammatory and immunosuppresssive properties are all key characteristics 
linked to their success in stem cell based therapies (6, 68, 76, 79, 222). Animal models are a 
vital aspect in the development of these cell-based therapies and are implemented to 
investigate the safety and efficacy of such therapies. The need to rapidly, practically and 
reproducibly assess optimal delivery routes, cell doses, tissue engraftment and cellular bio-
distribution patterns whilst also minimising the number of animals implemented has driven 
the need for non-invasive techniques of monitoring in vivo cell fate. The combined use of 
Magnetic Resonance Imaging (MRI) and superparamagnetic iron oxide nanoparticles 
(SPIONs) have been proposed as one such non-invasive strategy. Therefore, this project has 
sought to develop a MRI and SPION based imaging strategy to potentially evaluate the 
success and risks of arthritic cell-based therapies whilst monitoring clinically relevant 
functional outcomes (pain and inflammation). This thesis is the first to report the use of 
SPIONs and MRI to track implanted MSCs within an AIA mouse model while monitoring 
joint swelling as an indication of inflammation. Furthermore, this thesis is the first to 
investigate the antinociceptive properties of MSCs in addition to tracking implanted cells 
within an MNX rat model of OA. 
Four commercially available SPIONs ranging in size from 25 nm-1000 nm (P904, Nanomag, 
Lumirem and SiMAG) were investigated as potential labelling agents for the application of 
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hMSCs and chondrocytes, in arthritic cell based therapies. Although, it is understood that 
passive incubation methods are limited to cells with a high degree of phagocytosis (a 
property not generally exhibited by stem cells), this technique was preferred over 
transfection agent (TA) mediated labelling due to the complications associated with TA 
labelling and limited clinical prospects. Following a passive incubation period of 24 hrs, 
greatest intracellular Fe content was detected for SiMAG (the largest particle; 1000 nm) 
when internalised by hMSCs or chondrocyte under serum free conditions, specifically. In 
comparison, significantly lower amount of Fe was detected for Lumirem, Nanomag and 
P904. By analysing this data one could assume a size dependant uptake of SPION by hMSCs, 
in particular with the following trend which was revealed (SiMAG; 1000 nm 21.8 pg/cell > 
Lumirem; 300 nm, 4.8 pg/cell > Nanomag; 50 nm 1.05 pg/cell > P904; 25nm 0.65 pg/cell). 
However, it cannot be assumed that these results follow a size dependant uptake relationship 
when assessing the uptake of particles of varying sizes by Fe quantification, due to variation 
in the Fe content of a single particle with varying particle size. Generally, the Fe content of 
a particle increases with increasing size (103, 161). This justifies the significantly higher Fe 
content of SiMAG–labelled cells (hMSCs and chondrocytes) in comparison to other SPIONs 
(Lumirem, Nanomag and P904) suggesting that this result is not related to the size dependant 
uptake of SPION.  
Despite the extensive number of cell labelling studies that have been performed with SPIONs 
of varying sizes, it is still unclear as to which particle size facilitates most efficient 
internalisation by stem cells. This is partially attributed to the limited particle configurations 
investigated in studies where contributing factors such as surface coating, surface charge and 
cell type are not taken into account. Further complications include data generated by using 
TA where the effect is seen to be dose dependant in addition to TA type dependant.  Few 
studies have systematically investigated the size dependant uptake of particles as 
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demonstrated by Thorek and colleagues (194). In their study, the cellular uptake of SPIONs 
of varying sizes (33 nm - 1.5 μm) by non-phagocytic T cells was systematically 
evaluated. Efficient labelling of cells was observed for particles up to 300 nm; however, 
micron-sized particle uptake was limited (194). A review by Li et al further suggested that 
particles sizes less than 100 nm were generally preferred for cell uptake, whilst positively 
charged surfaces further encouraged internalisation. This may be due to the electrostatic 
interactions between the positively charged particles and the negatively charged cell 
membrane (8). In summary, it can be deciphered that particle uptake by cells must be 
evaluated in a case to case manner and according to the desired application. For applications 
in cell imaging and tracking there is an interest in particles that can be internalised in 
sufficient quantities, generating significant contrast when MR imaged. 
The ideal particle size range for cell tracking purposes has further been debated (97, 160, 
194). Contrast is dependent on total intracellular Fe content post labelling. The Fe content 
of a single particle is thought to increase with increasing particle size, subsequently causing 
an increase in magnetic moment (103, 161). Although reports have highlighted the efficient 
uptake of nano-sized particles (< 300 nm), particle of this size range often have relatively 
low Fe content in comparison to their larger (micron-sized) counterparts. This in turn, 
demands the internalisation of many more nanometre sized particles than would be required 
of larger micron-size particles. This calls for a highly efficient and robust labelling protocol 
with higher particle concentrations often requiring the use of TA for the labelling of stem 
cells with nano-sized particles in order to achieve quantities that will generate in vivo contrast 
by MRI (160). On the other hand, larger micro-sized particles may not necessarily facilitate 
better uptake (194) in non-phagocytic cells but the higher Fe content of each particle implies 
that few particles would need to be taken up (ideal for cells with a low degree of phagocytosis) 
in order to generate contrast by MRI. This argument is clearly demonstrated in literature. 
Chapter 6 - Discussion 
253 | P a g e  
 
Passive incubation methods have not demonstrated the significant in vitro internalisation of 
popular FDA approved particles; Endorem, Resovist and Feraheme (20 nm-150 nm) by non-
phagocytic stem cells in sufficient quantities to generate satisfactory in vivo contrast, thus 
relying on the use of TA. This has been observed repeatedly through a wide range of studies 
(107, 188, 223). In comparison, studies by Hinds et al , Shapiro et al  and Saldanha et al  for 
example have all demonstrated the non-transfection mediated uptake of micron-sized 
particles at realistic doses to generate significant contrast in vivo (103, 160, 186). 
Understandably, the clinical approval of FDA approved particles is highly attractive. 
However, the need for transfection agents in my opinion questions the potential clinical 
applicability of using such labelling strategies. 
Our findings have demonstrated that exclusively SiMAG (a micron sized particle) was 
internalised in significant quantities by both hMSCs and chondrocytes to develop dose 
dependant contrast when MR imaged using a 2.35T MRI scanner under these labelling 
conditions. It is essential to establish MRI visibility thresholds in terms of particle 
concentration and cell number, both in vitro and in vivo and to appreciate that the detection 
threshold is affected by magnetic field strength and MRI acquisition parameters (152). The 
overall detection threshold of a population of cells is dependent on the combination of 
intracellular Fe content and the number of cells. The detection thresholds of SiMAG-labelled 
cells within this system was set at 5 μgFe/ml (5x105 labelled cells) in terms of minimum 
particle concentration and 105 cells (10 μgFe/ml) in terms of cell dose. This demonstrates 
the relationship between labelling concentration and cell dose. The lower the labelling 
concentration, the more cells are required for detection.  
MRI scanner strength significantly influences resolution and contrast, not only defining MRI 
detection threshold but also defining the quality of images and the extent to which 
information can be gathered. In general, higher strength scanners (similar to those used in 
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research; 4.7, 7 and 11.7 T) offer better contrast, resolution and specificity (130). These are 
all highly attractive qualities in the evaluation of cellular therapies in vivo. For example, 
single hepatocytes have been reportedly to be imaged by Shapiro et al  and could be detected 
in the liver one month post implantation using a 7 T scanner (161). Hinds et al also 
successfully managed to image a single cell labelled with 900 nm SPION with 11.7 T scanner 
(186). However, it is difficult to achieve such resolution on clinical grade scanners (1.5 T, 3 
T). To my knowledge, only one group has succeeded in achieving single SPION-labelled 
cell detection on clinical systems (1.5 and 3 T). In achieving this, elaborate theoretical 
models were applied pre-imaging, in order to extensively modify standard pulse sequences 
in addition to building customised gradients and RF coils required to achieve such resolution 
(202, 224). Therefore, it is unrealistic to design pre-clinical tracking approaches to high 
strength scanners knowing that such resolution will not be achieved under standard 
conditions. To this end, we have optimised towards current clinical MRI modalities 
commonly found in hospitals which are 1.5 T and 3 T scanners.  
We have adopted two relevant models of arthritis to evaluate the feasibility of the developed 
labelling and tracking strategy (SiMAG; Bruker 2.35T MRI) to evaluate arthritic cell based 
therapies in the future. In addition, we sought to assess the effects of mMSC administration 
on the clinically relevant functional outcomes (pain and inflammation) and ensure that 
SiMAG-labelling of mMSCs does not impair their therapeutic potential in vivo. MRI and 
SPION based technologies offer a practical and non-invasive means of gathering data linked 
to the success and risks of cell based therapies. Although most published studies remain as 
proof-of concept studies, mainly optimising in vitro labelling and detection threshold; few 
cell based tracking studies have managed to offer conclusive data of migratory patterns and 
tissue integration within the knee over time, with reliance on histology. In particular, a 
successful case of cell tracking within an osteoarthritic joint was demonstrated by Jing et al, 
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where serial MRI imaging over 12 weeks highlighted hypointensity associated with MSC 
implantation within synovial fluid (one hour) post implantation using T2 weighted sequences. 
Hypointensity persisted within the synovial fluid for 2 weeks until significant signal changes 
were detected within the defect and intensified over the next 4 weeks, implying that the 
implanted SPION-labelled cells had migrated towards the defect site and repopulated the 
defect. This data was further cross-validated by histological evaluation (83), which 
highlighted the potential of such tracking techniques in non-invasively monitoring cell 
migration in vivo. A key aspect of gathering information on the cellular bio-distribution and 
tissue integration is serial and longitudinal imaging of the same animal. This requires access 
to an MRI suite linked to the animal house to allow for animals to be anesthetised prior to 
being MR imaged facilitating imaging at multiple time points throughout the study. 
Unfortunately, this was not possible in our studies as the MRI suite and the animal houses 
were situated in different universities (MRI; Nottingham Trent University, Mice; Liverpool 
John Moors University; Rat; Nottingham University). Consequently, serial imaging could 
not be performed. This is a significant limitation of the studies presented in this thesis as 
migratory patterns and tissue integration with time could not be assessed. 
Good contrast of implanted cell population was demonstrated for both models over 7 days 
in the RA mouse model and 29 days in the OA rat model when MR imaged. The intracellular 
Fe disturbs the local magnetic field thus allowing cells to be visualised as negative contrast 
or  lack of signal when MR imaged (103, 104, 106, 152, 155, 199, 225). The generation of 
negative contrast by SPIONs is particularly hindering in cell tracking as it becomes difficult 
to discriminate between labelled cells presented as dark exaggerated marks and artefacts 
such as air. In addition, it is also difficult to quantify the effect of particle concentration on 
the extent of signal loss as the signal cannot be quantified below 0, where particles cannot 
be unambiguously distinguished from background (97, 135). Bulte et al suggested the 
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application of a specific “white marker” pulse sequence which would allow SPIONs to be 
detected and quantified as a positive contrast (97).  
The question of particle dilution becomes a concern particularly in the long term OA model. 
Particle dilution is an inherent limitation of all SPION and MRI based tracking in cell-based 
therapies. This defines the loss of the particle labelled cells by either exocytosis or by cell 
division beyond detectable levels. Released particles may be taken up by neighbouring cells 
or phagocytosed by macrophages. In general, small particles are thought to be exocytosed 
more efficiently than larger micro-sized particles. However, larger particles are more 
efficiently taken up by macrophages and removed (159). This may introduce false positives 
where released particles (either taken up my neighbouring cells, macrophages or freely 
moving) are tracked instead of the cells, further limiting the reliability of long term tracking 
studies. In an in vivo study by Baligand et al , the label was visible in tissues for 3 months 
apparently overestimating cell survival by more than 1 week (226). Berman et al suggested 
that particle dilution was an indication of viable cells, as non-viable cells retained the particle 
due to the inability to actively exocytose (227). However, distinguishing between live cells, 
pre-particle loss, released particles and non-viable cells retaining particles is impossible at 
this stage. Furthermore, gathering conclusive data on cell viability, cell activity and the 
differentiation state of cells post labelling is impossible highlighting an additional limitation 
of applying such tracking techniques (95). Overcoming such limitations may require the 
development and implementation of novel particles. Nonetheless, cell viability may be 
indirectly assessed by evaluating the effects of implanted cells in terms of functional 
outcomes over time as presented in this thesis. The positive joint swelling and weight bearing 
asymmetry results imply that cells are active in their role of secreting biological factors 
responsible for reducing joint swelling and minimising pain. Importantly, SiMAG labelling 
did not influence the effects of MSCs on joint swelling or weight bearing asymmetry.   
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6.2 Future Work 
 
This thesis has investigated the potential of four commercially available superparamagnetic 
iron oxide nanoparticles as likely labelling agents in MRI mediated cell tracking. Of the four 
particles, only SiMAG was deemed suitable given the potential to be internalised under 
passive incubation conditions, generate contrast at relevant cell doses on clinical MRI 
systems over a 29 day period with no impaired biological functions. Given the opportunity, 
the potential of the other three particles would be more closely evaluated to determine if 
higher particle concentrations would have facilitated better contrast when MR imaged. 
Furthermore, in terms of tracking studies, pre-implantation images would be taken of every 
animal and subsequently imaged at multiple time points to allow not only the migratory 
patterns and tissue integration to be evaluated, but to more closely link the location of cells 
with measurable functional outcomes such as pain and inflammation. For this to be possible 
it is necessary to fabricate a knee coil for all subsequent experiment. This ensures that images 
of better resolution would be obtained allowing the location of cells to be more precisely 
evaluated in relation to anatomical structures whilst analysing tissue repair. This has been 
difficult to achieve in this particular study due to the anatomical dimension of rats and in 
particular mice. Ideally, future experiments would be performed on larger animals such as 
pigs or goats where the larger joint dimension would facilitate greater anatomical detail. 
Furthermore, greater emphasis would be placed on the clinical success of MSC 
administration in terms of disease progression and tissue repair. Finally, the in vitro and in 
vivo degradation rates of SiMAG would be closely evaluated to assess important aspect such 
as long term tracking potential, physicochemical properties and toxicity.   
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6.3 Concluding Remarks 
 
The data presented in this thesis introduces the application of SiMAG (a 1 μm 
superparamagnetic iron oxide nanoparticle) as a possible tracking agent in arthritic cell-
based therapies. The labelling protocol has been established as the passive incubation of 1-
10 μgFe/ml SiMAG under serum free conditions for 24 hrs and has been validated for 
hMSCs and chondrocytes. Referring to the list presented in Chapter 3 (Figure 3.2) defining 
the pre-perquisites for an in vivo cell tracking agent, we can conclude that SiMAG largely 
meets these criteria. Furthermore, the application of a mouse model of RA and a rat model 
of OA demonstrates the potential to detect implanted cell population over a 29 day period 
using a 2.35T animal MRI scanner. Overall, the proposed labelling and imaging strategy 
lays the foundation for further developments and holds great potential in monitoring the 
success and risks not only arthritic cell-based therapies but cell-therapies in general.    
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A 1. Equations 
 
A 1.1 SPION labelling of cells.   
Equation A.1.1 Example calculation for the labelling of 1x106 cells with 100 μgFe/ml of 
Nanomag 
 
For the labelling of 1x106 cells with Nanomag at an iron concentration of 100 μgFe/ml 
Equation 1: 
𝐹𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑆𝑡𝑜𝑐𝑘 𝐹𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
= 𝐴 
 
100
2400
= 0.041𝑚𝑙 
Equation 2: 𝐴 𝑥
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑡𝑜 𝑏𝑒 𝑙𝑎𝑏𝑒𝑙𝑙𝑒𝑑
200000
=B 
 0.041𝑚𝑙 𝑥
1000,000
200,000
= 0.2𝑚𝑙 
 
Therefore; add 0.2ml of stock Nanomag to the required volume of media for the 
specific flask size.  
 
 
A 1.2 Collagen Gels 
Equation A.1.2. Equations to make up collagen gel. 
 
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 10 𝑋 𝑫𝑴𝑬𝑴 𝑡𝑜 𝑏𝑒 𝑎𝑑𝑑𝑒𝑑(𝑚𝑙) =
𝐴
10
= 𝐷 
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑠𝑡𝑜𝑐𝑘 𝒄𝒐𝒍𝒍𝒂𝒈𝒆𝒏 (𝑚𝑙) =
𝐴 𝑥 𝐵
𝐶
= 𝐸 
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑵𝒂𝑶𝑯 𝑡𝑜 𝑏𝑒 𝑎𝑑𝑑𝑒𝑑 (𝑚𝑙) = 𝐸 𝑥 0.023 = 𝐹  
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝒘𝒂𝒕𝒆𝒓 𝑡𝑜 𝑏𝑒 𝑎𝑑𝑑𝑒𝑑 (𝑚𝑙) = 𝐴 − 𝐷 − 𝐹 
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Where A: Total gel volume required, B: Required collagen concentration, C: Stock collagen 
concentration 
A 2 Iron Content Validation (ICP-OES). 
 
The Fe content (as reported by the manufacturer, shown in Table A 2.1) of each particle was 
validated using ICP-OES. This technique allows the accurate evaluation of Fe within a 
sample. The Fe content of SiMAG was not supplied by the manufactured and for this reason 
was quantified by ICP-OES as 15 mg/ml and validated in the same way. Based on the values 
in Table A 2.1, a range of particle concentration (0.001, 0.01, 0.1, 1, 5, 10 μgFe/ml) were 
made up in dH20, digested, analysed and compared to an ICP-OES Fe standard curve. The 
unit of measurement of the ICP-OES instrument is PPM (1 PPM = 1 μg/ml).  The Fe content 
of SiMAG and P904 has been confirmed in this system to be similar to the reported values 
(Figure A 2.1 and Table A 2.1); whilst Lumirem and Nanomag seemed to be 58 % and 70 % 
respectively of the reported value.   
Table A 2.1 Fe quantification of each of the four particles: SiMAG, Lumirem, 
Nanomag and P904 as reported by the supplier where appropriate. 
Particle Fe content (μgFe/ml) 
SiMAG 15000 
Lumirem 175 
Nanomag 2400 
P904 22000 
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Figure A 2.1. Particle concentration curve for each particle (SiMAG, Lumirem, 
Nanomag and P904) against an ICP-OES Fe standard (1-10 μgFe/ml) as a validation of 
the Fe content of each particle as reported by the manufacturer. Data = mean Fe (n=3) 
± SD. 
 
In addition, the detection limits of ICP-OES have been determined as 0.1 PPM. The ICP-
OES handbook states that the detection threshold of ICP-OES in terms of Fe to be 0.001 
PPM. However as can be seen in Table A 2.2, accuracy is lost below the 0.01 PPM mark 
and for this reason, 0.1 PPM will be considered the detection threshold in this system and 
not 0.001PPM. 
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Table A 2.2. ICP-OES values for SiMAG, Lumirem, Nanomag and P904 ranging in 
concentration from 0.0001 μgFe/ml to 10 μgFe/ml. Red line indicates detection levels 
(0.1 PPM) 
 
 
 
 
